Canadian Patents Database / Patent 2362003 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 2362003
(54) English Title: HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS
(54) French Title: COMPOSES UTILES EN TANT QU'AGENTS ANTI-INFLAMMATOIRES
(51) International Patent Classification (IPC):
  • C07D 413/06 (2006.01)
  • A61K 31/44 (2006.01)
  • A61K 31/5377 (2006.01)
  • A61P 29/00 (2006.01)
  • C07D 213/36 (2006.01)
  • C07D 401/12 (2006.01)
  • C07D 401/14 (2006.01)
  • C07D 405/12 (2006.01)
  • C07D 409/12 (2006.01)
  • C07D 413/14 (2006.01)
(72) Inventors :
  • BETAGERI, RAJASHEKHAR (United States of America)
  • BREITFELDER, STEFFEN (United States of America)
  • CIRILLO, PIER, F. (United States of America)
  • GILMORE, THOMAS, A. (United States of America)
  • HICKEY, EUGENE, R. (United States of America)
  • KIRRANE, THOMAS, M. (United States of America)
  • MORIAK, MONICA, H. (United States of America)
  • MOSS, NEIL (United States of America)
  • PATEL, USHA, R. (United States of America)
  • PROUDFOOT, JOHN, R. (United States of America)
  • REGAN, JOHN, R. (United States of America)
  • SHARMA, RAJIV (United States of America)
  • SUN, SANXING (United States of America)
  • SWINAMER, ALAN, D. (United States of America)
  • TAKAHASHI, HIDENORI (United States of America)
(73) Owners :
  • BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (United States of America)
(71) Applicants :
  • BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (United States of America)
(74) Agent: FETHERSTONHAUGH & CO.
(74) Associate agent:
(45) Issued: 2009-04-21
(86) PCT Filing Date: 2000-02-16
(87) Open to Public Inspection: 2000-09-21
Examination requested: 2003-11-19
(30) Availability of licence: N/A
(30) Language of filing: English

(30) Application Priority Data:
Application No. Country/Territory Date
60/124,148 United States of America 1999-03-12
60/165,867 United States of America 1999-11-16

English Abstract



Disclosed are novel aromatic compounds which are useful for treating diseases
or pathological conditions involving
inflammation such as chronic inflammatory diseases. Also disclosed are
pharmaceutical compositions containing and processes of
making such compounds.


French Abstract

L'invention se rapporte à de nouveaux composés aromatiques qui s'avèrent utiles pour le traitement de maladies ou des troubles pathologiques associés à une inflammation, du type maladies inflammatoires chroniques. L'invention se rapporte également à des compositions pharmaceutiques contenant de tels composés et à des procédés de fabrication de tels composés.


Note: Claims are shown in the official language in which they were submitted.



CLAIMS:

1. A compound of the formula (III):

Image
wherein:

G is

phenyl, pyridinyl, 5-indolyl, 3-oxo-3,4-dihydro-
2H-benzo[1,4]oxazin-8-yl, benzooxalolyl, 2,3-dihydrobenzo-
oxazol-7-yl, 2-oxo-2,3-dihydro-1H-indol-5-yl or 2-naphthyl
wherein G is optionally substituted by one or more R1,

R2 or R3;

E is NH;
W is O;

Ar is 1-naphthyl;
X is:

imidazolyl, pyridinyl, pyrimidinyl or pyrazinyl;
Y is:

a bond, CH2 (CN) CH2-NH-CH2, -CH2-, -NH-CH2CH2CH2- or
-NH-;

Z is morpholin-4yl, dioxolan-2yl,
tetrahydrofuranyl, pyridinyl, 2-oxa-5-aza-
bicyclo[2.2.1]hept-5yl, methoxyphenylpiperazinyl, hydroxy,

201


methyl, N,N-dimethoxyethylamino, acetylamino, methylsulfonyl
or cyanoethyl;

each R1 is independently:

tert-butyl, sec-butyl, tert-amyl, phenyl,
tetrahydropyran-2-yloxypropynyl, hydroxypropynyl,
trihalomethyl, 2,2-diethylpropionyl or cyclohexanyl;

R2 is chloro, nitro, amino, nitrile,
methylsulfonylamino, diacetylamino, phenylsulfonylamino,
N,N-di(methylsulfonyl)amino, methylsulfonyl or
trihalomethylsulfonyl;

R3 is independently:

methyl, C1-3 alkoxy, methoxymethyl, hydroxypropyl,
dimethylamino, C1-4 alkylamino, NH2C(O)methoxy, acetyl,
pyrrolidinyl, imidazolyl, pyrazolyl, morpholino or
morpholinocarbonyl.

2. The compound according to claim 1 wherein
X is pyridinyl.

3. The compound according to claim 2 wherein the
pyridinyl is attached to Ar via the 3-pyridinyl position.
4. 1-(2-tert-Butyl-5-methyl-pyridin-4-yl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
5. 1-(3-tert-Butyl-phenyl)-3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; or a
pharmaceutically acceptable derivative thereof.

6. 1-(4-Methyl-biphenyl-3-yl)-3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; or a
pharmaceutically acceptable derivative thereof.

202


7. 1-(4-tert-Butyl-biphenyl-2-yl)-3-[4-(6-morpholin-
4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea; or a
pharmaceutically acceptable derivative thereof.

8. 1-(5-Isopropyl-2-methyl-phenyl)-3-[4-(6-morpholin-
4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; or a
pharmaceutically acceptable derivative thereof.

9. 1-(5-sec-Butyl-2-methoxy-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
10. 1-(5-tert-Butyl-2-methoxymethyl-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
11. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-

[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
12. 1-(5-tert-Butyl-2-methyl-phenyl)-3-
(4-{6-[(3-methoxy-propyl)-methyl-amino]-pyridin-3-yl}-
naphthalen-1-yl)-urea; or a pharmaceutically acceptable
derivative thereof.

13. 1-(5-tert-Butyl-2-methyl-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
14. 1-(5-tert-Butyl-2-methyl-pyridin-3-yl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
15. 1-[5-(1,1-Dimethyl-propyl)-2-methoxy-phenyl]-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.

203


16. 1-[5-tert-Butyl-2-(2-methyl-pyrimidin-5-yl)-
phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-1-yl]-urea; or a pharmaceutically acceptable
derivative thereof.

17. 1-[5-tert-Butyl-2-(3-hydroxy-propyl)-phenyl]-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
18. 1-[5-tert-Butyl-2-(morpholine-4-carbonyl)-phenyl]-
3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
19. N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-
acetamide; or a pharmaceutically acceptable derivative
thereof.

20. 1-(3-Methyl-naphthalen-2-yl)-3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; or a
pharmaceutically acceptable derivative thereof.

21. N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-
acetamide; or a pharmaceutically acceptable derivative
thereof.

22. 1-[5-tert-Butyl-3-(2,3-dihydroxy-propyl)-2-
hydroxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-1-yl]-urea; or a pharmaceutically acceptable
derivative thereof.

23. 1-(2,3-Dimethyl-1H-indol-5-yl)-3-[4-(6-morpholin-
4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea; or a
pharmaceutically acceptable derivative thereof.

204


24. 1-{5-tert-Butyl-2-methyl-3-[3-(tetrahydro-pyran-2-
yloxy)-prop-1-ynyl]-phenyl}-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-naphthalen-1-yl]-urea; or a pharmaceutically
acceptable derivative thereof.

25. 1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
26. 1-[5-(2,2-Dimethyl-propionyl)-2-methyl-phenyl]-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
27. 1-[5-tert-Butyl-3-(3-hydroxy-prop-1-ynyl)-2-
methyl-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-1-yl]-urea; or a pharmaceutically acceptable
derivative thereof.

28. 1-[5-tert-Butyl-2-(3-hydroxy-prop-1-ynyl)-phenyl]-
3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
29. 1-[5-tert-Butyl-3-(2,2-dimethyl-[1,3]dioxolan-4-
ylmethyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-naphthalen-1-yl]-urea; or a pharmaceutically
acceptable derivative thereof.

30. 1-[5-tert-Butyl-3-(2,3-dihydroxy-propyl)-2-
methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-1-yl]-urea; or a pharmaceutically acceptable
derivative thereof.

31. 1-(5-tert-Butoxy-2-methoxy-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.

205


32. 1-[5-(1-Cyano-cyclopropyl)-2-methoxy-phenyl]-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
33. 1-[5-tert-Butyl-3-(2-diethylamino-ethyl)-2-
methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea; or a pharmaceutically acceptable
derivative thereof.

34. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
[4-(6-[1,3]dioxolan-2-yl-pyridin-3-yl)-naphthalen-l-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
35. 1-(5-tert-Butyl-2-pyrrolidin-1-yl-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
36. 1-(5-tert-Butyl-2-dimethylamino-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
37. 1-(5-tert-Butyl-2-propoxy-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
38. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
[4-(6-hydroxymethyl-pyridin-3-yl)-naphthalen-l-yl]-urea; or
a pharmaceutically acceptable derivative thereof.

39. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(2,6-dimethyl-morpholin-4-ylmethyl)-pyridin-3-yl]-
naphthalen-l-yl}-urea; or a pharmaceutically acceptable
derivative thereof.

40. 1-(5-Cyclohexyl-2-methoxy-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea; or a pharmaceutically acceptable derivative thereof.

206


41. 1-(2,4-Dimethoxy-5-trifluoromethyl-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
42. 1-(5-tert-Butyl-2-methoxy-3-nitro-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
43. 1-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-3-
[4-(6-methyl-pyridin-3-yl)-naphthalen-1-yl]-urea; or a
pharmaceutically acceptable derivative thereof.

44. N-Acetyl-N-(5-tert-butyl-2-methoxy-3-
{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-ureido}-phenyl)-acetamide; or a pharmaceutically
acceptable derivative thereof.

45. 1-(6-tert-Butyl-4-methyl-3-oxo-3,4-dihydro-2H-
benzo[1,4]oxazin-8-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-naphthalen-1-yl]-urea; or a pharmaceutically
acceptable derivative thereof.

46. 1-(5-tert-Butyl-2-ethoxy-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
47. 1-(5-tert-Butyl-2-isopropoxy-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
48. 1-(5-tert-Butyl-2-imidazol-1-yl-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
49. 1-(5-tert-Butyl-3-ethylamino-2-methoxy-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.

207


50. N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-
bis(methanesulfon)amide; or a pharmaceutically acceptable
derivative thereof.

51. 1-[5-tert-Butyl-2-(1-methyl-1H-pyrazol-4-yl)-
phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-1-yl]-urea; or a pharmaceutically acceptable
derivative thereof.

52. 1-(2-Methanesulfinyl-5-trifluoromethyl-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
53. 1-[4-(6-{[bis-(2-Methoxy-ethyl)-amino]-methyl}-
pyridin-3-yl)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-
phenyl)-urea; or a pharmaceutically acceptable derivative
thereof.

54. N-[1-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-
ureido]-naphthalen-1-yl}-pyridin-2-ylmethyl)-pyrrolidin-3-
yl]-acetamide; or a pharmaceutically acceptable derivative
thereof.

55. 1-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1H-indol-5-
yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-urea; or a pharmaceutically acceptable derivative
thereof.

56. N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-ureido}-phenyl)-
propionamide; or a pharmaceutically acceptable derivative
thereof.

57. 1-(5-tert-Butyl-2-methyl-benzooxazol-7-yl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
208


58. 1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-1-yl]-3-(3-trifluoromethanesulfonyl-phenyl)-urea;
or a pharmaceutically acceptable derivative thereof.

59. N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-
isobutyramide; or a pharmaceutically acceptable derivative
thereof.

60. 2-(4-tert-Butyl-2-{3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenoxy)-acetamide;
or a pharmaceutically acceptable derivative thereof.

61. 1-(5-tert-Butyl-2-oxo-2,3-dihydro-benzooxazol-7-
yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-
yl]-urea; or a pharmaceutically acceptable derivative
thereof.

62. 1-(5-tert-Butyl-3-cyano-2-methoxy-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
63. 1-(5-tert-Butyl-benzooxazol-7-yl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
64. N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-
benzenesulfonamide; or a pharmaceutically acceptable
derivative thereof.

65. Ethanesulfonic acid (5-tert-butyl-2-methoxy-3-
{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-
yl]-ureido}-phenyl)-amide; or a pharmaceutically acceptable
derivative thereof.

209


66. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
[4-(2-morpholin-4-ylmethyl-pyrimidin-5-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
67. 1-(5-tert-Butyl-2-methylsulfanyl-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
68. 1-(5-tert-Butyl-2-methoxy-pyridin-3-yl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
69. 2,2,2-Trifluoro-ethanesulfonic acid
(5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-amide; or a
pharmaceutically acceptable derivative thereof.

70. N-(5-{4-[3-(5-tert-Butyl-2-methyl-phenyl)-ureido]-
naphthalen-1-yl}-pyrazin-2-yl)-methanesulfonamide; or a
pharmaceutically acceptable derivative thereof.

71. 1-[4-(6-{[bis-(2-Cyano-ethyl)-amino]-methyl}-
pyridin-3-yl)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-
phenyl)-urea; or a pharmaceutically acceptable derivative
thereof.

72. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(4-methyl-piperazin-1-ylmethyl)-pyridin-3-yl]-
naphthalen-1-yl}-urea; or a pharmaceutically acceptable
derivative thereof.

73. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
[4-(6-thiomorpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-urea; or a pharmaceutically acceptable derivative
thereof.

210


74. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(2,6-dimethyl-piperidin-1-ylmethyl)-pyridin-3-yl]-
naphthalen-1-yl}-urea; or a pharmaceutically acceptable
derivative thereof.

75. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(1-oxo-tetrahydro-thiopyran-4-ylamino)-pyridin-3-yl]-
naphthalen-1-yl}-urea; or a pharmaceutically acceptable
derivative thereof.

76. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(tetrahydro-pyran-4-ylamino)-pyridin-3-yl]-naphthalen-
1-yl}-urea; or a pharmaceutically acceptable derivative
thereof.

77. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
[4-(6-{[(2-cyano-ethyl)-(tetrahydro-furan-2-ylmethyl)-
amino]-methyl}-pyridin-3-yl)-naphthalen-1-yl]-urea; or a
pharmaceutically acceptable derivative thereof.

78. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(2-methoxymethyl-morpholin-4-ylmethyl)-pyridin-3-yl]-
naphthalen-1-yl}-urea; or a pharmaceutically acceptable
derivative thereof.

79. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(2-methyl-3-oxo-piperazin-1-ylmethyl)-pyridin-3-yl]-
naphthalen-1-yl}-urea; or a pharmaceutically acceptable
derivative thereof.

80. 1-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-
ureido]-naphthalen-1-yl}-pyridin-2-ylmethyl)-piperidine-3-
carboxylic acid amide; or a pharmaceutically acceptable
derivative thereof.

81. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(1-oxo-114-thiomorpholin-4-ylmethyl)-pyridin-3-yl]-
211



naphthalen-1-yl}-urea; or a pharmaceutically acceptable
derivative thereof.

82. 1-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-
3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
83. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(3-oxo-piperazin-1-ylmethyl)-pyridin-3-yl]-naphthalen-
1-yl}-urea; or a pharmaceutically acceptable derivative
thereof.

84. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
(4-{6-[(tetrahydro-furan-3-ylamino)-methyl]-pyridin-3-yl}-
naphthalen-1-yl)-urea; or a pharmaceutically acceptable
derivative thereof.

85. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
[4-(6-{[(2-cyano-ethyl)-pyridin-3-ylmethyl-amino]-methyl}-
pyridin-3-yl)-naphthalen-1-yl]-urea; or a pharmaceutically
acceptable derivative thereof.

86. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-ylmethyl)-pyridin-3-
yl]-naphthalen-1-yl}-urea; or a pharmaceutically acceptable
derivative thereof.

87. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(2,6-dimethyl-morpholin-4-ylmethyl)-pyridin-3-yl]-
naphthalen-1-yl}-urea; or a pharmaceutically acceptable
derivative thereof.

88. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
(4-{6-[4-(3-methoxy-phenyl)-piperazin-1-ylmethyl]-pyridin-3-
yl}-naphthalen-1-yl)-urea; or a pharmaceutically acceptable
derivative thereof.


212




89. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(morpholine-4-carbonyl)-pyridin-3-yl]-naphthalen-1-
yl}-urea; or a pharmaceutically acceptable derivative
thereof.

90. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
[4-(5-morpholin-4-ylmethyl-pyrazin-2-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
91. 1-(6-tert-Butyl-3-oxo-3,4-dihydro-2H-
benzo[1,4]oxazin-8-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-naphthalen-1-yl]-urea; or a pharmaceutically
acceptable derivative thereof.

92. 1-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-3-
[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-
urea; or a pharmaceutically acceptable derivative thereof.
93. N-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-
ureido]-naphthalen-1-yl}-pyridin-2-yl)-acetamide; or a
pharmaceutically acceptable derivative thereof.

94. N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-N-
methyl-acetamide; or a pharmaceutically acceptable
derivative thereof.

95. N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-
2,2,2-trifluoro-acetamide; or a pharmaceutically acceptable
derivative thereof.

96. 1-(5-tert-Butyl-2-methoxy-phenyl)-3-
{4-[6-(pyridin-3-yloxy)-pyridin-3-yl]-naphthalen-1-yl}-urea;
or a pharmaceutically acceptable derivative thereof.



213



97. [4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-1-yl]-carbamic acid 3-tert-butyl-phenyl ester; or
a pharmaceutically acceptable derivative thereof.

98. N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-
methanesulfonamide; or a pharmaceutically acceptable
derivative thereof.

99. A pharmaceutical composition comprising a compound
according to any one of claims 1 to 98, and a
pharmaceutically acceptable carrier or diluent.

100. The pharmaceutical composition of claim 99 for
inhibition of production of cytokines involved in an
inflammatory process.

101. The pharmaceutical composition of claim 99 for
treating a disease or pathological condition that displays
inflammation as a symptom thereof.

102. The pharmaceutical composition of claim 101
wherein the disease or condition is chronic inflammatory
disease.

103. Use of the compound defined in any one of claims 1
to 98 in preparation of a pharmaceutical composition for
inhibition of production of cytokines involved in an
inflammatory process.

104. Use of the compound defined in any one of claims 1
to 98 in preparation of a pharmaceutical composition for
treating a disease or pathological condition that displays
inflammation as a symptom thereof.

105. The use of claim 104, wherein the disease or
condition is chronic inflammatory disease.



214



106. Use of the compound defined in any one of claims 1
to 98 for inhibition of production of cytokines involved in
an inflammatory process.

107. Use of the compound defined in any one of claims 1
to 98 for treating a disease or pathological condition that
displays inflammation as a symptom thereof.

108. The use of claim 107, wherein the disease or
condition is chronic inflammatory disease.

109. The compound defined in any one of claims 1 to 98
for inhibition of production of cytokines involved in an
inflammatory process.

110. The compound defined in any one of claims 1 to 98
for treating a disease or pathological condition that
displays inflammation as a symptom thereof.

111. The compound of claim 110, wherein the disease or
condition is chronic inflammatory disease.

112. A method of making a compound of the formula (III)
according to claim 1, comprising:

a) reacting an arylamine with phenyl chloroformate
in a suitable halogenated solvent with a suitable base at
0-85°C for about 2-24 hours:

Image
b) isolating and subsequently reacting the product
of step a) with an arylamine shown below in a non-protic



215



anhydrous solvent at 0-110°C for about 2-24 hours, to
produce a compound of the formula (III):

Image
wherein E is N-H, W is O and G, Ar, X, Y and Z are as
defined in claim 1.



216

Note: Descriptions are shown in the official language in which they were submitted.


CA 02362003 2008-01-24
25771-701

HETEROCYCLIC UREA AND RELATED COMPOUNDS
USEFUL AS ANTI-INFLAMMATORY AGENTS
TECHNICAL FIELD OF THE INVENTION

lo This invention relates to novel compounds which inhibit production of
cytokines
involved in inflammatory processes and are thus useful for treating diseases
and
pathological conditions involving inflammation such as chronic inflammatory
disease.
This invention also relates to processes for preparing these compounds and to
pharmaceuticaI compositions comprising these conipounds.

BACKGROUND OF THE INVENTION

Tumor necrosis factor (TNF) and interleukin-I (IL-1) are important biological
entities
collectively referred to as proinflamrnatory cytokines. These; along with
several other
2o related molecules, mediate the inflammatory response associated with the
immunological
xecognition of infectious agents. The inflammatory response plays an important
role in
limiting aiid controlling pathogenic infections.

Elevated levels of proinflammatory cytokines are also associated with a number
of
diseases of autoimrnunity such as toxic shock syndrome, rheumatoid arthritis,
osteoarthritis, diabetes and inflammatory bowel disease (Dinarello, C.A:, et
a1.,1984,
Rev. Infect. Disease 6:51). In these diseases, chronic elevation of
inflammation
exacerbates or causes much of the pathophysiology observed. For example,
rheumatoid
synovial tissue becomes invaded with inflammatory cells that result in
destruction to
cartilage and bone (Koch, A.E., et al., 1995, J. Invest. llfed. 43: 28-38).
Animportant
and accepted therapeutic approach for potential drug intervention in these
diseases is the
reduction of proinflammatory cytokines such as TNF (also referred to in its
secreted cell-
1


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
free form as TNFa) and IL-1(3. A number of anti-cytokine therapies are
currently in
clinical trials. Efficacy has been demonstrated with a monoclonal antibody
directed
against TNFa in a number of autoimmune diseases (Heath, P., "CDP571: An
Engineered
Human IgG4 Anti-TNF(x Antibody" IBC Meeting on Cytokine Antagonists,

Philadelphia, PA. April 24-5, 1997). These include the treatment of rheumatoid
arthritis,
Crohn's disease and ulcerative colitis (Rankin, E.C.C.. et al., 1997, Bi-itish
J. Rheum. 35:
334-342 and Stack. W.A., et al., 1997. Lancet 349: 521-524). The monoclonal
antibody
is thought to function by binding to both soluble TNFa and to membrane bound
TNF.

A soluble TNFa receptor has been engineered that interacts with TNFa. The
approach is
similar to that described above for the monoclonal antibodies directed against
TNFa;
both agents bind to soluble TNFa, thus reducing its concentration. One version
of this
construct, called Enbrel (Immunex, Seattle, WA) recently demonstrated efficacy
in a
Phase III clinical trial for the treatment of rheumatoid arthritis (Brower et
al., 1997,

Nature Biotechnology 15: 1240). Another version of the TNFa receptor, Ro 45-
2081
(Hoffman-LaRoche Inc., Nutley, NJ) has demonstrated efficacy in various animal
models
of allergic lung inflammation and acute lung injury. Ro 45-2081 is a
recombinant
chimeric molecule constructed from the soluble 55 kDa human TNF receptor fused
to the
hinge region of the heavy chain IgGI gene and expressed in eukaryotic cells
(Renzetti, et
al., 1997, Inflamm. Res. 46: S143).

IL-1 has been implicated as an immunological effector molecule in a large
number of
disease processes. IL-1 receptor antagonist (IL-lra) had been examined in
human
clinical trials. Efficacy has been demonstrated for the treatment of
rheumatoid arthritis
(Antril, Amgen). In a phase III human clinical trial IL-lra reduced the
mortality rate in
patients with septic shock syndrome (Dinarello, 1995, Nutrution 11, 492).
Osteoarthritis
is a slow progressive disease characterized by destruction of the articular
cartilage. IL-1
is detected in synovial fluid and in the cartilage matrix of osteoarthritic
joints.
Antagonists of IL-1 have been shown to diminish the degradation of cartilage
matrix
components in a variety of experimental models of arthritis (Chevalier, 1997,
Biomed
Pharmacother. 51, 58). Nitric oxide (NO) is a mediator of cardiovascular
homeostasis,

2


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
neurotransmission and immune function; recently it has been shown to have
important
effects in the modulation of bone remodeling. Cytokines such as IL-I and TNF
are
potent stimulators of NO production. NO is an important regulatory niolecule
in bone
with effects on cells of the osteoblast and osteoclast lineage (Evans, et
crl., 1996, JBone
Miner Res. 11, 300). The promotion of beta-cell destruction leading to insulin
dependent
diabetes mellitus shows dependence on IL-1. Some of this damage may be
mediated
through other effectors such as prostaglandins and thromboxanes. IL-1 can
effect this
process by controlling the level of both cyclooxygenase II and inducible
nitric oxide
synthetase expression (McDaniel et al., 1996, Proc Soc Exp Biol Med. 211, 24).

Inhibitors of cytokine production are expected to block inducible
cyclooxygenase (COX-
2) expression. COX-2 expression has been shown to be increased by cytokines
and it is
believed to be the isoform of cyclooxygenase responsible for inflammation
(M.K.
O'Banion et al., Proc. Natl. Acad. Sci. U.S.A, 1992, 89, 4888.) Accordingly,
inhibitors of
cytokines such as IL-1 would be expected to exhibit efficacy against those
disorders
currently treated with COX inhibitors such as the familiar NSAIDs. These
disorders
include acute and chronic pain as well as symptoms of inflammation and
cardiovascular
disease.

2o Elevation of several cytokines have been demonstrated during active
inflammatory bowel
disease (IBD). A mucosal imbalance of intestinal IL-1 and IL-lra is present in
patients
with IBD. Insufficient production of endogenous IL-lra may contribute to the
pathogenesis of IBD (Cominelli, et al., 1996, Aliment Pharmacol Ther. 10, 49).
Alzheimer disease is characterized by the presence of beta-amyloid protein
deposits,
neurofibrillary tangles and cholinergic dysfunction throughout the hippocampal
region.
The structural and metabolic damage found in Alzheimer disease is possibly due
to a
sustained elevation of IL-1 (Holden, et al., 1995, Med Hypotheses, 45. 559). A
role for
IL-1 in the pathogenesis of human immunodeficiency virus (HIV) has been
identified.
IL-lra showed a clear relationship to acute inflammatory events as well as to
the different
disease stages in the pathophysiology of HIV infection (Kreuzer, et al., 1997,
Clin Exp
Immunol. 109, 54). IL-1 and TNF are both involved in periodontal disease. The

3


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
destructive process associated with periodontal disease may be due to a
disregulation of
both IL-1 and TNF (Howells, 1995, Oral Dis. 1, 266).

Proinflammatory cytokines such as TNFa and IL-1(3 are also important mediators
of
septic shock and associated cardiopulmonary dysfunction, acute respiratory
distress
syndrome (ARDS) and multiple organ failure. TNFa has also been implicated in
cachexia and muscle degradation, associated with HIV infection (Lahdiverta et
al., 1988,
Amer. J. Med., 85, 289). Obesity is associated with an increase incidence of
infection,
diabetes and cardiovascular disease. Abnormalities in TNFa expression have
been noted

for each of the above conditions (Loffreda, et al., 1998, FASEB J. 12, 57). It
has been
proposed that elevated levels of TNFa are involved in other eating related
disorders such
as anorexia and bulimia nervosa. Pathophysiological parallels are drawn
between
anorexia nervosa and cancer cachexia (Holden, et al., 1996, Med Hypotheses 47,
423).
An inhibitor of TNFa production, HU-211, was shown to improve the outcome of
closed
brain injury in an experimental model (Shohami, et al., 1997, JNeuroimmunol.
72, 169).
Atherosclerosis is known to have an inflammatory component and cytokines such
as IL-1
and TNF have been suggested to promote the disease. In an animal model an IL-1
receptor antagonist was shown to inhibit fatty streak formation (Elhage et
al., 1998,
Circulation, 97, 242).


The abnormal expression of inducible nitric oxide synthetase (iNOS) has been
associated
with hypertension in the spontaneously hypertensive rat (Chou et al., 1998,
Hypertension,
31, 643). IL-1 has a role in the expression of iNOS and therefore may also
have a role in
the pathogenesis of hypertension (Singh et al., 1996, Amer. J. Hypertension,
9, 867).


IL-1 has also been shown to induce uveitis in rats which could be inhibited
with IL-1
blockers. (Xuan et al., 1998, J. Ocular Pharmacol. and Ther., 14, 31).
Cytokines
including IL-1, TNF and GM-CSF have been shown to stimulate proliferation of
acute
myelogenous leukemia blasts (Bruserud, 1996, Leukemia Res. 20, 65). IL-1 was
shown
to be essential for the development of both irritant and allergic contact
dermatitis.
Epicutaneous sensitization can be prevented by the administration of an anti-
IL-1
4


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
monoclonal antibody before epicutaneous application of an allergen (Muller, et
al., 1996,
Am J Contact Dei-mat. 7. 177). Data obtained from IL-1 knock out niice
indicates the
critical involvement in fever for this cytokine (Kluger et al., 1998, Clin Exp
Phcrrniacol
Physiol. 25, 141). A variety of cytokines including TNF, IL-1, IL-6 and IL-8
initiate the
acute-phase reaction which is stereotyped in fever, malaise, myalgia,
headaches, cellular
hypermetabolism and multiple endocrine and enzyme responses (Beisel, 1995, Am
J Clin
Nutr. 62, 813). The production of these inflammatory cytokines rapidly follows
trauma
or pathogenic organism invasion.

Other proinflammatory cytokines have been correlated with a variety of disease
states.
IL-8 correlates with influx of neutrophils into sites of inflammation or
injury. Blocking
antibodies against IL-8 have demonstrated a role for IL-8 in the neutrophil
associated
tissue injury in acute inflammation (Harada et al., 1996, Molecular Medicine
Today 2,
482). Therefore, an inhibitor of IL-8 production may be useful in the
treatment of
diseases mediated predominantly by neutrophils such as stroke and myocardial
infarction,
alone or following thrombolytic therapy, thermal injury, adult respiratory
distress
syndrome (ARDS), multiple organ injury secondary to trauma, acute
glomerulonephritis,
dermatoses with acute inflammatory components, acute purulent meningitis or
other
central nervous system disorders, hemodialysis, leukopherisis, granulocyte
transfusion
2o associated syndromes, and necrotizing enterocolitis.

Rhinovirus triggers the production of various proinflammatory cytokines,
predominantly
IL-8, which results in symptomatic illnesses such as acute rhinitis (Winther
et al., 1998,
Am J Rhinol. 12, 17).

Other diseases that are effected by IL-8 include myocardial ischemia and
reperfusion,
inflammatory bowel disease and many others.

The proinflammatory cytokine IL-6 has been implicated with the acute phase
response.
IL-6 is a growth factor in a number in oncological diseases including multiple
myeloma
and related plasma cell dyscrasias (Treon, et al., 1998, Current Opinion in
Hematology 5:
42). It has also been shown to be an important mediator of inflammation within
the
5


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
central nervous system. Elevated levels of IL-6 are found in several
neurological
disorders including AIDS dementia complex. Alzheimer's disease, multiple
sclerosis,
systemic lupus erythematosus, CNS trauma and viral and bacterial meningitis
(Gruol, el
al., 1997, Molecular Neurobiology 15: 307). IL-6 also plays a significant role
in
osteoporosis. In murine models it has been shown to effect bone resorption and
to induce
osteoclast activity (Ershler et al., 1997, Development and Comparative
Immunol. 21:
487). Marked cytokine differences, such as IL-6 levels, exist in vivo between
osteoclasts
of normal bone and bone from patients with Paget's disease (Mills, et al.,
1997, Calcif
Tissue Int. 61, 16). A number of cytokines have been shown to be involved in
cancer
cachexia. The severity of key parameters of cachexia can be reduced by
treatment with
anti IL-6 antibodies or with IL-6 receptor antagonists (Strassmann, et al.,
1995, Cytokins
Mol Ther. 1. 107). Several infectious diseases, such as influenza, indicate IL-
6 and IFN
alpha as key factors in both symptom formation and in host defense (Hayden, et
al.,
1998, JClin Invest. 101, 643). Overexpression of IL-6 has been implicated in
the
pathology of a number of diseases including multiple myeloma, rheumatoid
arthritis,
Castleman's disease, psoriasis and post-menopausal osteoporosis (Simpson, et
al., 1997,
Protein Sci. 6, 929). Compounds that interfered with the production of
cytokines
including IL-6, and TNF were effective in blocking a passive cutaneous
anaphylaxis in
mice (Scholz et al., 1998, J. Med. Chem., 41, 1050).

GM-CSF is another proinflammatory cytokine with relevance to a number of
therapeutic
diseases. It influences not only proliferation and differentiation of stem
cells but also
regulates several other cells involved in acute and chronic inflammation.
Treatment with
GM-CSF has been attempted in a number of disease states including burn-wound
healing,
skin-graft resolution as well as cytostatic and radiotherapy induced mucositis
(Masucci,
1996, Medical Oncology 13: 149). GM-CSF also appears to play a role in the
replication
of human immunodeficiency virus (HIV) in cells of macrophage lineage with
relevance
to AIDS therapy (Crowe et al., 1997, Journal of Leukocyte Biology 62, 41).
Bronchial
asthma is characterised by an inflammatory process in lungs. Involved
cytokines include
GM-CSF amongst others (Lee, 1998, JR Coll Physicians Lond 32, 56).
6


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
Interferon y (IFN y) has been implicated in a number of diseases. It has been
associated
with increased collagen deposition that is a central histopathological feature
of araft-
versus-hostdisease (Parkman. 1998, ('in-r Opin Hematol. 5, 22). Follo"ving
kidney
transplantation, a patient was diagnosed with acute myelogenous leukemia.
Retrospective analysis of peripheral blood cytokines revealed elevated levels
of GM-CSF
and IFN y. These elevated levels coincided with a rise in peripheral blood
white cell
count (Burke, et al., 1995, Leuk Lynzphonzcr. 19, 173). The development of
insulin-
dependent diabetes (Type 1) can be correlated with the accumulation in
pancreatic islet
cells of T-cells producing IFN y(Ablumunits, et crl., 1998, JAutoimmun. 11,
73). IFN y

along with TNF, IL-2 and IL-6 lead to the activation of most peripheral T-
cells prior to
the development of lesions in the central nervous system for diseases such as
multiple
sclerosis (MS) and AIDS dementia complex (Martino et al., 1998, Ann iVeui ol.
43, 340).
Atherosclerotic lesions result in arterial disease that can lead to cardiac
and cerebral
infarction. Many activated immune cells are present in these lesions, mainly T-
cells and
macrophages. These cells produce large amounts of proinflammatory cytokines
such as
TNF, IL-1 and IFN y. These cytokines are thought to be involved in promoting
apoptosis
or programmed cell death of the surrounding vascular smooth muscle cells
resulting in
the atherosclerotic lesions (Geng, 1997, Heart Vessels Suppl 12, 76). Allergic
subjects
produce mRNA specific for IFN y following challenge with Vespula venom (Bonay,
et
al., 1997, Clin Exp Immunol. 109, 342). The expression of a number of
cytokines,
including IFN y has been shown to increase following a delayed type
hypersensitivity
reaction thus indicating a role for IFN y in atopic dermatitis (Szepietowski,
et al., 1997,
Br JDermatol. 137, 195). Histopathologic and immunohistologic studies were

performed in cases of fatal cerebral malaria. Evidence for elevated IFN y
amongst other
cytokines was observed indicating a role in this disease (Udomsangpetch et
al., 1997, Am
J Trop Med Hyg. 57, 501). The importance of free radical species in the
pathogenesis of
various infectious diseases has been established. The nitric oxide synthesis
pathway is
activated in response to infection with certain viruses via the induction of
proinflammatory cytokines such as IFN y(Akaike, et al., 1998, Proc Soc Exp
Biol Med.

217, 64). Patients, chronically infected with hepatitis B virus (HBV) can
develop
cirrhosis and hepatocellular carcinoma. Viral gene expression and replication
in HBV
7


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
transgenic mice can be suppressed by a post-transcriptional mechanism mediated
by IFN
y, TNF and IL-2 (Chisari. et ul., 1995. Springer Semifz Immunopathol. 1?,
261). IFN y
can selectively inhibit cytokine induced bone resorption. It appears to do
this via the
intermediacy of nitric oxide (NO) which is an important regulatory molecule in
bone
remodeling. NO may be involved as a mediator of bone disease for such diseases
as: the
rheumatoid arthritis, tumor associated osteolysis and postmenopausal
osteoporosis
(Evans, et al., 1996, JBone Miner Res. 11, 300). Studies with gene deficient
mice have
demonstrated that the IL-12 dependent production of IFN y is critical in the
control of
early parasitic growth. Although this process is independent of nitric oxide
the control of
chronic infection does appear to be NO dependent (Alexander et al., 1997,
Philos Trans
R Soc LondB Biol Sci 352, 1355). NO is an important vasodilator and convincing
evidence exists for its role in cardiovascular shock (Kilbourn, et al., 1997,
Dis Mon. 43,
277). IFN y is required for progression of chronic intestinal inflammation in
such
diseases as Crohn's disease and inflammatory bowel disease (IBD) presumably
through
the intermediacy of CD4+ lymphocytes probably of the THl phenotype (Sartor
1996,
Aliment Pharmacol Ther. 10 Suppl 2, 43). An elevated level of serum IgE is
associated
with various atopic diseases such as bronchial asthma and atopic dermatitis.
The level of
IFN y was negatively correlated with serum IgE suggesting a role for IFN y in
atopic
patients (Teramoto et al., 1998, Clin Exp Allergy 28, 74).

Compounds which modulate release of one or more of the aforementioned
inflammatory
cytokines can be useful in treating diseases associated with release of these
cytokines. For
example, WO 98/52558 discloses heteroaryl urea compounds which are indicated
to be
useful in treating cytokine mediated diseases. WO 99/23091 discloses another
class of
urea compounds which are useful as anti-inflammatory agents.

U.S. Pat. No. 5,162,360 discloses N-substituted aryl-N'-heterocyclic
substituted urea
compounds which are described as being useful for treating
hypercholesterolemia and
atheroclerosis.

8


CA 02362003 2007-08-27
25771-701

The work cited above supports the principle that inhibition of cytokine
production will be
beneficial in the treatment of various disease states. Some protein
therapeutics are in late
development or have been approved for use in particular diseases. Protein
therapeutics
are costly to produce and have bioavailability- and stability problems.
Therefore a need
exists for new small molecule inhibitors of cytokine production with optimized
efficacy,
pharmacokinetic and safety profiles.

BRIEF SUMMARYOF THE INVENTION

t o In view of the work cited above there is a clear need for compounds that
inhibit cytokine
production in order to treat various disease states.

It is therefore an object of the invention to provide novel compounds which
inhibit the
release of inflammatory cytokines such as interleukin-1 and tumor necrosis
factor.

It is a fiirther object of the invention to provide methods for treating
diseases and
pathological conditions involving inflammation such as chronic inflammatory
disease,
using the novel compounds of the invention.

Zo It is yet a further object of the invention to provide processes of
preparation of the above-
mentioned novel compounds.

9


CA 02362003 2007-08-27
25771-701

According to one aspect of the present invention, there is
provided a compound of the formula (III):

W
G~E'K NI.Ar-X-Y-Z
I
H

(III)
wherein:

G is

phenyl, pyridinyl, 5-indolyl, 3-oxo-3,4-dihydro-
2H-benzo[1,4]oxazin-8-yl, benzooxalolyl, 2,3-dihydrobenzo-
oxazol-7-yl, 2-oxo-2,3-dihydro-lH-indol-5-yl or 2-naphthyl
wherein G is optionally substituted by one or more R1r

R2 or R3;

E is NH;
W is 0;

Ar is 1-naphthyl;
X is:

imidazolyl, pyridinyl, pyrimidinyl or pyrazinyl;
Y is:

a bond, CHZ (CN) CH2-NH-CH2, -CH2-, -NH-CH2CH2CH2- or
-NH-;

Z is morpholin-4y1, dioxolan-2y1,
tetrahydrofuranyl, pyridinyl, 2-oxa-5-aza-
bicyclo[2.2.1]hept-5yl, methoxyphenylpiperazinyl, hydroxy,

9a


CA 02362003 2007-08-27
25771-701

methyl, N,N-dimethoxyethylamino, acetylamino, methylsulfonyl
or cyanoethyl;

each R1 is independently:

tert-butyl, sec-butyl, tert-amyl, phenyl,
tetrahydropyran-2-yloxypropynyl, hydroxypropynyl,
trihalomethyl, 2,2-diethylpropionyl or cyclohexanyl;

R2 is chloro, nitro, amino, nitrile,
methylsulfonylamino, diacetylamino, phenylsulfonylamino,
N,N-di(methylsulfonyl)amino, methylsulfonyl or
trihalomethylsulfonyl;

R3 is independently:

methyl, C1_3 alkoxy, methoxymethyl, hydroxypropyl,
dimethylamino, C1-9 alkylamino, NH2C(O)methoxy, acetyl,
pyrrolidinyl, imidazolyl, pyrazolyl, morpholino or
morpholinocarbonyl.

DETAILED DESCRIPTION OF THE INVENTION

In one generic aspect of the invention, there is provided
compounds of the formula (I):

9b


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
W
Ar '-' N N ,-Ar2 X-Y-Z
I I
H H
(I)
wherein:

Ar, is selected from the group consisting of:

pyrrole, pyrrolidine, pyrazole, imidazole, oxazole, thiazole, furan and
thiophene;
wherein Arl may be substituted bv one or more Ri, R, or R3;

Ar2 is:

phenyl, naphthyl, quinoline, isoquinoline, tetrahydronaphthyl,
tetrahydroquinoline,
tetrahydroisoquinoline, benzimidazole, benzofuran, indanyl, indenyl or indole
each being
optionally substituted with zero to three R~ groups;

X is:

a) a C5_8 cycloalkyl or cycloalkenyl optionally substituted with 0-2 oxo
groups or 0-3 C1 _4
branched or unbranched alkyl, Ci_4 alkoxy or C1 _4 alkylamino chains;
b) phenyl, furan, thiophene, pyrrole, imidazolyl, pyridine, pyrimidine,
pyridinone,
dihydropyridinone, maleimide, dihydromaleimide, piperdine, piperazine or
pyrazine each
being optionally independently substituted with 0-3 C1 _4 branched or
unbranched alkyl,
Cl4alkoxy, hydroxy, nitrile, mono- or di-(C1_3 alkyl)amino, C1_6 alkyl-
S(O),,,, or halogen;
Y is:

a bond or a C1_4 saturated or unsaturated branched or unbranched carbon chain
optionally
partially or fully halogenated, wherein one or more methylene groups are
optionally
replaced by 0, NH, S(O), S(0)2 or S and wherein Y is optionally independently



CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
substituted with 0-2 oxo groups and one or more Ci_a branched or unbranched
alkyl
which may be substituted by one or more halogen atoms;

Z is:

a) phenyl, pyridine, pyrimidine, pyridazine, imidazole, furan, thiophene,
pyran, which
are optionally substituted with one to three groups consisting of halogen,
CI_6 alkyl,
C1_6 alkoxy, hydroxy, mono- or di-(C1_3 alkyl)amino, C1_6 alkyl-S(O),,, , COOH
and
phenylamino wherein the phenyl ring is optionally substituted with one to two
groups
consisting of halogen, C1_6 alkyl and C1_6 alkoxy;

b) tetrahydropyran, tetrahydrofuran, 1,3-dioxolanone, 1,3-dioxanone, 1.4-
dioxane,
morpholine, thiomorpholine, thiomorpholine sulfoxide, piperidine,
piperidinone,
piperazine, tetrahydropyrimidone, cyclohexanone, cyclohexanol, pentamethylene
sulfide, pentamethylene sulfoxide, pentamethylene sulfone, tetramethylene
sulfide,
tetramethylene sulfoxide or tetramethylene sulfone which are optionally
substituted
with one to three groups consisting of nitrile, CI_6 alkyl, C 1_6 alkoxy,
hydroxy, mono-
or di-(C 1_3 alkyl)amino-C 1_3 alkyl, phenylamino-C 1_3 alkyl and C1 _3 alkoxy-
C 1_3 alkyl;
c) CI_6 alkoxy, secondary or tertiary amine wherein the amino nitrogen is
covalently
bonded to groups selected from the group consisting of C 1_3 alkyl, C 1_;
alkoxyalkyl,
pyridinyl-C1_3 alkyl, imidazolyl-C1_3 alkyl, tetrahydrofuranyl-C1_3 alkyl,
phenylamino,
wherein the phenyl ring is optionally substituted with one to two halogen, C1
_6
alkoxy, hydroxy or mono- or di-(C1_3 alkyl)amino, C1_6 alkyl-S(O)n,, and
phenyl-
S(O),,,, wherein the phenyl ring is optionally substituted with one to two
halogen, C1_6
alkoxy, hydroxy or mono- or di-(C1_3 alkyl)amino;

R, is :

(a) C3_10 branched or unbranched alkyl optionally partially or fully
halogenated and
optionally substituted with one to three phenyl, naphthyl or heterocyclic
groups
selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl,
pyridazinyl,
pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl and isothiazolyl;
each such
11


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
phenyl, naphthvl or heterocvcle selected from the group hereinabove described
in this
paragraph. and being substituted with 0 to 5 groups selected from the group
consisting of halogen, C1_6 branched or unbranched alkyl which is optionally
partially
or fully halogenated, C3_8 cycloalkyl, C;_8 cycloalkenyl, hydroxy. nitrile,
Ci_3 alkyloxy
which is optionally partially or fullv halogenated, NH2C(O) and
di(C i _3)alkylaminocarbonyl;

(b) C3_7 cycloalkyl selected from the group consisting of cyclopropyl,
cyclobutyl,
cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl, bicyclohexanyl
and
bicycloheptanyl each being optionally be partially or ftilly halogenated and
optionally
substituted with one to three C1 _3 alkyl groups, or an analog of such
cycloalkyl group
wherein one to three ring methylene groups are replaced by groups
independently
selected from the group consisting of 0, S, CHOH, >C=O, >C=S and NH;
(c) C3_10 branched alkenyl optionally partially or fully halogenated and
optionally
substituted with one to three C1_5 branched or unbranched alkyl, phenyl,
naphthyl or
heterocyclic groups, with each such heterocyclic group being independently
selected

from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,
pyrrolyl,
imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl and isothiazolyl, and each
such
phenyl, naphthyl or heterocyclic group being substituted with 0 to 5 groups
selected
from the group consisting of halogen, C1_6 branched or unbranched alkyl which
is
optionally partially or fully halogenated, cyclopropyl, cyclobutyl,
cyclopentanyl,
cyclohexanyl, cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl,
hydroxy, nitrile, C1_3 alkoxy which is optionally partially or fully
halogenated,
NH2C(O) and mono- or di(C1_3)alkylaminocarbonyl;
(d) a C5_7 cycloalkenyl selected from the group consisting of cyclopentenyl,
cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, bicyclohexenyl
and
bicycloheptenyl, wherein such cycloalkenyl group is optionally substituted
with one
to three CI_3 alkyl groups;
(e) nitrile; or

(f) C1 _6 branched or unbranched alkoxycarbonyl, C i_6 branched or unbranched
alkylaminocarbonyl, C1_6 branched or unbranched alkylcarbonylamino-C1_3-alkyl;
12


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
R-) is:

a Ci_6 branched or unbranched alkvl optionally partially or ftilly
halogenated, acetyl,
aroyl, CI_4 branched or unbranched alkoxy optionally partially or fully
halogenated,
halogen, methoxycarbonyl or phenylsulfonyl;

R3 is:

a) phenyl, naphthyl or heterocyclic group selected from the group consisting
of
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl,
pyrazolyl,
thienyl, furyl, tetrahydrofuryl, isoxazolyl, isothiazolyl, quinolinyl,
isoquinolinyl,
indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl,
benzpyrazolyl,
benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl, naphthypyridinyl,
quinoxalinyl, quinazolinyl, purinyl and indazolyl, wherein such phenyl,
naphthyl or
heterocyclic group is optionally substituted with one to five groups selected
from the
group consisting of phenyl, naphthyl, heterocycle selected from the group
hereinabove described in this paragraph, C1_6 branched or unbranched alkyl
which is
optionally partially or fully halogenated, cyclopropyl, cyclobutyl,
cyclopentyl,
cyclohexyl, cycloheptyl, bicyclopentyl, bicyclohexyl, bicycloheptyl, phenyl
C1_;
alkyl, naphthyl CI_5 alkyl, halogen, hydroxy, nitrile, CI_3 alkyloxy which may
optionally be partially or fully halogenated, phenyloxy, naphthyloxy,
heteraryloxy
wherein the heterocyclic moiety is selected from the group hereinabove
described in
this paragraph, nitro, amino, mono- or di-(C1_3)alkylamino, phenylamino,
naphthylamino, heterocyclylamino wherein the heterocyclyl moiety is selected
from
the group hereinabove described in this paragraph, NH2C(O), a mono- or di-(CI_
3)alkyl aminocarbonyl, CI_; alkyl-C(O)-CI_a alkyl, amino-CI_; alkyl, mono- or
di-(Cl_
3)alkylamino-C1 _; alkyl, amino-S(O)2, di-(C1_3)alkylamino-S(O)2, R4 -C1 _;
alkyl, R5 -
C1_5 alkoxy, R6 -C(O)-Ci_5 alkyl and R7 -CI_; alkyl(R8)N, carboxy-mono- or di-
(C1_5)-
alkyl-amino;

b) a fused aryl selected from the group consisting of benzocyclobutanyl,
indanyl,
indenyl, dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl and

13


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
benzocvcloheptenyl, or a fiised heterocvclvl selected from the group
consisting of
cyclopentenopyridine. cyclohexanopvridine, cvclopentanopyrimidine,
cyclohexanopyrimidine, cyclopentanopyrazine, cvclohexanopyrazine,
cyclopentanopvridazine, cyclohexanopvridazine. cyclopentanoquinoline,
cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline,
cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole,
cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole,
cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and
cyclohexanothiophene; wherein the fiised aryl or fused heterocyclyl ring is
substituted
with 0 to 3 groups independently selected from the group consisting of phenyl,
naphthyl and heterocyclyl selected from the group consisting of pyridinyl,
pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl,
furyl,
isoxazolyl, and isothiazolyl, C1_6 branched or unbranched alkyl which is
optionally
partially or fully halogenated, halogen, nitrile, CI_3 alkoxy which is
optionally
partially or fully halogenated, phenyloxy, naphthyloxy, heterocyclyloxy
wherein the
heterocyclyl moiety is selected from the group hereinabove described in this
paragraph, nitro, amino, mono- or di-(C1_3)alkylamino, phenylamino,
naphthylamino,
heterocyclylamino wherein the heterocyclyl moiety is selected from the group
hereinabove described in this paragraph, NH2C(O), a mono- or di-(C1_3)alkyl
aminocarbonyl, C1 _4 alkyl-OC(O), C1_; alkyl-C(O)-C1_4 branched or unbranched
alkyl,
an amino-C 1 _5 alkyl, mono- or di-(C 1_3)alkylamino-C 1_5 alkyl, R9 -C I_5
alkyl, Rl o-C 1_;
alkoxy, R1 l-C(O)-CI_; alkyl, and R1, -CI_; alkyl(R13)N;
c) cycloalkyl selected from the group consisting of cyclopentyl, cyclohexyl,
cycloheptyl, bicyclopentyl, bicyclohexyl and bicycloheptyl, wherein the
cycloalkyl is
optionally partially or fully halogenated and optionally substituted with one
to three
C1_3 alkyl groups;

d) C;_7 cycloalkenyl selected from the group consisting of cyclopentenyl,
cyclohexenyl,
cyclohexadienyl, cycloheptenyl, cycloheptadienyl, bicyclohexenyl and

bicycloheptenyl, wherein such cycloalkenyl group is optionally substituted
with one
to three C1_3 alkyl groups;

14


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
e) acetyl, aroyl. alkoxycarbonylalkyl or phenylsulfonyl; or

f) CI_6 branched or unbranched alkyl optionally partially or fullv
halo"enated;
or R, and R-? taken together may optionally form a fused phenyl or pyridinyl
ring;
each R8 and R13 is independently selected from the group consisting of:
hydrogen and C1_4 branched or unbranched alkyl optionally be partially or
ftilly
halogenated;

each R4, R;, R6. R7, R9, Rlo, R, i and R12 is independently selected from the
group
consisting of morpholine, piperidine, piperazine, imidazole and tetrazole;

mis0,1or2;
WisOorS and

pharmaceutically acceptable derivatives thereof.

In one embodiment of the invention there are compounds of the formula(I) as
provided
above and wherein:

Ar2 is naphthyl, tetrahydronaphthyl, indanyl or indenyl and
WisO.

In another embodiment of the invention, there are the compounds of the formula
(I) as
provided immediately above and wherein:
Arl is selected from thiophene and pyrazole;


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
X is C5_7 cycloalkyl or C5_7cycloalkenyl optionally substituted Nvith 0-2 oxo
groups
or 0-3 C 1_4 branched or unbranched alkyl, C 1_4 alkoxy or C 1_4 alkylamino;
or X is phenyl,
pyridine, tetrahvdropyridine, pyrimidine, furan or thiophene each being
optionally
independently substituted with 0-3 C1_4 branched or unbranched alkyl.
Cl_4alkoxy,
hydroxv, nitrile, mono- or di-(Ci_3 alkyl)amino, C1_6 alkyl-S(O)m or halogen;
Ri is Ci-4alkyl branched or unbranched, cyclopropyl or cyclohexyl optionally
partially or fully halogenated and optionally substituted with one to three
Ci_3 alkyl
groups;
R3 is CI _aalkyl branched or unbranched, phenyl, pyrimidinyl, pvrazolyl or
l0 pyridinyl each being optionally substituted as described hereinabove in the
broadest
generic aspect, alkoxycarbonylalkyl or cyclopropyl or cyclopentyl optionally
substituted
as described hereinabove in the broadest generic aspect.

In yet another embodiment of the invention are the compounds of the formula(I)
as
provided immediately above and wherein:

Arl is pyrazole;

X is cyclopentenyl, cyclohexenyl or cycloheptenyl, optionally substituted with
an
oxo group or 0-3 C1_4 branched or unbranched alkyl, C1_4alkoxy or
C1_aalkylamino; or X
is phenyl, pyridine, furan or thiophene each being optionally independently
substituted
with 0-3 C1 _a branched or unbranched alkyl, CI _4alkoxy, hydroxy, nitrile,
mono- or di-
(C1_3 alkyl)amino, C1_6 alkyl-S(O),,, or halogen.

In yet still another embodiment of the invention there the compounds of the
formula(I) as
provided immediately above and wherein:
Y is -CH2-, -CH2CH2-, -CH2NH-, -CH2CH2NH- or a bond;
and
Z is

phenyl, imidazole, furan, piperazine, tetrahydropyran, morpholine,
thiomorpholine,
thiomorpholine sulfoxide, piperidine, pyridine, secondary or tertiary amine
wherein the
amino nitrogen is covalently bonded to groups selected from the group
consisting of C1_3
16


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
alkyl and Ci_; alkoxyalk\1l. phenvlamino wherein the phenyl ring is optionally
substituted
with one to two halogen. C i_6 alkoxy. hvdroxy or mono- or di-(C i_3
alkvl)amino, CI_6
alkyl-S(O),,, and phenyl-S(O),,, wherein the phenvl ring is optionallv
substituted with one
to two halogen, Ci_6 alkoxy, hydroxy or mono- or di-(Cl_3 alkyl)amino.

In yet a further embodiment of the invention there are the compounds of the
formula(I) as
provided immediately above and wherein:
Arl is 5-tert-butyl-pyrazol-3-yl; wherein the pyrazole ring may be substituted
by
R3;
R3 is C14alkyl branched or unbranched, phenyl, pyrimidinyl, pyrazolyl,
pyridinyl
each being optionally substituted as described hereinabove in the broadest
generic aspect,
alkoxycarbonylalkvl or cyclopropyl or cyclopentyl optionally substituted as
described
hereinabove in the broadest generic aspect.

In a still yet further embodiment of the invention there are the compounds of
the
formula(I) as provided immediately above and wherein X is pyridinyl.

In yet another further embodiment of the invention there are the compounds of
the
formula(I) as provided immediately above and wherein the pyridinyl is attached
to Arl
via the 3-pyridinyl position.

The following are representative compounds of formula(I) of the invention:
1-[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-
yl)phenyl)naphthalen-l-
yl]urea;

1-[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl-
methyl)phenyl)naphthalen-l-yl]urea;
1 -[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(2-(morpholin-4-
yl)ethyl)phenyl)naphthalen-l-yl]urea;
1 -[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-
dimethylaminophenyl)naphthalen-l-
yl]urea;

17


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-[5-tert-butyl-2p-tolti 1-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-
yl)phenyl)naphthalen-1-
yl]urea;

1-[5-tert-butyl-2p-tolvl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl-
methyl)phenyl)naphthalen-l-yl]urea;

1 -[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)naphthalen-l-yl]urea;

1- [5-tert-butyl-2p-tolyl-2H-pyrazol-3-yl]-3-[4-(5 -morpholin-4-ylmethyl-
pyridin-2-
yl)naphthalen-l-yl]urea;

1-[5-tert-butyl-2p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-morpholin-4-ylmethyl-fur-2-
yl)naphthalen-l-yl]urea;
1- [5-tert-butyl-2-(6-methyl-pyridin-3 -yl )-2H-pyrazo l -3 -yl] -3 - [4-(6-
morpholin-4-
ylmethyl-pyridin-3-yl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-
yl)naphthalen-l-yl]urea;

1-[5-tert-butyl-2-phenyl-2H-pyrazol-3-yl]-3-[4-(4-piperdin-l-ylmethyl-
phenyl)naphthalen-l-yl]urea;

1-[5-tert-butyl-2-phenyl-2H-pyrazol-3-yl]-3-[4-(4-(4-methylpiperazin-l-
yl)methylphenyl)naphthalen-l-yl]urea;
1 -[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(3,4-di(morpholin-4-yl-
methyl)phenyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-pyridin-4-
ylmethyl-
pyridin-3-yl)naphthalen-1-yl]urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-
thiomorpholin-4-ylmethyl)pyridin-3-yl)naphthalen-l-yl]urea;

1 -[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-thiomorpholin-4-
ylmethyl)pyridin-3-yl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-
tetrahydropyran-4-
ylmethyl-pyridin-3-yl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-
tetrahydrothiophen-3-ylmethyl)pyridin-3-yl)naphthalen-l-yl]urea;

18


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(imidazol-l-

ylmethyl)pyridin-3-yl)naphthalen-l-yl]urea;
1-[2-(3-dimethylaminomethylphenyl)-5-(1-methyl-cyclohexyl)-2H-p-razol-3-yl]-3-
[4-(6-
morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-l-yl]urea;
1-[2-(5-(1-methyl-cyclohexyl)-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-
(6-
morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-l-yl]urea;

1-[5-tert-butyl-2p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylmethyl-
pyrimidin-5-
yl)naphthalen-l-yl]urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-methoxy-5-
(2-
morpholin-4-yl-ethoxy)phenyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-
morpholin-4-yl-
ethoxy)phenyl)naphthalen-l-yl]urea;

1- [5-tert-butyl-2-(6-methyl-pyridin-3 -yl )-2 H-pyrazol-3 -yl] -3 - [4-3 -
(dimethylamino)phenyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-3-
(methylsulfonyl)phenyl)naphthalen-l-yl] urea;

5-tert-butyl-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-l-
yl]ureido}thiophene-2-carboxylic acid methyl ester;

5-tert-butyl-3- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3 -yl)naphthalen-l-
yl]ureido } thiophene-2-carboxylic acid methylamide;
5-tert-butyl-l-methyl-3-{ 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-
1-
yl]ureido}-1H-pyrrole-2-carboxylic acid methyl ester;

5-tert-butyl-l-methyl-3 - { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)naphthalen-l-
yl]ureido}-1H-pyrrole-2-carboxylic acid methylamide;

2-acetylamino N-(5-tert-butyl-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)naphthalen-
1-yl]ureido } thiophen-2-ylmethyl) acetamide;

1-[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-morpholin-4-yl-cyclohex-l-
enyl)naphthalen-l-yl]urea;

1-[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-morpholin-4-yl-cylohept-l-
enyl)naphthalen-l-yl]urea;

19


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-[5-tei-t-butyl-2-p-toly1-2H-pyrazol-3-yl]-3-[4-(3-(2-morpholin-4-vl-
ethylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-morpholin-4-yl-cvclohept-l-
enyl)naphthalen-l-yl]urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-y1)-2H-pyrazol-3-yl]-3-[4-(3-(pyridin-4-
yl-
methylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-( 6-methyl-pyridin-3 -yl )-2H-pyrazol-3-yl]-3 -[4-(3 -
(dimethylaminoethylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tet=t-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(pyridin-3-
yl-
methylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3 -yl)-2H-pyrazol-3-yl]-3 -[4-(3 -(phenyl-
methylamino)cvclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-
phenylethylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(furan-2-yl-

methylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-pyridin-
2-yl-
ethylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-piperdin-
l-yl-
ethylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tes t-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-
imidazol-4-yl-
ethylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3- [4-(3-(p),-ridin-
2-yl-
methylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-(4-
methoxyphenyl)ethylamino)cyclohex-l-enyl)naphthalen-l-yl]urea;

1-[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-morpholin-4-ylmethvl-3-oxo-
cyclohex-l-enyl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(1-oxo-tetrahydrothiophen-3-

ylmethyl)-3-oxo-cyclohex-l-enyl)naphthalen-l-yl]urea;



CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(1-oxo-thiomorpholin-4-
ylmethyl)-3-
oxo-cyclohex-l-enyl )naphthalen-l-yl]urea;

1 -[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-methylpiperazin-l-
ylmethyl)-3-oxo-
cyclohex-l-enyl)naphthalen-l-yl]urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4- { 6-oxo-1-
(tetrahydro-
pyran-4-ylmethyl)-1,2,3,6-tetrahydro-pyridin-4-yl} naphthalen- l -yl]urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(2-oxo-l-
pyridin-4-
ylmethyl-piperdin-4-yl)naphthalen-l-yl]urea;
1 -[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-oxo-l-pyridin-4-yl-1,2,3,6-
tetrahydro-
pyridin-4-yl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-oxo-l-
pyridin-4-yl-
1,2,3,6-tetrahydro-pyridin-4-yl)naphthalen-l-yl]urea;
5-tert-butyl-3- { 3-[4-(6-oxo-l-pyridin-4-yl-1,2,3.6-tetrahydro-pyridin-4-
yl)naphthalen-l-
yl]ureido}thiophene-2-carboxylic acid methyl ester;

5-tert-butyl-l-methyl-3- { 3-[4-(6-oxo-l-pyridin-4-yl-1,2,3,6-tetrahydro-
pyridin-4-
yl)naphthalen-l-yl]ureido}pyrrole-2-carboxylic acid methyl ester;

5-tert-butyl-l-methyl-3-{3-[4-(6-oxo-l-pyridin-4-yl-1,2,3,6-tetrahydro-pyridin-
4-
yl)naphthalen-l-yl]ureido}pyrrole-2-carboxylic acid methyl amide;
5-tert-butyl-3-{3-[4-(3-morpholin-4-yl-cyclohex-l-enyl)naphthalen-l-
yl]ureido}thiophene-2-carboxylic acid methyl ester;
5-tert-butyl-l-methyl-3-{ 3-[4-(3-morpholin-4-yl-cyclohex-l-enyl)naphthalen-1-
yl]ureido}pyrrole-2-carboxylic acid methyl ester; and

5-tert-butyl-l-methyl-3 - { 3-[4-(3-morpholin-4-yl-cyclohex-l-enyl)naphthalen-
l-
yl]ureido}pyrrole-2-carboxylic acid methyl amide and

the pharmaceutically acceptable derivatives thereof.

In another embodiment of the invention there are provided the following
compounds of
formula(I):

1-[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl-
methyl)phenyl)naphthalen-l-yl]urea;

21


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1 -[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(2-(morpholin-4-
y1)ethyl)phenyl)naphthalen-l-yl]urea;

1-[5-tei=t-butyl-2p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-yl-
methyl)phenyl)naphthalen-l-yl]urea;

1 -[5-tert-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)naphthalen-l-yl]urea;

1- [5-tert-butyl-2p-tolyl-2H-pyrazol-3 -yl] -3 -[4-(5-morpholin-4-ylmethyl-
pyridin-2-
yl)naphthalen-l-yl]urea;

1 -[5-te7 t-butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-morpholin-4-ylmethyl-fur-
2-
yl)naphthalen-l-yl]urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-y1)-2H-pyrazol-3-yl]-3-[4-(6-morpholin-4-

ylmethyl-pyridin-3 -yl)naphthalen-l-yl]urea:
1-[5-ter=t-butyl-2-methyl-2H-pyrazol-3-yl]-3 -[4-(6-morpholin-4-ylmethyl-
pyridin-3 -
yl)naphthalen- l -yl]urea and

the pharmaceutically acceptable derivatives thereof.
In another generic aspect of the invention, there are provided compounds of
the formula
(Ia):

W
Ar'--N N ,Ar2 X-Y-Z
I I
H H
(Ia)
wherein:

Arl is:

pyrrole, pyrrolidine, pyrazole, imidazole. oxazole, thiazole, furan and
thiophene;
22


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
wherein Arl is optionally substituted bv one or more Ri. R, or R;:

Ar2 is:

phenyl, naphthyl, quinoline, isoquinoline. tetrahydronaphthyl,
tetrahydroquinoline,
tetrahvdroisoquinoline, benzimidazole. benzofuran, indanyl, indenyl and indole
each
being optionally substituted with zero to three R2 groups;

Xis:
a C5_8 cycloalkyl or cycloalkenyl optionally substituted with one to two oxo
groups or one
to three C 1_4 alkyl, C1 -4 alkoxy or C 1_4 alkylamino chains each being
branched or
unbranched;

phenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, pyridinyl,
tetrahydropyridinyl,
pyrimidinyl, pyridinonyl, dihydropyridinonyl, maleimidyl, dihydromaleimidyl,
piperdinyl, benzimidazole, 3H-imidazo[4,5-b]pyridine, piperazinyl, pyridazinyl
or
pyrazinyl; each being optionally independently substituted with one to three
C1_4 alkyl,
Cl4alkoxy, hydroxy, nitrile, amino, mono- or di-(Ci_3 alkyl)amino, mono- or di-
(CI_3
alkylamino)carbonyl, NH2C(O), C1_6 alkyl-S(O)., or halogen;
Y is:

a bond or a C1 _4 saturated or unsaturated branched or unbranched carbon chain
optionally
partially or fully halogenated, wherein one or more C atoms are optionally
replaced by 0,
N, or S(O),,, and wherein Y is optionally independently substituted with one
to two oxo
groups, nitrile, phenyl, hydroxy or one or more C1 _4 alkyl optionally
substituted by one or
more halogen atoms;

Z is:

23


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
aryl, indanyl, heteroaryl selected from benzimidazolyl. pyridinyl,
pyrimidinyl,
pyridazinyl. pyrazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl.
thienyl and
pyranyl, heterocycle selected from piperazinyl, tetrahydropyrimidonyl,
cyclohexanonyl,
cyclohexanolyl. 2-oxa- or 2-thia-5-aza-bicyclo[2.2.1 ]heptanyl, pentamethylene
sulfidyl,
pentamethylene sulfoxidyl, pentamethylene sulfonyl, tetramethylene sulfidyl,
tetramethylene sulfoxidyl or tetramethylene sulfonyl, tetrahydropyranyl,
tetrahydrofuranyl, 1,3-dioxolanonyl, 1,3-dioxanonyl, 1,4-dioxanyl, morpholino,
thiomorpholino, thiomorpholino sulfoxidyl, thiomorpholino sulfonyl,
piperidinyl,
piperidinonyl, pyrrolidinyl and dioxolanyl,

lo each of the aforementioned Z are optionally substituted with one to three
halogen, C1_6
alkyl, CI_6 alkoxy, C i_3 alkoxy-C 1_3 alkyl, CI_6 alkoxycarbonyl, aroyl,
heteroaroyl,
heterocycleC I _3acy1 wherein the heteroaryl and heterocycle are as defined
hereinabove in
this paragraph, C1_3acyl, oxo, hydroxy, pyridinyl-C1 _3 alkyl, imidazolyl-C1_3
alkyl,
tetrahydrofuranyl-C1_3 alkyl, nitrile-C1_3 alkyl, nitrile, carboxy, phenyl
wherein the phenyl
ring is optionally substituted with one to two halogen, C1_6 alkoxy, hydroxy
or mono- or
di-(C1_3 alkyl)amino, amino-S(O),,,, C1_6 alkyl-S(O),, or phenyl-S(O),,,
wherein the phenyl
ring is optionally substituted with one to two halogen, C1_6 alkoxy, hydroxy,
halogen or
mono- or di-(C1_3 alkyl)amino;

or Z is optionally substituted with one to three amino, aminocarbonyl or amino-
C1_3 alkyl
wherein the N atom is optionally independently mono- or di-substituted by
aminoCl
6alkyl, C i_3alkyl, ary1C0_3alkyl, C i_; alkoxyC 1_3 alkyl, C1 _; alkoxy,
aroyl, CI _3acyl, CI _
3alkyl-S(O)m- or ary1C0_3alkyl-S(O),,,- each of the aforementioned alkyl and
aryl attached
to the amino group is optionally substituted with one to two halogen, C1_6
alkyl, C1_6
alkoxy, hydroxy or mono- or di-(C1_3 alkyl)amino;

or Z is optionally substituted with one to three aryl, heterocycle or
heteroaryl as
hereinabove described in this paragraph each in turn is optionally substituted
by halogen,
C1-6 alkyl or C1_6 alkoxy;

or Z is hydroxy, hydroxyC1.3alkyl, halogen, nitrile, amino wherein the N atom
is
optionally independently mono- or di-substituted by C1_6alkyl, aminoC1_6alkyl,
arylCo_
3alkyl, CI_; alkoxyC1_3 alkyl, C1_; alkoxy, aroyl, C1_3acy1, C1_3alkyl-S(O),n-
, ary1C0_3alkyl-
24


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
S(O),,,- , nitrileCi_4alkvl or Ci_3alkoxyCi_3alkyl, each ofthe aforementioned
alkyl and aryl
attached to the amino group is optionally substituted with one to two halogen,
Ci_6 alkyl,
Ci_6 alkoxy, hydroxy or mono- or di-(Ci_; alkvl)amino. CI_b
alkoxyheteroarvlCo_3alkyl,
heteroarylCO_3alkyl or heterocvcyleCO_3alkvl wherein the heteroaryl and
heterocycle is
hereinabove described in this paragraph,

or Z is C1_6alkyl branched or unbranched, C i_6alkoxy, C1_3acylamino, nitrileC
1_4alkyl, C1 _6
alkyl-S(O),,, and phenyl-S(O),,,. wherein the phenyl ring is optionally
substituted with
one to two halogen, C1_6 alkoxy, hydroxy or mono- or di-(CI_3 alkyl)amino;

R, is :

a) Ci_io branched or unbranched alkyl optionally partially or fully
halogenated, and
optionally substituted with one to three phenyl, naphthyl or heterocyclic
groups selected
from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,
pyrrolyl,
imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl and isothiazolyl; each such
phenyl,
naphthyl or heterocycle, selected from the group hereinabove described, being
substituted
with 0 to 5 groups selected from the group consisting of halogen, C1_6
branched or
unbranched alkyl which is optionally partially or ftilly halogenated, C3_8
cycloalkyl, C5_8
cycloalkenyl, hydroxy, nitrile, C1_3 alkyloxy which is optionally partially or
fully
halogenated, NH2C(O) and di(C I _3)alkylaminocarbonyl;
b) C3_7 cycloalkyl selected from the group consisting of cyclopropyl,
cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, bicyclopentyl, bicyclohexyl and
bicycloheptyl,
each optionally partially or fully halogenated and optionally substituted with
one to three
C1-3 alkyl groups, or an analog of such cycloalkyl group wherein one to three
ring
methylene groups are replaced by groups independently selected from the group
consisting of O, S, CHOH, >C=O, >C=S and NH;

c) C3_10 branched alkenyl optionally partially or fully halogenated and
optionally
substituted with one to three CI_; branched or unbranched alkyl, phenyl,
naphthyl or
heterocyclic groups, with each such heterocyclic group being independently
selected
10 from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl,
pyridazinyl, pyrrolyl,
imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl and isothiazolyl, and each
such phenyl,


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
naphthyl or heterocyclic group being substituted with 0 to 5 groups selected
from the
group consisting of halogen, CI_6 branched or unbranched alkyl which is
optionally
partially or fully halogenated, cyclopropyl. cyclobutyl. cyclopentanyl,
cyclohexanyl,
cycloheptanyl. bicyclopentanyl, bicvclohexanyl, bicycloheptanyl, hydroxy,
nitrile. Ci_;
alkoxy which is optionally partially or fully halogenated, NH2C(O) and mono-
or di(Cl_
3)alkylaminocarbonyl;

d) a C5_7 cycloalkenyl selected from the aroup consisting of cyclopentenyl,
cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, bicyclohexenyl
and
bicycloheptenyl, wherein such cycloalkenyl group is optionally substituted
with one to
three C1 _3 alkyl groups;
e) nitrile; or

f) CI_6 branched or unbranched alkoxvcarbonyl. C i_6 branched or unbranched
alkylaminocarbonyl, C1_6 branched or unbranched alkylcarbonvlamino-C1_3-alkyl;
R2 is:

a C1_6 branched or unbranched alkyl optionally partially or fully halogenated
and
optionally substituted with nitrile,
or R2 is acetyl, aroyl, CI_a branched or unbranched alkoxy optionally
partially or fully
halogenated, halogen, methoxycarbonyl or phenylsulfonyl;

R3 is:

a) phenyl, naphthyl or heterocyclic group selected from the group consisting
of
pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl,
pyrazolyl, thienyl,
furyl, tetrahydrofuryl, isoxazolyl, isothiazolyl, quinolinyl, isoquinolinyl,
indolyl,
benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl,
benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl, naphthypyridinyl,
quinoxalinyl,
quinazolinyl, purinyl and indazolyl, wherein such phenyl, naphthyl or
heterocyclic group
is optionally substituted with one to five groups selected from the group
consisting of a
phenyl, naphthyl, heterocycle selected from the group hereinabove described in
this

26


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
paragraph, C1_6 branched or unbranched alkyl which is optionally partially or
fully
halogenated, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
bicyclopentyl, bicyclohexyl, bicycloheptyl, phenyl C1 _; alkyl, naphthyl CI_;
alkyl,
halogen, hydroxy, oxo. nitrile, C1_3 alkoxy optionally partially or fully
halogenated, C1_3
alkoxyC j_;alkyl, CI_3thioalkyl, C i_3thioalkylC j_;alkyl, phenyloxy,
naphthyloxy,
heteraryloxy wherein the heterocyclic moiety is selected from the group
hereinabove
described in this paragraph, nitro, amino, mono- or di-(C1_3)alkylamino,
phenylamino,
naphthylamino, heterocyclylamino wherein the heterocyclyl moiety is selected
from the
group hereinabove described in this paragraph, NH2C(O), a mono- or di-
(C1_3)alkyl
aminocarbonyl, CI_; alkyl-C(O)-C i_4 alkyl, amino-C 1_; alkyl, mono- or di-(C
l_
3)alkylamino-C1_5 alkyl, amino-S(O)2, di-(C1_3)alkylamino-S(O)z, R4 -
C1_;alkyl, R5-C1 _5
alkoxy, R6 -C(O)-C 1_; alkyl and R7 -C 1_; alkyl(Rs)N, carboxy-mono- or di-(C
1_; )-alkyl-
amino;

b) a fused aryl selected from the group consisting of benzocyclobutanyl,
indanyl,
indenyl, dihydronaphthyl, tetrahydronaphthyl, benzocycloheptanyl and
benzocycloheptenyl, or a fused heterocyclyl selected from the group consisting
of
cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine,
cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine,
cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline,
cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline,
cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole,
cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole,
cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and
cyclohexanothiophene; wherein the fused aryl or fused heterocyclyl ring is
substituted
with 0 to 3 groups independently selected from the group consisting of phenyl,
naphthyl
and heterocyclyl selected from the group consisting of pyridinyl, pyrimidinyl,
pyrazinyl,
pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl. thienyl, furyl, isoxazolyl, and
isothiazolyl,
C1_6 branched or unbranched alkyl which is optionally partially or fully
halogenated,
halogen, nitrile, C1_3 alkoxy which is optionally partially or fully
halogenated, phenyloxy,
naphthyloxy, heterocyclyloxy wherein the heterocyclyl moiety is selected from
the group
hereinabove described, nitro, amino, mono- or di-(C1_3)alkylamino,
phenylamino,

27


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
naphthylamino. heterocyclylamino wherein the heterocyclyl moiety is selected
from the
group hereinabove described. NH)C(O), a mono- or di-(CI_3)alkyl aminocarbonyl,
Cl_4
alkyl-OC(O), CI _; alkvl-C(O)-C1 _4 branched or unbranched alkyl, an amino-CI
_; alkyl,
mono-ordi-(Ci_3)alkvlamino-Ci alkyl. R9-Cialkvl. R 10 -CIalkoxy. RiI -C(O)-Ci
alkyl and R i z-C Ialkyl(R i 3)N;
c) cycloalkvl selected from the group consisting of cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, bicyclopentyl, bicyclohexyl and
bicycloheptyl,
wherein the cycloalkyl is optionally partially or fully halogenated and
optionally
substituted with one to three C1_3 alkyl groups;

d) C5_7 cycloalkenyl selected from the group consisting of cyclopentenyl,
cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, bicyclohexenyl
and
bicycloheptenyl, wherein such cycloalkenyl group is optionally substituted
with one to
three C1 _3 alkyl groups;

e) acetyl, aroyl, C1_6alkoxycarbonylC1_6alkyl or phenylsulfonyl; or

f) C1_6 branched or unbranched alkyl optionally partially or fully
halogenated;
or RI and R2 taken together optionally form a fused phenyl or pyridinyl ring;

each R8 and R13 is independently selected from the group consisting of:
hydrogen and C i4 branched or unbranched alkyl optionally partially or fully
halogenated;

each R4, R5, R6, R7, R9, Rio. R, i and R12 is independently selected from the
group
consisting of morpholine, piperidine, piperazine, imidazole and tetrazole;

m is 0, 1 or 2;
WisOorS;

28


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
wherein X is directly attached to one or two -Y-Z, and
pharmaceuticallv acceptable derivatives thereof.

In one embodiment of the invention there are compounds of the formula(la) as
provided
above and wherein:

Ar2 is naphthyl, tetrahydronaphthyl. indanyl or indenyl and
WisO.

In another embodiment of the invention are compounds of the formula (Ia) as
provided
immediately above and wherein:


Ar] is thiophene or pyrazole each substituted independently by one to three
Ri, R2
or R3;

X is:

a C5_7 cycloalkyl or cycloalkenyl optionally substituted with one to two oxo
groups or one
to three C 1-4 alkyl, C1 -4 alkoxy or C i_4 alkylamino chains each being
branched or
unbranched;

phenyl, indanyl, furanyl, thienyl, imidazolyl, pyridinyl, pyrazinyl,
tetrahydrapyridinyl,
pyrimidinyl, pyridinonyl, piperdinyl, benzimidazole or piperazinyl; each being
optionally
independently substituted with one to three C1_4 alkyl. CI _4alkoxy, hydroxy,
nitrile, amino,
mono- or di-(C1_3 alkyl)amino, mono- or di-(C1_3 alkylamino)carbonyl, NH2C(O),
C1_6
alkyl-S(O),n or halogen;

Y is:

29


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
a bond or a Ci_4 saturated or unsaturated branched or unbranched carbon chain
optionally
partiallv or fullv halogenated, wherein one or more C atoms are optionally
replaced by 0
or N, and wherein Y is optionally independently substituted with one to two
oxo groups,
nitrile, phenyl, hydroxy or one or more CI_4alkyl optionally substituted by
one or more
halogen atoms;
Z is:

phenyl, heteroaryl selected from pyridinyl, imidazolyl, furanyl and thienyl,
heterocycle
1 o selected from piperazinyl, 2-oxa-5-aza-bicyclo [2.2. 1 ]heptanyl,
pentamethylene sulfidyl,
pentamethylene sulfoxidyl, pentamethylene sulfonyl, tetrahydrofuranyl,
morpholino,
thiomorpholino and piperidinyl,

each of the aforementioned Z are optionally substituted with one to three
halogen, C1_6
alkyl, C 1_6 alkoxy, C 1_3 alkoxy-C I_3 alkyl, C1 _6 alkoxycarbonyl, aroyl,
morpholinocarbonyl, C1_3acyl, oxo, hydroxy, pyridinyl-C1_3 alkyl, imidazolyl-
C1_3 alkyl,
tetrahydrofuranyl-C1_3 alkyl, nitrile-C1_3 alkyl, nitrile, carboxy, phenyl
wherein the phenyl
ring is optionally substituted with one to two halogen, C1 _6 alkoxy, hydroxy
or mono- or
di-(C1_3 alkyl)amino, amino-S(O),,,, C1_6 alkyl-S(O),,, or phenyl-S(O)rõ
wherein the phenyl
ring is optionally substituted with one to two halogen, CI_6 alkoxy, hydroxy,
halogen or
mono- or di-(C1_3 alkyl)amino;

or Z is optionally substituted with one to three amino, aminocarbonyl or amino-
C1_3 alkyl
wherein the N atom is optionally independently mono- or di-substituted by
aminoCl
6alkyl, C1_3alkyl, arylCO_3alkyl, C1_; alkoxyC1_3 alkyl, CI _; alkoxy, aroyl,
C1_3acyl, CI_
3alkyl-S(O),,,- or arylCo_3alkyl-S(O),,,- each of the aforementioned alkyl and
aryl attached
to the amino group are optionally substituted with one to two halogen, C1_6
alkyl or C1_6
alkoxy;

or Z is optionally substituted with one to three aryl. heterocycle or
heteroaryl as
hereinabove described in this paragraph each in turn is optionally substituted
by halogen,
C 1 -6 alkyl or C1 _6 alkoxy;




CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
or Z is hydroxy. hvdroxyCi_;alkyl, halo-en. nitrile, amino wherein the N atom
is
optionally independently mono- or di-substituted by aroyl, CI_3acy1,
Ci_6alkyl, Cj_;
alkoxyCi_3 alkyl, pyridinvlCi_;alkyl, tetrahydrafuranylC1_3alkyl.
nitrileC1_aalkyl or phenyl
wherein the phenyl ring is optionally substituted with one to two halogen,
Ci_6 alkoxy,
hydroxy or mono- or di-(Ci_3 alkyl)amino,

or Z is C1_6alkyl branched or unbranched, C1_6alkoxy or nitrileC1_4alkyl;
R, is:

Ci_a branched or unbranched alkyl optionally partially or fully halogenated;
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl optionally
partially or
fully halogenated and optionally substituted with one to three C1_3 alkyl
groups, or an
analog of such cycloalkyl group wherein one to three ring methylene groups are
replaced
by groups independently selected from the group consisting of 0, S and NH;

C3_10 branched alkenyl optionally partially or fully halogenated and
optionally substituted
with one to three Cl_; branched or unbranched alkyl;

cyclopentenyl and cyclohexenyl optionally substituted with one to three C1 _3
alkyl groups;
R2 is:

a C1_6 branched or unbranched alkyl optionally partially or fully halogenated
and
optionally substituted with nitrile;

R3 is:

phenyl or heterocyclic group selected from the group consisting of pyridinyl,
pyrimidinyl, pyrazinyl, pyridazinyl and pyrazolyl, wherein such phenyl or
heterocyclic
31


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
group is optionally substituted with one to five oroups selected from the
aroup consisting
of a phenyl, heterocycle selected from the group hereinabove described in this
paragraph,
CI_6 branched or unbranched alkyl which is optionally partially or fully
halogenated,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclopentyl,
bicyclohexyl, bicycloheptyl, phenyl C i_; alkyl, naphthyl C i_; alkyl.
halogen, hydroxy,
oxo, nitrile, C1 _3 alkoxy optionally be partially or fully halogenated, C1 _3
alkoxyC1 _;alkyl,
C1_3thioalkyl, Ci_3thioalkylCi_;alkyl, phenyloxy, naphthyloxy, heteraryloxy
wherein the
heterocyclic moiety is selected from the group hereinabove described in this
paragraph,
nitro, amino, mono- or di-(CI_3)alkylamino, phenylamino, naphthylamino,
1 o heterocyclylamino wherein the heterocyclyl moiety is selected from the
group
hereinabove described in this paragraph, NH?C(O), a mono- or di-(Ci_3)alkyl
aminocarbonyl.. C i_; alkyl-C(O)-C i_4 alkyl, amino-C i_; alkyl, mono- or di-
(C l_
3)alkylamino-C 1 _5 alkyl, amino-S(O)z, di-(C 1 _3)alkylamino-S(O)2, R4 -C 1
_5 alkyl, R5 -C 1 _5
alkoxy, R6 -C(O)-C 1 _; alkyl and R7 -C 1_; alkyl(R8)N, carboxy-mono- or di-(C
1_5 )-alkyl-
amino;
a fused aryl selected from the group consisting of benzocyclobutanyl, indanyl,
indenyl;
wherein the fused aryl is substituted with 0 to 3 groups independently
selected from the
group consisting of phenyl, naphthyl and heterocyclyl selected from the group
consisting
of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl,
pyrazolyl, thienyl,
furyl, isoxazolyl, and isothiazolyl, C1_6 branched or unbranched alkyl which
is optionally
partially or fully halogenated, halogen, nitrile, C1_3 alkoxy which is
optionally partially or
fully halogenated, phenyloxy, naphthyloxy, heterocyclyloxy wherein the
heterocyclyl
moiety is selected from the group hereinabove described in this paragraph,
nitro, amino,
mono- or di-(C1_3)alkylamino, phenylamino, naphthylamino, heterocyclylamino
wherein
the heterocyclyl moiety is selected from the group hereinabove described in
this
paragraph, NH2C(O), a mono- or di-(CI_3)alkyl aminocarbonyl, C1_4 alkyl-OC(O),
C1_5
alkyl-C(O)-C 1_4 branched or unbranched alkyl, an amino-C 1_; alkyl, mono- or
di-(C i_
3)alkylamino-C I_; alkyl, R9 -C 1_5 alkyl, RIo -C1_; alkoxy, RI1-C(O)-C 1_5
alkyl and RI Z-C i_
; alkyl(R13)N;


32


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
cycloalkyl selected from the group consisting of cyclopropyl, cyclobutyl,
cyclopentyl,
cyclohexyl, cvcloheptvl. wherein the cycloalkyl is optionally partially or
fully
halogenated and optionally substituted with one to three C1_3 alkyl groups;

C i _6alkoxycarbonylC 1_6alkyl;

or R, and R2 taken together optionally form a fused phenyl or pyridinvl ring;
each R8 and R13 is independently selected from the group consisting of:
hydrogen and CI_4 branched or unbranched alkyl optionally partially or fully
halogenated;
and

each R4, R5, R6, R7, R9, Rlo, Rl l and R12 is independently selected from the
group
consisting of morpholine, piperidine, piperazine, imidazole and tetrazole;


wherein X is directly attached to one -Y-Z.

In yet still another embodiment of the invention there are the compounds of
the
formula(Ia) as provided immediately above and wherein:

Arl is pyrazole;
X is:

cyclopentenyl, cyclohexenyl, cycloheptenyl, optionally substituted with an oxo
group or
one to three C1-4 alkyl, C I_4 alkoxy or C1 _4 alkylamino chains each being
branched or
unbranched;

33


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
phenyl, furanyl, thienyl, pyridinyl, pyrazinyl piperidinyl or pyrimidinyl each
beina
optionally independently substituted with one to three Ci_2 alkyl. Ci_2alkoxy,
hydroxy or
halogen;

Z is:

phenyl, heteroaryl selected from pyridinyl. imidazolyl and furanyl,
heterocycle selected
from 2-oxa-5-aza-bicyclo [2.2. 1 ]heptanyl, pentamethylene sulfidyl,
pentamethylene
sulfoxidyl, pentamethylene sulfonyl, tetrahydrofuranyl, tetrahydropyranyl,
piperazinyl,
morpholino, thiomorpholino, thiomorpholino sulfoxide and piperidinyl,
each of the aforementioned Z are optionally substituted with one to three
halogen, C1_6
alkyl, C i_6 alkoxy, C i_3 alkoxy-C I_3 alkyl, CI_6 alkoxycarbonyl, aroyl,
morpholinocarbonyl, C 1_3acyl, oxo, hydroxy, pyridinyl-C 1 _3 alkyl,
imidazolyl-C 1_3 alkyl,
tetrahydrofuranyl-C1_3 alkyl, nitrile-C1_3 alkyl, nitrile, carboxy, phenyl
wherein the phenyl
ring is optionally substituted with one to two halogen, C1_6 alkoxy, hydroxy
or mono- or
di-(C1_3 alkyl)amino, amino-S(O),,,, C1_6 alkyl-S(O),,,, or phenyl-S(O)Tõ
wherein the phenyl
ring is optionally substituted with one to two halogen, C1_6 alkoxy, hydroxy,
halogen or
mono- or di-(C1_3 alkyl)amino;
or Z is optionally substituted with one to three amino, aminocarbonyl or amino-
Ci_3 alkyl
wherein the N atom is optionally independently mono- or di-substituted by
aminoC ]_
6alkyl, C1 _3alkyl, arylCo_3alkyl, C1_; alkoxyC 1 _3 alkyl, C1_; alkoxy,
aroyl, CI _3acy1, CI _
3alkyl-S(O),n-, pyridinylCO_3alkyl, tetrahydrafuranylCO_3alkyl, or
arylCO_3alkyl-S(O),,,-
each of the aforementioned alkyl and aryl attached to the amino group is
optionally
substituted with one to two halogen, C1_6 alkyl or C1 _6 alkoxy;


or Z is hydroxy, hydroxyC1_3alkyl, halogen, nitrile, amino wherein the N atom
is
optionally independently mono- or di-substituted by C1_6alkyl,
pyridinylCO_3alkyl,
tetrahydrafuranylCO_3alkyl, Ci_; alkoxyC1_3 alkyl, C1_3acyl, nitrileC1_4alkyl
or phenyl
wherein the phenyl ring is optionally substituted with one to two halogen,
C1_6 alkoxv,
hydroxy or mono- or di-(C1_3 alkyl)amino,

or Z is C 1_6alkyl branched or unbranched, CI _6alkoxy or nitrileC 1_4alkyl;
34


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
RI is:

CI-4 branched or unbranched alkyl optionally partially or fully halogenated;

cyclopropyl, cyclobutyl, cyclopentanyl. cyclohexanyl and cycloheptanyl
optionally
partially or fully halogenated and optionally substituted with one to three C1-
3 alkyl
groups, or an analog of such cycloalkyl group wherein one to three ring
methylene
groups are replaced by groups independently selected from the group consisting
of O, S
1 o and NH;

C3-10 branched alkenyl optionally partially or fully halogenated and
optionally substituted
with one to three C I-3 branched or unbranched alkyl;

cyclopentenyl and cyclohexenyl optionally substituted with one to three C1-3
alkyl groups;
R2 is:

a C1_6 branched or unbranched alkyl optionally partially or fully halogenated
and
optionally substituted with nitrile;

R3 is:

phenyl or heterocyclic group selected from the group consisting of pyridinyl,
pyrimidinyl, pyridazinyl and pyrazolyl, wherein such phenyl or heterocyclic
group is
optionally substituted with one to five groups selected from the group
consisting of a
phenyl, heterocycle selected from the group hereinabove described in this
paragraph, C1-6
branched or unbranched alkyl which is optionally partially or fully
halogenated, phenyl
CI-5alkyl, halogen, hydroxy, oxo, nitrile, C1-3 alkoxy optionally partially or
fully
halogenated, C1-3thioalkyl, CI-3thioalkylCl-;alkyl, amino, mono- or di-
(C1_3)alkylamino,
NH2C(O) or a mono- or di-(C 1-3)alkyl aminocarbonyl,



CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
C 1_6alkoxycarbonyl C 1_6alkyl;

or R3 is cyclopropyl or cyclopentyl each optionally partially or fully
halogenated and
optionally substituted with one to three Cl_3 alkyl groups

or R, and R, taken together optionally form a fused phenyl or pyridinyl ring.

to In yet a further embodiment of the invention there are the compounds of the
formula(Ia)
as provided immediately above and wherein:

Y is -CH?-, -O-(CH2)0_3-, -CH2~CH-2-, -CH2NH-. -CH2CH2-NH-, NH-CH2CH2-,
-CH2-NH-CH2-, -NH-, -NH-C(O)-, -C(O)-, -CH(OH)-, -CH2(CH2CH3)- or a bond;

X is:
cyclohexenyl optionally substituted with an oxo group or one to three C1_4
alkyl, C1_4
alkoxy or CI_4 alkylamino chains each being branched or unbranched;

phenyl, pyridinyl, pyrazinyl, piperidinyl or pyrimidinyl each being optionally
independently substituted with one to three Ci_2 alkyl, C1_2alkoxy, hydroxy or
halogen;
Z is:

phenyl, heteroaryl selected from pyridinyl, imidazolyl and furanyl,
heterocycle selected
from 2-oxa-5-aza-bicyclo[2.2.1]heptanyl, pentamethylene sulfidyl,
pentamethylene
sulfoxidyl, pentamethylene sulfonyl, tetrahydrofuranyl, tetrahydropyranyl,
piperazinyl,
morpholino, thiomorpholino, thiomorpholino sulfoxide and piperidinyl,
each of the aforementioned Z are optionally substituted with one to three
halogen, C1_6
3o alkyl, C 1_6 alkoxy, C 1_3 alkoxy-C 1_3 alkyl, C 1_6 alkoxycarbonyl, aroyl,
morpholinocarbonyl, C1_3acyl, oxo, hydroxy, pyridinyl-C1_3 alkyl, imidazolyl-
C1_3 alkyl,

36


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
tetrahydrofuranyl-C 1 _; alkyl. nitrile-C i_; alkyl. nitrile, carboxy, phenyl
wherein the phenyl
ring is optionally substituted with one to tvo halogen, C1_6 alkoxy, hydroxy
or mono- or
di-(Ci_3 alkyl)amino. amino-S(O),,,, CI_6 alkyl-S(O),,,, or phenyl-S(O),,,
wherein the phenyl
ring is optionally substituted with one to txvo halogen, Ci_6 alkoxy, hydroxy,
halogen or
mono- or di-(C I_3 alkvl)amino;
or Z is optionally substituted with one to three amino or aminocarbonyl
wherein the N
atom is optionally independently mono- or di-substituted by aminoC1_6alkyl,
C1_3alkyl,
ary1C0_3alkyl, C i_5 alkoxyC 1_3 alkyl, Cj_; alkoxy, aroyl, CI_3acyl,
Cj_3alkyl-S(O),,,- or
arylCo_3alkyl-S(O),n- each of the aforementioned alkyl and aryl attached to
the amino
group is optionally substituted with one to two halogen, C1 _6 alkyl or C 1_6
alkoxy;
or Z is hydroxy, hydroxyCI _3alkyl, halogen. nitrile, amino wherein the N atom
is
optionally independently mono- or di-substituted by C1_3alkyl,
pyridinylCl_,alkyl,
tetrahydrafuranylC 1_2alkyl, C1 _3 alkoxyC 1_3 alkyl, CI _3acy1, nitrileC
i_aalkyl, phenyl
wherein the phenyl ring is optionally substituted with one to two halogen, C1
_6 alkoxy,
hydroxy or mono- or di-(C1_3 alkyl)amino,
or Z is C1_6alkyl branched or unbranched, C1_6alkoxy or nitrileCi_4alkyl;
Ri is:

Ci_4 branched or unbranched alkyl optionally partially or fully halogenated;
R2 is:

a CI-3 branched or unbranched alkyl optionally partially or fully halogenated
and
optionally substituted with nitrile;

R3 is:

phenyl or heterocyclic group selected from the group consisting of pyridinyl,
pyrimidinyl, and pyrazolyl, wherein such phenyl or heterocyclic group is
optionally
37


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
substituted with one to five groups selected from the group consisting of Ci_3
branched or
unbranched alkyl which is optionally partially or fully halogenated, C i_;
alkoxy which
optionally partially or fully halogenated. C i_3thioalkyl, C1_3thioalkylC 1
_;alkyl, amino or
NH-)C(O);
C I_3alkoxycarbonyl;

or R3 is cyclopropyl or cyclopentyl each optionally partially or fully
halogenated and
optionally substituted with one to three CI_3 alkyl groups.

In a yet still further embodiment of the invention there are the compounds of
the
formula(Ia) as provided immediately above and wherein:

Ari is 5-tert-butyl-pyrazol-3-yl; wherein the pyrazole ring is substituted
independently by one to two R2 or R3;

X is:
cyclohexenyl;

phenyl, pyridinyl, pyrazinyl, piperidinyl or pyrimidinyl each being optionally
independently substituted with C1_2alkoxy or hydroxy;

Z is:

phenyl, heteroaryl selected from pyridinyl and furanyl, heterocycle selected
from 2-oxa-
5-aza-bicyclo[2.2.1]heptanyl, pentamethylene sulfidyl, pentamethylene
sulfoxidyl,
tetrahydrofuranyl, piperazinyl, morpholino, thiomorpholino and piperidinyl,
each of the aforementioned Z are optionally substituted with one to three C1_3
alkyl, C1_3
alkoxy, oxo , hydroxy or NH2C(O)-;

38


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
or Z is hydroxyC i_ 3alkyl, amino wherein the N atom is optionally
independently mono- or
di-substituted by pyridinylmethyl, tetrahydraftiranylmethyl, Ci_3 alkoxyC1_3
alkyl, Ci_3acyl
or nitrileCI_aalkyl,
or Z is nitrileCi_aalkyl;
R3 is:

phenyl or heterocyclic group selected from the group consisting of pyridinyl,
pyrimidinyl, and pyrazolyl, wherein such phenyl or heterocyclic group is
optionally
substituted with one to two groups selected from the group consisting of C1_2
alkyl which
is optionally partially or fully halogenated. C1_2 alkoxy which optionally
partially or fully
halogenated, CI_zthioalkyl, CI_zthioalkylC i_3alkyl, amino or NHzC(O);
Ci_3alkoxycarbonyl;


or R3 is cyclopropyl or cyclopentyl each optionally partially or fully
halogenated and
optionally substituted with one to three C1_3 alkyl groups.

In an even further embodiment of the invention there are the compounds of the
formula(Ia) as provided immediately above and wherein X is pyridinyl.

In a yet still even further embodiment of the invention there are compounds of
the
formula(la) as provided immediately above and wherein the pyridinyl is
attached to Arl
via the 3-pyridinyl position.

The following are representative compounds of formula(la) of the invention:
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3 -yl]-3-[4-(4-morpholin-4-yl-
methylphenyl)-
naphthalen-l-yl]-urea;

39


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[3-(4-morpholin-4-yl-
methylphenyl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-morpholin-4-yl-methylfuran-
2-yl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-4-y1-
methyl)cyclohexenyl)-naphthalen-l-yl]-urea; 10

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(4-morpholin-4-
yl)ethylphenyl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3 -yl]-3 -[4-(4-
dimethylaminomethylphenyl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-4-yl-
methyl)pyridin-2-yl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-
methyl)pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3 -yl]-3-[4-(6-(morpholin-
4-yl-
methyl)pyridin-3-yl)-naphthalen-l-yl] -urea;
1-[5-tert-butyl-2-methyl-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-
methyl)pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-
(morpholin-4-
yl)ethylamino)cyclohexenyl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3,4-(morpholin-4-yl-
methyl)phenyl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-methylpiperzin-l-yl-
methyl)phenyl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3 -yl]-3-[4-(piperdin-l-yl-methyl)phenyl)-

naphthalen- I -yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-(pyridin-
2-
yl)ethylamino)cyclohexenyl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(2-(pyridin-4-
yl)ethylaminomethyl)phenyl)naphthalen-l-yl]-urea;


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-[5-tert-butyl-2-p-tolvl-2H-pyrazol-3-yl]-3-[4-(4-(pvridin-3-yl-
methylaminomethyl)phenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(3,4-
dimethoxyphenylmethyl)-3-hydroxyphenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3 -yl]-3-[4-(6-oxo-1,6-dihydro-pyridin-3-
yl)naphthalen- I -vl]-urea;

t 0 1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-
(morpholin-4-yl-
methyl)phenyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-
4-yl-
methyl)imidazol-l-yl)naphthalen-1-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-4-yl-
methyl)imidazol-l-
yl)naphthalen-1-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl] -3-[4-(4-(furan-3-
yl-methyl)-3-
hydroxyphenyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3 -yl]-3-[4-(6-(4-
hydroxybutylamino)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(pyridin-3-
yl-methyl)-
3-hydroxyphenyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(4-methyl-3-carbamylphenyl)-2H-pyrazol-3-yl]-3-[4-(6-
(morpholin-4-
yl-methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(imidazol-2-
yl-
methyl)-3-hydroxyphenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(3-
hydroxymorpholin-
4-yl-methyl)phenyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3 -yl]-3-[4-(4-(N-2-
methoxyethy-N-
methylaminomethyl)phenyl)naphthalen-l-yl] -urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(4-
hydroxymorpholin-
4-yl-methyl)phenyl)naphthalen-l-yl] -urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-
4-yl-
methyl)cyclohexenyl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-
(tetrahydrofuran-3-yl-
41


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
methyl)-3-hydroxyphenvl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N.N-di-(2-
methoxyethyl)aminomethyl)phenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(3-
cyanopropoxy)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-morpholin-4-
yl-

methyl-piperdinyl)naphthalen-l-yl]-urea; 1-[5-tert-butyl-2-(6-methyl-pyridin-3-
yl)-2H-pyrazol-3-yl]-3-[4-(4-(N.N-di-(2-
cyanoethyl)aminomethyl)phenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(1-morpholin-4-yl-indan-5-yl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(furan-2-yl-
methyl)-3-
hydroxyphenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-
(thiomorpholin-4-yl-
methyl)phenyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3 -yl)-2H-pyrazol-3-yl]-3 -[4-(4-(3 -
carboxamidomorpholin-4-yl-methyl)phenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(2-methyl-3-
oxo-
piperzin-l-yl-methyl)phenyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-
4-yl-
methyl)pyridin-3 -yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3 -yl)-2H-pyrazol-3-yl]-3-[4-(6-(4-
hydroxybutyloxy)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[3-tert-butyl-1'H-[ 1,4']bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-
methyl)pyridin-3-
yl)naphthalen-I -yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(furan-2-yl-
methyl)-3-
methoxyphenyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-
4carbonyl)pyrazin-2-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3 -yl)-2H-pyrazol-3-yl]-3-[4-(6-
(tetrahydrothiopyran-
4-yl-amino)pyridin-3 -yl)-naphthalen-l-yl] -urea;
42


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-[5-tert-butyl-2-(2-cyanoethyl)-2H-pyrazol-3 -yl]-3-[4-(6-(morpholin-4-yl-
methyl)pyridin-3 -y l )-naphthalen-l-yl] -urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(2.6-
dimethylmorpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methoxypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-
4-yl-
methyl)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-aminoypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-
yl-
methyl)pyridin-3 -y 1)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-oxo-1,6-dihydropyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-
(morpholin-
4-yl-methyl)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-
4-y1-4-
carbonyl)pyridin-3-yl)-naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(2-oxa-5-
aza-
bicyclo[2.2.1 ]hept-5-yl-methyl)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(3-
carbamylphenyl)naphthalen-1-yl]-
urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-(2-
cyanoethyl)-N-
(pyridin-3-yl-methyl)aminomethyl)phenyl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-(2-
cyanoethyl)-N-
(pyridin-2-yl-methyl)aminomethyl)phenyl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-(2-
cyanoethyl)-N-
(tetrahydrofuran-2-yl-methyl)aminomethyl)phenyl)-naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-
4-yl-
methyl)-4-methoxypyridin-3 -yl)-naphthalen-l-yl] -urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-
morpholin-4-yl-
propyl)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(N-(3-
methoxypropyl)amino)pyridin-3 -yl)-naphthalen-l-yl] -urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(N-(3-
methoxypropyl)-N-methylamino)pyridin-3-yl)-naphthalen-l-yl]-urea;
43


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-[3-tert-butyl-1 '-methyl- I'H-[ 1,4']bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-

methyl)pyridin-3-yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-benzyl-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-
methyl)pyridin-3-yl)-
naphthalen- l -yl]-urea;

1-[5-tert-butvl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-N-di-(2-
cyanoethyl)aminomethyl)phenyl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(4-
carbamylphenyl)naphthalen-l-yl]-
urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)=2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-
tetrahydrothiopyran-4yl-amino)pyridin-3 -yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-
(tetrahydropyran-4yl-
amino)pyridin-3-yl)-naphthalen-l-yl]-urea; 1-[3-tert-butyl-1'-(3-cyanopropyl)-
1'H-[ 1,4']bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-

methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-
methanesulfinylphenyl)naphthalen-l-
yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-
methanesulfonylphenyl)naphthalen-l-
yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-
sulfonamidophenyl)naphthalen-l-yl]-
urea;
1-[5-tert-butyl-2-p-to lyl-2H-pyrazol-3 -yl]-3 - [4-(3 -(morphol in-4-
yl)carbonylphenvl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3- [4-(5-
(tetrahydrothiopyran-
4yl-amino)pyrazin-2-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl] -3-[4-(6-
(methylcarbony l am ino)py ridin-3 -yl )-naphthalen-l-y l]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3 -yl]-3-[4-(6-(morpholin-4-yl-4-
carbonyl)phenyl)-
naphthalen-l-yl]-urea;

1-[3-tert-butyl-1'-(3-methylsulfanylpropyl)-1'H-[1,4']bipyrazol-5-yl]-3-[4-(6-
(morpholin-
4-yl-methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3 -yl]-3-[4-(5-(morpholin-4-yl-
carbonyl)pyridin-3-
44


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
yl)-naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-
4-yl-
methyl)pyrazin-2-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-
aminopyridin-3-
yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-
methylpiperdin-4-
1 o yl-amino)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(2-methyl-
3-oxo-
piperzin-l-yl-methvl)pyridin-3-yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-
4-yl-
carbonyl)pyridin-3 -vl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(N,N-di-(2-

methoxyethyl)aminomethyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-
thiomorpholin-4-yl-methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-
(tetrahydropyran-4-
yl-amino)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-
4-yl-
methyl)pyrazin-2-yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(2-methylthiopyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-
(morpholin-4-
yl-methyl)pyridin-3 -yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3 -yl]-3-[4-(6-(2-methyl-3-oxo-piperzin-l-
yl-
methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1 -[5-tert-butyl-2-p-tolyl-2H-pyrazol-3 -yl]-3- [4-(6-(pyridin-3-yl-
oxy)pyridin-3-
yl)naphthalen-l-yl]-urea
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(pyridin-3-yl-amino)pyridin-
3-
yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methoxypyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-
(morpholin-4-yl-
methyl)pyridin-3-yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-carbamylpyridin-3-
yl)naphthalen-l-
yl]-urea;



CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-[5 -tert-butyl-2-(2-aminopyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-
4-yl-
methyl)pyridin-3-yl)naphthalen-l-vl]-urea;

1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(4-(morpholin-
4-yl-
methyl)phenyl)naphthalen-l-yl]-urea;

1-[3-tert-butyl-1'-methyl-1'H-[1,4']bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-
methyl)phenyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(2-cyclopropylpyrimidin-5-vl)-2H-pyrazol-3-yl]-3-[4-(6-
(morpholin-4-
yl-methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(pyridin-3-yl-
amino)pyrimidin-5-
yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-tetrahydrothiopyran-
4-yl-
amino)pyridin-3-yl)naphthalen-1-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(thiomorpholin-4-yl-
methyl)pyridin-3-
yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3-benzyl-3H-imidazo [4,5-
b]pyridin-6-
yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3 -yl)-2H-pyrazol-3-yl]-3-[4-(6-(pyridin-3-
yl-
methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-
carbonyl)pyrimidin-5-
yl)naphthalen-1-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-
methyl)pyrimidin-5-
yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(3 -amino-4-
carbamylphenyl)naphthalen-
1 -yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-thiomorpholin-4-yl-
methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(pyridin-3-yl-
methyl)pyridin-3-
yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(hydroxy-pyridin-3-yl-
methyl)pyridin-
3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-
4-yl-
46


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
methyl)pyrimidin-5-v1)naphthalen-l-yl]-urea;
and the pharmaceutically acceptable derivatives thereof.

In another embodiment of the invention there are provided the following
compounds of
the formula(Ia):

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(5-(morpholin-4-yl-
methyl)pyridin-2-yl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-yl-
methyl)pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(2-(pyridin-
2-
yl)ethylamino)cyclohexenyl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(4-(pyridin-3-yl-
methylaminomethyl)phenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3- [4-(4-(morpholin-
4-yl-
methyl)phenyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(4-
hydroxybutylamino)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(4-methyl-3 -carbamylphenyl)-2H-pyrazol-3-yl]-3-[4-(6-
(morpholin-4-
yl-methyl)pyridin-3-yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl] -3-[4-(4-(3-
hydroxypiperidin-
1-yl-methyl)phenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(4-
hydroxymorpholin-
4-yl-methyl)phenyl)naphthalen-l-yl] -urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(3-(morpholin-
4-yl-
methyl)cyclohexenyl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-
(tetrahydrofuran-3-yl-
methyl)-3-hydroxyphenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl.-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N,N-di-(2-

47


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
methoxyethyl)aminomethyl)phenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(3-
cyanopropoxy)pyridin-3-yl )naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-( 6-methyl-pyridin-3-yl)-2H-pyrazol-3 -yl] -3-[4-(4-
morpholin-4-yl-
methyl-piperdinyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N,N-di-(2-
cyanoethyl)aminomethyl)phenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(furan-2-yl-
methyl)-3-
hydroxyphenyl)naphthalen-l-yl] -urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3- [4-(4-
(thiomorpholin-4-yl-
methyl)phenyl)naphthalen-l-vl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(3-
carboxamidopiperidin-l-yl-methyl)phenyl)naphthalen-l-yl]-urea;
1- [5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3 -[4-(4-(2-methyl-
3-oxo-
piperzin-l-yl-methyl)phenyl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-
4-yl-
methyl)pyridin-3-yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(4-
hydroxybutyloxy)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[3-tert-butyl-1'H-[ 1,4']bipyrazol-5-yl] -3 -[4-(6-(morpholin-4-yl-
methyl)pyridin-3-
yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-
(tetrahydrothiopyran-
4-yl-amino)pyridin-3-yl)-naphthalen-l-yl]-urea;
1 -[5-tert-butyl-2-(2-cyanoethyl)-2H-pyrazol-3 -yl]-3-[4-(6-(morpholin-4-yl-
methyl)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(2,6-
dimethylmorpholin-4-yl-methyl)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methoxypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-
4-yl-
methyl)pyridin-3-yl)-naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(2-aminoypyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-4-
yl-
methyl)pyridin-3-yl)-naphthalen-l-yl]-urea;
48


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-[5-tert-butyl-2-( 6-methyl-pvridin-3-yl)-2H-pvrazol-3-vl]-3-[4-(6-(morpholin-
4-yl-4-
carbonyl)pyridin-3-yl)-naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(2-oxa-5-
aza-
bicyclo[2.2.1 ]hept-5-yl-methyl)pyridin-3-yl)-naphthalen-l -yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-(2-
cyanoethyl)-N-
(pyridin-3-yl-methyl)aminomethyl)phenyl)-naphthalen-l-yl]-urea;
lo
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(4-(N-(2-
cyanoethyl)-N-
(tetrahydrofuran-2-vl-methyl)aminomethyl)phenyl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-
4-yl-
methyl)-4-methoxypyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-
morpholin-4-yl-
propyl)pyridin-3-yl)-naphthalen-l-yl]-urea;

1-[3-tert-butyl-1'-methyl-1'H-[ 1,4']bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-
methyl)pyridin-3 -yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-
tetrahydrothiopyran-4yl-amino)pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-
(tetrahydropyran-4yl-
amino)pyridin-3-yl)-naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(5-
(tetrahydrothiopyran-
4yl-amino)pyrazin-2-yl)-naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-3-[4-(6-
(methylcarbonylamino)pyridin-3 -yl)-naphthalen-l-yl]-urea;

1-[3-tert-butyl-1'-(3-methylsulfanylpropyl)-1'H- [ 1,4']bipyrazol-5-yl]-3 -[4-
(6-(morpholin-
4-yl-methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3 -[4-(6-(1-oxo-
thiomorpholin-4-yl-methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-
(tetrahydropyran-4-
yl-amino)pyridin-3-vl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-metlrylthiopyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-
(morpholin-4-
yl-methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
49


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-[5-tert-butyl-2-(2-aminopyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(6-(morpholin-
4-yl-
methyl)pyridin-3-yl)naphthalen-l-yl]-urea;

1-[3-tert-butyl-1'-methyl-1'H-[1,4']bipyrazol-5-yl]-3-[4-(6-(morpholin-4-yl-
methyl)phenyl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-vl]-3-[4-(6-(1-oxo-tetrahydrothiopyran-
4-yl-
amino)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(thiomorpholin-4-yl-
methyl)pyridin-3-
yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-4-yl-
carbonyl)pyrimidin-5-
yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-vl]-3-[4-(2-(morpholin-4-yl-
methyl)pyrimidin-5-
yl)naphthalen-l-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-[4-(6-(1-oxo-thiomorpholin-4-yl-
methyl)pyridin-3-yl)naphthalen-l-yl]-urea;
1-[5-tert-butyl-2-(2-methylpyrimidin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-(morpholin-
4-yl-
methyl)pyrimidin-5-yl)naphthalen-l-yl]-urea and

the pharmaceutically acceptable derivatives thereof.
In yet another generic aspect of the invention, there are provided compounds
of the
formula (II):

W
G\ N N /Ar-X-Y-Z
I I
H H
(II)
wherein:



CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
Gis:
an aromatic C6_i0carbocycle or a nonaromatic C3_10 carbocycle saturated or
unsaturated;
a 6-10 membered heteroaryl containing 1 or more heteroatoms chosen from O, N
and S
a 5-8 membered monocyclic heterocycle containing one or more heteroatoms
chosen
from 0, N and S;

or
an 8-11 membered bicyclic heterocycle, containing one or more heteroatoms
chosen from
O,NandS;
wherein G is substituted by one or more RI, R-) or R3;
Ar is:

phenyl, naphthyl, quinolinyl, isoquinolinyl, tetrahydronaphthyl,
tetrahydroquinolinyl,
tetrahydroisoquinolinyl, benzimidazolyl, benzofuranyl, dihydrobenzofuranyl,
indolinyl,
benzothienyl, dihydrobenzothienyl, indanyl, indenyl or indolyl each being
optionally
substituted by one or more R4 or R5;

X is:
a C;_g cycloalkyl or cycloalkenyl optionally substituted with one to two oxo
groups or one
to three C1 _4 alkyl, C 14 alkoxy or C 1_a alkylamino chains;


phenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, pyridinyl,
pyrimidinyl,
pyridinonyl, dihydropyridinonyl, maleimidyl, dihydromaleimidyl, piperdinyl,
benzimidazole, 3H-imidazo[4,5-b]pyridine, piperazinyl, pyridazinyl or
pyrazinyl;
Y is:

51


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
a bond or a Ci_4 saturated or unsaturated branched or unbranclled carbon chain
optionally
partially or fully halogenated. wherein one or more methylene groups are
optionally
replaced by O. N. or S(O)1 ,, and wherein Y is optionally independently
substituted with
one to two oxo groups, phenyl or one or more C 1_4 alkyl optionally
substituted by one or
more halogen atoms;

Z is:

phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, imidazolyl, pyrazolyl,
triazolyl,
tetrazolyl, furanyl. thienyl, pyranyl each being optionally substituted with
one to three
halogen, C1_6 alkyl, CI_6 alkoxy, hydroxy. amino, mono- or di-(C1_3
alkyl)amino, C1_6
alkyl-S(O)r,,, CN, CONH2, COOH or phenylamino wherein the phenyl ring is
optionally
substituted with one to two halogen, C1_6 alkyl or C1_6 alkoxy;

tetrahydropyranyl, tetrahydrofuranyl, 1,3-dioxolanonyl, 1,3-dioxanonyl, 1,4-
dioxanyl,
morpholinyl, thiomorpholinyl, thiomorpholino sulfoxidyl, thiomorpholino
sulfonyl,
piperidinyl, piperidinonyl, piperazinyl, tetrahydropyrimidonyl,
cyclohexanonyl,
cyclohexanolyl, pentamethylene sulfidyl, pentamethylene sulfoxidyl,
pentamethylene
sulfonyl, tetramethylene sulfide, tetramethylene sulfoxidyl or tetramethylene
sulfonyl
each being optionally substituted with one to three nitrile, C1 _6 alkyl, C1_6
alkoxy,
hydroxy, amino, mono- or di-(CI_3 alkyl)amino-CI_3 alkyl, CONH2, phenylamino-
CI_3
alkyl or Ci_3 alkoxy-C1 _3 alkyl;

halogen, Ci-4 alkyl, nitrile, amino, hydroxy, Ci_6 alkoxy, NH2C(O), mono- or
di(C1_3alkyl)
aminocarbonyl, mono- or di(C1_6alkyl)amino, secondary or tertiary amine
wherein the
amino nitrogen is covalently bonded to C1_3 alkyl or CI_; alkoxyalkyl,
pyridinyl-C1_3 alkyl,
imidazolyl-C 1 _3 alkyl, tetrahydrofuranyl-C 1 _3 alkyl, nitrile-C 1 _3 alkyl,
carboxamide-C 1_3
alkyl, phenyl, wherein the phenyl ring is optionally substituted with one to
two halogen,
C1_6 alkoxy, hydroxy or mono- or di-(Cl_3 alkyl)amino, C1_6 alkyl-S(O),,,, or
phenyl-
52


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
S(O)1,1, wherein the phenyl ring is optionally substituted with one to two
halogen, Cl_6
alkoxy, hydroxy, halogen or mono- or di-(C 1_3 alkyl)amino;

C1_6 alkyl-S(O),,,, and phenyl-S(O),,,. wherein the phenyl ring is optionally
substituted
with one to two halogen. Ci_6 alkoxy, hydroxy or mono- or di-(C1_3
alkyl)amino;
each R, is independently:

Ci_1o alkyl optionally be partially or fully halogenated, and optionally
substituted with
1o one to three C3_10 cycloalkanyl, hydroxy, phenyl, naphthyl, pyridinyl,
pyrimidinyl,
pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl,
isoxazolyl or
isothiazolyl; each of the aforementioned being optionally substituted with one
to five
groups selected from halogen, C1_6 alkyl which is optionally partially or
fully
halogenated, C3_8 cycloalkanyl, C;_g cycloalkenyl, hydroxy, nitrile, Cl_3
alkoxy which is
optionally partially or fully halogenated or NH2C(O), mono- or di(CI
_3alkyl)amino, and
mono- or di(C1_3alkyl)aminocarbonyl;

cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, or
cycloheptyloxy each
being optionally partially or fully halogenated and optionally substituted
with one to three
C1_3 alkyl groups optionally partially or fully halogenated, CN,
hydroxyC1_3alkyl or aryl;
or an analog of such cycloalkyl group wherein one to three ring methylene
groups are
independently replaced by 0, S(O),,,, CHOH, >C=O, >C=S or NH;

phenyloxy or benzyloxy each being optionally partially or fully halogenated
and
optionally substituted with one to three C1_3 alkyl groups optionally
partially or fully
halogenated, CN, hydroxyC1_3alkyl or aryl; or an analog of such cycloaryl
group wherein
one to two ring methyne groups are independently replaced by N;

cyclopropanyl, cyclobutanyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,
3o bicyclopentanyl, bicyclohexanyl or bicycloheptanyl, each being optionally
partially or
fullv halogenated and optionally substituted with one to three C1_3 alkyl
groups optionally
53


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
partially or fully halogenated, CN. hvdroxyCi_3alkvl or arvl: or an analog of
such
cycloalkyl group wherein one to three ring methylene groups are independently
replaced
by 0. S(O)1,,. CHOH, >C=O, >C=S or NH;

C3_10 branched or unbranced alkenvl each being optionallv partially or fullv
halogenated,
and optionally be substituted with one to three Ci_; branched or unbranched
alkyl, phenyl,
naphthyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl,
imidazolyl, pyrazolyl,
thienyl, furyl. isoxazolyl or isothiazolyl, each of the aforementioned being
substituted
with zero to five halogen, C1_6 alkyl which is optionally partially or fully
halogenated,
cyclopropanyl, cyclobutanyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,
bicyclopentanyl, bicyclohexanyl and bicycloheptanyl, hydroxy, nitrile, C1_3
alkyloxy
which is optionally partially or fully halogenated, NH2C(O). mono- or di(Cl_
3alkyl)aminocarbonyl; the C3_10 branched or unbranced alkenyl being optionally
interrupted by one or more heteroatoms chosen from 0, N and S(O)1,,;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl,
bicyclohexenyl or bicycloheptenyl, wherein such cycloalkenyl group is
optionally
substituted with one to three CI_3 alkyl groups;

nitrile, halogen;

methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl;

silyl containing three Ci_4 alkyl groups optionally partially or fully
halogenated;

C3_6 alkynyl branched or unbranched carbon chain optionally partially or fully
halogenated, wherein one or more methylene groups are optionally replaced by
0, NH or
S(O),n and wherein said alkynyl group is optionally independently substituted
with one to
two oxo groups, pyrrolidinyl, pyrrolyl, one or more C1.4 alkyl optionally
substituted by
one or more halogen atoms, nitrile, morpholino, piperidinyl, piperazinyl,
imidazolyl,
phenyl, pyridinyl, tetrazolyl, or mono- or di(C1_3alkyl)amino optionally
substituted by
54


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
one or more halogen atoms;

each R-,. R4. and R; is

a CI_6 branched or unbranched alkyl optionally partially or fully halogenated,
acetvl,
aroyl, CI_4 branched or unbranched alkoxv. each being optionally partially or
fully
halogenated, halogen, nitrile, methoxvcarbonyl. CI_3 alkyl-S(O),,, optionally
partially or
fully halogenated. or phenylsulfonyl;

CI_6 alkoxy, hydroxy, amino, or mono- or di-(C I_4 alkyl)amino, nitrile,
halogen;
OR6;

nitro; or
mono- or di-(C I_a alkyl)amino-S(O)Z optionally partially or fully
halogenated, or
H2NSO2;

each R3 is independently:

phenyl, naphthyl, morpholinyl, pyridinyl. pyrimidinyl, pyrazinyl, pyridazinyl,
pyrrolyl,
pyrrolidinyl, imidazolyl, pyrazolyl, thiazolyl, oxazoyl, triazolyl,
tetrazolyl, thienyl, furyl,
tetrahydrofuryl, isoxazolyl, isothiazolyl. quinolinyl, isoquinolinyl, indolyl,
benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl,
benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl, naphthypyridinyl,
quinoxalinyl,
quinazolinyl, purinyl or indazolyl, each of the aforementioned is optionally
substituted
with one to three phenyl, naphthyl, heterocycle or heteroaryl as hereinabove
described in
this paragraph, CI_6 branched or unbranched alkyl which is optionally
partially or fully
halogenated., cyclopropanyl, cyclobutanyl, cyclopentanyl, cyclohexanyl,
cycloheptanyl,
bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenyl C1 _; alkyl, naphthyl
CI_; alkyl,
halogen, hydroxy, oxo, nitrile, Ci_3 alkyloxy optionally partially or fully
halogenated,


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
phenyloxy, naphthyloxy, heteroaryloxy or heterocyclicoxy wherein the
heterocyclic or
heteroaryl moiety is as hereinabove described in this paragraph, nitro. amino,
mono- or
di-(Ci_3alkyl)amino. phenylamino, naphthylamino, heteroaryl or heterocyclic
amino
wherein the heteroaiyl heterocyclic moiety is as hereinabove described in this
paragraph,
NH,C(O), a mono- or di-(C 1_3alkyl) aminocarbonyl, C i_; alkyl-C(O)-C 1_4
alkyl, amino-C i
; alkyl, mono- or di-(CI_3alkyl)amino-CI_; alkyl, amino-S(O)2, di-
(Cl_3alkyl)amino-S(O)2,
R7-C i_; alkyl, Rg-C j_; alkoxy. Rc,-C(O)-C j_; alkyl, Rjo-C i_; alkyl(R> >)N.
carboxy-mono- or
di-(C 1 _>alkyl)-amino;

1 o a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,
dihydronaphthyl,
tetrahydronaphthyl, benzocycloheptanyl and benzocycloheptenyl, or a fused
heteroaryl
selected from cyclopentenopyridinyl, cyclohexanopyridinyl,
cyclopentanopyrimidinyl,
cyclohexanopyrimidinyl, cyclopentanopyrazinyl, cyclohexanopyrazinyl,
cyclopentanopyridazinyl, cyclohexanopyridazinyl, cyclopentanoquinolinyl,
cyclohexanoquinolinyl, cyclopentanoisoquinolinyl, cyclohexanoisoquinolinyl,
cyclopentanoindolyl, cyclohexanoindolyl, cyclopentanobenzimidazolyl,
cyclohexanobenzimidazolyl, cyclopentanobenzoxazolyl, cyclohexanobenzoxazolyl,
cyclopentanoimidazolyl, cyclohexanoimidazolyl, cyclopentanothienyl and
cyclohexanothienyl; wherein the fused aryl or fused heteroaryl ring is
independently
substituted with zero to three phenyl, naphthyl, pyridinyl, pyrimidinyl,
pyrazinyl,
pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl,
isothiazolyl. C 1 _6
alkyl which is optionally partially or fully halogenated, halogen, nitrile,
C1_3 alkyloxy
which is optionally partially or fully halogenated, phenyloxy, naphthyloxy,
heteroaryloxy
or heterocyclicoxy wherein the heteroaryl or heterocyclic moiety is as
hereinabove
described in this paragraph, nitro, amino, mono- or di-(C1_3alkyl)amino,
phenylamino,
naphthylamino, heteroaryl or heterocyclic amino wherein the heteroaryl or
heterocyclic
moiety is as hereinabove described in this paragraph, NHZC(O), mono- or di-
(CI_
3alkyl)aminocarbonyl, Ci_a alkyl-OC(O), C1_; alkyl-C(O)-C1 _4 alkyl, amino-
Ci_; alkyl,
mono- or di-(C1_3)alkylamino-C1_; alkyl, Ri2-C1 _; alkyl, RI 3-C1 _; alkoxy,
Ri4-C(O)-C1_;
alkyl or R15-Cl_; alkyl(R16)N;

56


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
cyclopropanyl. cyclobutanyl. cyclopentanyl. cyclohexanyl, cycloheptanyl,
bicyclopentanyl, bicyclohexanyl or bicycloheptanyl, each being optionally
partially or
fully halogenated and optionally substituted with one to three CI_3 alkyl
groups, or an
analog of such cycloalkyl group wherein one to three ring methylene groups are
independently replaced by 0. S. CHOH, >C=O, >C=S or NH;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl,
bicyclohexenyl or bicycloheptenyl, each optionally substituted with one to
three C1 _3 alkyl
groups;

C1_4 alkyl-phenyl-C(O)-C1 _4 alkyl-, Ci_4 alkyl-C(O)-Ci_a alkyl- or C1_4 alkyl-
phenyl-
S(O)m-CI_4 alkyl-;

C1_6 alkyl or C1_6 branched or unbranched alkoxy each of which is optionally
partially or
fully halogenated or optionally substituted with R17;

OR18 or C1_6 alkyl optionally substituted with ORIg;

amino or mono- or di-(Ci_;alkyl)amino optionally substituted with R19;
R20C(O)N(R21)-, R-120- or R23R24NC(O)-; R26(CH2),,,C(O)N(R21)- or
R26C(O)(CH2)mN(R2 1)-;

C2_6alkenyl substituted by R23R24NC(O)-;
C2_6 alkynyl branched or unbranched carbon chain, optionally partially or
fully
halogenated, wherein one or more methylene groups are optionally replaced by
0, NH,
S(O)n, and wherein said alkynyl group is optionally independently substituted
with one to
two oxo groups, pyrroldinyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl,
imidazolyl,
phenyl, pyridinyl, tetrazolyl one or more C1_4 alkyl optionally substituted by
one or more
halogen atoms, nitrile, morpholino, piperidinyl, piperazinyl, imidazolyl,
phenyl,

57


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
pyridinyl, tetrazolyl, or mono- or di(C 1_4 alkyl)amino optionally substituted
by one or
more halogen atoms: or

aroyl;
R6 is a:

Ci_a alkyl optionally partially or fully halogenated and optionally
substituted with R26;
each R7, R8, R9, Rio, R12, R13_ R14, R1;, R17
, R19, Rz; and R26 is independently:
nitrile, phenyl, morpholino, piperidinyl, piperazinyl, imidazolyl, pyridinyl,
tetrazolyl,
amino or mono- or di-(C1_4alkyl)amino optionally partially or fully
halogenated;
each R>> and R16 is independently:
hydrogen or Cl_4 alkyl optionally partially or fully halogenated;
R18 is independently:
hydrogen or a C1_4 alkyl optionally independently substituted with oxo or Rz;;
R20 is independently:
C1_1o alkyl optionally partially or fully halogenated, phenyl, or pyridinyl;
R21 is independently:

hydrogen or C1-3 alkyl optionally partially or fully halogenated;
each R22, R23 and R24 is independently:
hydrogen, C1_6 alkyl optionally partially or fully halogenated, said C1_6
alkyl is optionally
interrupted by one or more 0, N or S, said C1 _6 alkyl also being
independently optionally
substituted by mono- or di-(C1_3alkyl)aminocarbonyl, phenyl, pyridinyl, amino
or mono-
or di-(C1-4alkyl)amino each of which is optionally partially or fully
halogenated and
optionally substituted with mono- or di-(C1_3alkyl)amino;
58


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
or R13 and Rz4 taken together optionally form a heterocyclic or heteroaryl
ring;
m=0, 1 or 2;

WisOorSand

pharmaceutically acceptable derivatives thereof.

In another embodiment of the invention there is provided compounds of the
formula(II)
as described immmediately above, and wherein

G is:

phenyl, naphthyl, benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl,
benzocycloheptanyl, benzocycloheptenyl, indanyl, indenyl;

pyridinyl, pyridonyl, quinolinyl, dihydroquinolinyl, tetrahydroquinoyl,
isoquinolinyl,
tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl,
benzthiazolyl,
benzoxazolyl, benzofuranyl, benzothiophenyl, benzpyrazolyl,
dihydrobenzofuranyl,
dihydrobenzothiophenyl, benzooxazolonyl, benzo[1,4]oxazin-3-onyl,
benzodioxolyl,
benzo[1,3]dioxol-2-onyl, benzofuran-3-onyl, tetrahydrobenzopyranyl, indolyl,
indolinyl,
indolonyl, indolinonyl, phthalimidyl;

oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,
piperazinyl,
morpholinyl, tetrahydropyranyl, dioxanyl, tetramethylene sulfonyl,
tetramethylene
sulfoxidyl, oxazolinyl, thiazolinyl, imidazolinyl, tertrahydropyridinyl,
homopiperidinyl,
pyrrolinyl, tetrahydropyrimidinyl, decahydroquinolinyl,
decahydroisoquinolinyl,
thiomorpholinyl, thiazolidinyl, dihydrooxazinyl, dihydropyranyl, oxocanyl,
heptacanyl,
thioxanyl or dithianyl;

wherein G is substituted by one or more Ri, R, or R3;

59


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
In another enlbodiment of the invention there is provided compounds of the
formula(II)
as described immediately above, and wherein

G is phenyl, pyridinyl, pyridonvl, naphthvl, quinolinyl, isoquinolinyl,
pvrazinyl,
benzimidazolyl, benzoxazolyl. benzofuranyl. benzothiophenyl, benzpyrazolvl,
dihydrobenzofuranyl. dihydrobenzothiophenyl, indanyl, indenyl, indolvl.
indolinyl,
indolonyl or indolinonyl, wherein G is substituted by one or more RI, R-, or
R3;

Ar is:

naphthvl, quinolinyl, isoquinolinyl, tetrahvdronaphthyl, tetrahydroquinolinyl.
tetrahydroisoquinolinyl, indanyl, indenyl or indolyl each being optionally
substituted by
one or more R4or R; groups;

X is:

phenyl, furanyl, thienyl, pyrrolyl, pyrazolvl, imidazolyl, pyridinyl,
pyrimidinyl,
pyridinonyl, dihydropyridinonyl, maleimidyl, dihydromaleimidyl, piperdinyl,
piperazinyl, pyridazinyl or pyrazinyl

Y is:
a bond or


a C1_4 saturated or unsaturated carbon chain wherein one of the carbon atoms
is optionally
replaced by 0, N, or S(O)1 ,, and wherein Y is optionally independently
substituted with
one to two oxo groups, phenyl or one or more CI_4 alkyl optionally substituted
by one or
more halogen atoms;

Z is:



CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
phenyl, pyridinyl, pyrimidinyl. pyridazinyl. pyrazinyl. imidazolyl, furanyl,
thienyl.
dihydrothiazolyl. dihydrothiazolti-l sulfoxidyl, pyranyl, pyrrolidinyl which
are optionally
substituted with one to three nitrile. Ci_; alkyl, CI_; alkoxy, amino, mono-
or di-(Ci_3
alkyl)amino, CONH-) or OH;


tetrahydropyranyl, tetrahydrofuranyl, 1,3-dioxolanonyl, 1,3-dioxanonyl, 1,4-
dioxanyl,
morpholinyl, thiomorpholinyl, thiomorpholino sulfoxidyl, piperidinyl.
piperidinonyl,
piperazinyl, tetrahydropyrimidonyl, pentamethylene sulfidyl, pentamethylene
sulfoxidyl,
pentamethylene sulfonyl, tetramethylene sulfidyl, tetramethylene sulfoxidyl or
1 o tetramethylene sulfonyl which are optionally substituted with one to three
nitrile, C i_3
alkyl, C1_3 alkoxy, amino, mono- or di-(C1_3 alkyl)amino, CONH2, or OH;
nitrile, C i_6 alkyl-S(O),,,, halogen. hydroxy. C i_4 alkoxy, amino, mono- or
di-(C I_6
alkyl)amino, mono- or di-(C1_3 alkyl)aminocarbonyl or NH2C(O);

each RI is independently:

C3_6 alkyl optionally partially or fully halogenated, and optionally
substituted with one to
three C3_6cycloalkyl, phenyl, thienyl, furyl, isoxazolyl or isothiazolyl; each
of the
aforementioned being optionally substituted with one to three groups selected
from
halogen, C1_3 alkyl which is optionally partially or fully halogenated,
hvdroxy, nitrile or
C1-3alkoxy which is optionally partially or fully halogenated;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, bicyclopentanyl or
bicyclohexanyl, each being optionally partially or fully halogenated and
optionally
substituted with one to three CI_3 alkyl groups optionally partially or fully
halogenated,
CN, hydroxyC1_3alkyl or phenyl; or an analog of such cycloalkyl group wherein
one to
three ring methylene groups are independently replaced by 0, S, CHOH, >C=O,
>C=S or
NH; or

silyl containing three CI_4 alkyl groups optionally partially or fully
halogenated;
61


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
R-, is independently:

halogen. Ci_3 alkoxv, CI_3 alkyl-S(O),,, optionally partially or fully
halogenated,
phenylsulfonyl or nitrile;


R3 is independently:

phenyl, morpholino, pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl,
pyrrolylidinyl,
imidazolyl, pyrazolyl, each being optionally substituted with one to three
phenyl,
naphthyl, heterocycle or heteroaryl as hereinabove described in this
paragraph, C1_6 alkyl
which is optionally partially or fully halogenated, cyclopropanyl,
cyclobutanyl,
cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl, bicyclohexanyl,
bicycloheptanyl, phenyl C1 _; alkyl, naphthyl C 1_; alkyl, halogen, oxo,
hydroxy, nitrile, C 1_3
alkyloxy optionally partially or fully halogenated, phenyloxy, naphthyloxy,
heteroaryloxy
or heterocyclicoxy wherein the heteroaryl or heterocyclic moiety is as
hereinabove
described in this paragraph, nitro, amino, mono- or di-(C1_3alkyl)amino,
phenylamino,
naphthylamino, heteroaryl or heterocyclic amino wherein the heteroaryl or
heterocyclic
moiety is as hereinabove described in this paragraph, NH-)C(O), a mono- or di-
(C1_
3alkyl)aminocarbonyl, Ci_5 alkyl-C(O)-CI_4 alkyl, mono- or di-
(C1_3alkyl)amino, mono- or
di-(C1_3)alkylamino-CI_5 alkyl, mono- or di-(Ci_3alkvl)amino-S(O)2, R7-C1_;
alkyl, R8-CI_5
alkoxy, R9-C(O)-C1 _5 alkyl, Rlo-CI _; alkyl(Ri I)N, carboxy-mono- or di-
(C1_5)-alkyl-
amino;
Ce_3 alkyl or C14 alkoxy each being optionally partially or fully halogenated
or optionally
substituted with R17;

OR18 or Ci_b alkyl optionally substituted with OR18;
amino or mono- or di- (CI-5 alkyl)amino optionally substituted with R19;
62


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
R,oC(O)N(R,i)-, R O- R-13R'4NC(O)-; R16CH,C(O)N(R21)- or R-6C(O)CH')N(R'?
C-1_4alkenyl substituted by R23R24NC(O)-; or

C-2_4 alkynyl branched or unbranched carbon chain optionally pai-tially or
fully
halogenated and optionally independently substituted with one to two oxo
groups,
pyrroldinyl, pyrrolyl, morpholinyl, piperidinyl, piperazinyl, imidazolyl,
phenyl, pyridinyl,
tetrazolyl or one or more C1_4 alkyl optionally substituted by one or more
halogen atoms;
and

1 o R23 and R24 taken together optionally form imidazolyl, piperidinyl,
morpholinyl,
piperazinyl or a pyridinyl ring.

In yet another embodiment of the invention there is provided compounds of the
formula(II) as described immediately above, and wherein:

G is phenyl, pyridinyl, pyridonyl, naphthyl, quinolinyl, isoquinolinyl,
pyrazinyl,
benzothiophenyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, indanyl,
indolyl,
indolinyl, indolonyl or indolinonyl, wherein G is substituted by one or more
RI, R2 or R3;
Ar is naphthyl;

X is

phenyl, imidazolyl, pyridinyl, pyrimidinyl, piperdinyl, piperazinyl,
pyridazinyl or
pyrazinyl each being optionally independently substituted with one to three
C1_4 alkyl, C1
4alkoxy, hydroxy, nitrile, amino, mono- or di-(C i_3 alkyl)amino, mono- or di-
(C I_3
alkylamino)carbonyl, NH2C(O), Ci_6 alkyl-S(O),,, or halogen;

Y is:
a bond or

63


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865

a CI_a saturated carbon chain wherein one of the carbon atoms is optionally
replaced by
O. N or S and wherein Y is optionally independently substituted xvith an oxo
group;

Z is:
phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, imidazolyl.
dihydrothiazolyl,
dihydrothiazolyl sulfoxide, pyranyl or pyrrolidinyl which are optionally
substituted with
one to two C 1 _2 alkyl or C 1_2 alkoxy;

tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholino sulfoxidyl,
piperidinyl,
piperidinonyl, piperazinyl or tetrahydropyrimidonyl which are optionally
substituted with
one to two C i_Z alkyl or C 1_2 alkoxy; or

C1_3 alkoxy;
each R, is independently:

C3_; alkyl optionally partially or fully halogenated, and optionally
substituted with phenyl
substituted with zero to three halogen, C1_3 alkyl which is optionally
partially or fully
halogenated, hydroxy, nitrile or C1_3alkoxy which is optionally partially or
fully
halogenated;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, bicyclopentanyl or
bicyclohexanyl, each being optionally partially or fully halogenated and
optionally
substituted with one to three C1_3 alkyl groups optionally partially or fully
halogenated,
CN, hydroxyC1_3alkyl or phenyl; and an analog of cyclopropyl, cyclobutyl,
cyclopentanyl, cyclohexanyl, bicyclopentanyl or bicyclohexanyl wherein one
ring
methylene group is replaced by 0; and

silyl containing three C1_, independently alkyl groups optionally partially or
fully
halogenated;

64


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
each R, is independently:

bromo, chloro. fluoro. methoxy, methylsulfonyl or nitrile;

each R3 is independently:

phenyl, morpholino, pyridinyl, pyrimidiriyl, pyrrolylidinyl, 2,5-pyrrolidin-
dionyl, 10 imidazolyl, pyrazolyl, each of the aforementioned is optionally
substituted with one to

three C1_3 alkyl which is optionally partially or fully halogenated, halogen,
oxo, hydroxy,
nitrile and C1_3 alkyloxy optionally partially or fully halogenated;

C1_3 alkyl or C1_3 alkoxy each being optionally partially or fully halogenated
or optionally
substituted with R17;

OR18 or C1_3 alkyl optionally substituted with OR18;
amino or mono- or di-(Ci-3 alkyl)amino optionally substituted with R19;

RZoC(O)N(RZ])-, R220- ; R23R24NC(O)-; R26CH~C(O)N(R21)- or R26C(O)CH2N(R21)-;
C2_4 alkenyl substituted by R23R24NC(O)-; or

C24 alkynyl substituted with pyrroldinyl or pyrrolyl;
and
R23 and R24 taken together optionally form morpholino.

In yet still another embodiment of the invention there is provided compounds
of the
formula(II) as described immediately above, and wherein



CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
G is phenyl, pyridinyl. pyridonyl, naphthyl, quinolinyl, isoquinolinyl,
dihydrobenzofuranyl, indanyl, indolinyl. indolonyl, or indolinonyl, wherein G
is
substituted bv one or more Ri, R,) or R3;


Ar is 1-naphthyl;
X is:

phenyl, imidazolyl, pyridinyl, pyrimidinyl, piperdinyl, piperazinyl,
pyridazinyl or
pyrazinyl;

Y is:
a bond or
-CH2-, -CH2CH2-, -C(O)-, -0-, -S-, -NH-CH~CH?CHZ-, -N(CH3)-, or -NH-;
each R, is independently:

C3_5 alkyl optionally partially or fully halogenated, and optionally
substituted with
phenyl;

cyclopropyl, cyclopentanyl, cyclohexanyl and bicyclopentanyl optionally
substituted with
one to three methyl groups optionally partially or fully halogenated, CN,
hydroxymethyl
or phenyl; or 2-tetrahydrofuranyl substituted by methyl; or
trimethyl silyl;

each R3 is independently:

66


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
phenyl, morpholinyl. pyridinyl, pyrimidinyl, pyrrolylidinyl, 2,5-pyrrolidin-
dionyl,
imidazolyl or pyrazolyl, wherein any of the aforementioned is optionally
substituted with
C1_2 alkyl which is optionally partially or fi.illy halogenated;

C 1-3 alkyl or C 1 _3 alkoxy each being optionally partially or ftilly
halogenated or optionally
substituted with diethylamino;

OR18 or CI-3 alkyl optionally substituted with OR18;

amino or mono- or di-(CI-3 alkyl)amino optionally substituted with R19;
CH3C(O)NH-, R?-,O- ; R-?3R?4NC(O)-; R26CH-,C(O)N(R21)- or R16C(O)CH,N(R,j)-;
C24alkenyl substituted by R23R24NC(O)-; or

C24 alkynyl substituted with pyrroldinyl or pyrrolyl;

R23 and R24 are H or R13 and R24 taken together optionally form morpholino;
and
R26 is morpholino.


In another embodiment of the invention there is provided of the formula(II) as
described
immediately above, and wherein

G is

phenyl, pyridinyl or naphthyl wherein G is substituted by one or more RI, R,
or R3;
X is:
imidazolyl or pyridinyl;

67


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
Y is:
-CH?_, -NH-CHzCH,CH,- or -NH-;
Z is morpholino;

each R, is independently:
tert-butyl, sec-butyl. tert-amyl or phenyl;
R, is chloro; 10

R3 is independently:

methyl, methoxy, methoxymethyl, hydroxypropyl, acetamide, morpholino or
morpholinocarbonyl.

In yet a further embodiment of the invention there is provided of the
formula(II) as
described immediately above, and wherein X is pyridinyl.

In yet a further embodiment of the invention there is provided of the
formula(II) as
described immediately above, and wherein the pyridinyl is attached to Ar via
the 3-
pyridinyl position.

The following are representative compounds of the formula(II):
1-(3-Cyano-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea
1-(3-Fluoro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-urea

1-(4-Chloro-2-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea

1-(2-Chloro-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea

68


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-(3.4-Dimethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea

1-(3-I odo-phenyl )-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-urea
1-[4-(6-Morpholin-4-ylmethvl-pyridin-3-yl)-naphthalen-l-yl]-3-m-tolyl-urea
1-(4-Methylsulfanyl-pheny1)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea
1-(3-Chloro-4-methyl-phenyl)-3-[4-(6-moipholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(4-Chloro-3-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(2,5-Dichloro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-naphthalen-2-yl-
urea
1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3 -phenyl-urea
1-(3-Chloro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-urea
1-(4-Chloro-3-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3 -
yl)-
naphthalen- I -yl] -urea

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(2,4,6-trichloro-
phenyl)-
urea

1-(2-Methyl-3-nitro-phenyl )-3 - [4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(4-Methyl-2-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(2,3-Dichloro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl] -
urea
1-(2-Methoxy-5-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-
1-yl]-urea

1-(2-Chloro-6-methyl-phenyl)-3 - [4-( 6-morpholin-4-ylmethyl-pyridin-3 -yl)-
naphthal en-1-
yl]-urea

69


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-(2,4-Dichloro-phenvl)-3-[4-(6-morpholin-4-ylmethyl-pvridin-3-yl)-naphthalen-
l-yl]-
urea

1-(4-Methyl-3-nitro-phenvl)-3-[4-(6-nlorpholin-4-vlmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(2,4-Dimethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea

1-(2,3-Dimethyl-phenyl)-3-[4-(6-morpholin-4-vlmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea

1-(4-Cyano-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea
1-[4-(6-Morpholin-4-ylmethyl-pvridin-3-yl)-naphthalen-l-yl]-3-(3,4,5-
trimethoxy-
phenyl)-urea

1-Biphenyl-4-yI-3-[4-(6-morpholin-4-vlmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea
1-(2,5-Difluoro-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea

1-(3-Chloro-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-
I -yl]-urea
1-(2-Fluoro-3-trifluoromethyl-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea

1-(4-Benzyloxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-
urea

1-(2-Methylsulfanyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(2-Fluoro-6-trifluoromethyl-phenyl)-3- [4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen- I -yl]-urea

1-(4-Fluoro-3-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea
1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(2,4,5-trimethyl-
phenyl)-
urea

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(4-
trifluoromethyl-
phenyl)-urea



CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-(3-Methylsulfanyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(2-Methoxy-phenvl)-3-[4-(6-morpholin-4-vlmethvl-pyridin-3-yl)-naphthalen-l-
yl]-urea
1 -(2-Fluoro-5-trifluoromethyl-phenyl )-3-[4-(6-morpholin-4-ylmethyl-pvridin-3-
yl)-
naphthalen-l-yl]-urea

1-(4-Methoxy-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-
1-yl]-urea

1-(2-Fluoro-5-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-vl)-
naphthalen-l-
yl]-urea

1-(4-Ethoxy-phenyl)-3-[4-(6-morpholin-4-vlmethyl-pyridin-3-yl)-naphthalen-l-
yl]-urea
1-(2,5-Dimethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea

1-(4,5-Dimethyl-2-nitro-phenyl)-3 - [4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-
I -yl]-urea

1-(5-Chloro-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea
1-(2-Isopropyl-6-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea

1-(2-Difluoromethoxy-phenyl)-3 - [4-(6-morpholin-4-ylmethyl-pyridin-3 -yl)-
naphthalen-
1-yl]-urea

1-(4-Isopropyl-phenyl)-3 - [4-(6-morpholin-4-vlmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea

1-(4-Methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-urea
1-(3-Ethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
urea
1-(2-Ethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-urea
1-(4-Butoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-urea
4-{3-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-ureido}-benzoic
acid
ethyl ester

71


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
1-(4-Butyl-2-methyl-phenyl)-3-[4-(6-nlorpholin-4-ylmethyl-pyridin-3-~,1)-
naphthalen-l-
yl]-urea

1-(2,6-Dibromo-4-isopropyl-phenyl )- 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen- l -yl]-urea

1-(3-Methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-urea
1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(4-
I o trifluoromethylsulfanyl-phenyl)-urea

5-{3-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-
isophthalic acid
dimethyl ester

1-(3-Cyclopentyloxy-4-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea

3-{3-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-ureido}-benzoic
acid
ethyl ester
1-(5-tert-Butyl-2-hydroxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl] -urea

1-(2-Hydroxymethy 1-4-phenyl-cyclohexyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea

1-(2-Methylsulfanyl-5-trifluoromethyl-phenyl)-3 - [4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(4-pentyloxy-
biphenyl-3-
yl)-urea

4-Methoxy-3 - { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3 -yl)-naphthalen-l-yl]-
ureido } -
benzoic acid methyl ester
1-(2,5-Diethoxy-phenyl)-3- [4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea

1-Benzothiazol-6-y1-3-[4-(6-morpholin-4-ylmethyl-pyridin-3 -yl)-naphthalen-l-
yl]-urea
N-(2,5-Diethoxy-4-{ 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-
ureido}-phenyl)-benzamide

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(3-phenoxy-
phenyl)-urea

72


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-(5-Ethanesulfonyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethvl-pyridin-3-
yl)-
naphthalen-l-yl]-urea

4-Methoxy-3- 1,3 -[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen- l -yl]-
ureido}-N-
phenyl-benzamide

1-(2-Methyl-1,3-dioxo-2,3-dihydro-1 H-isoindol-5-yl)-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea

1-(2,3-Dimethyl-1 H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-
1-yl]-urea

N-Butyl-4-methoxy-3 - { 3- [4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
ureido } -benzenesulfonamide
1-[3 -(2-Methyl- [ 1,3 ] dioxolan-2-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen- I -yl]-urea

1 -(3 -Methoxy-5 -tri fluoromethy l-phenyl)-3 -[4-( 6-morpholin-4-ylmethvl-
pyridin-3 -y l)-
2o naphthalen- l -yl]-urea

1-(2,4-Dimethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea

1-(2-Methyl-4-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-vl)-
naphthalen-l-
yl]-urea

1-(2-Methoxy-4-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea
1-(4-Chloro-2-nitro-phenyl)-3- [4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(5-Chloro-2-methoxy-phenyl)-3 - [4-( 6-morphol in-4-ylmethyl-pyri din-3 -yl)-
naphthalen-
1-yl]-urea

1-(3,5-Dimethoxy-phenyl)-3-[4-(6-morphol in-4-ylmethyl-pyridin-3 -yl)-
naphthalen-l-yl]-
urea

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3 -yl)-naphthalen-l-yl]-3-(4-
trifluoromethoxy-
phenyl)-urea

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3 -yl)-naphthalen-l-yl]-3-(3 -
trifluoromethylsulfanyl-phenyl )-urea
1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-vl)-naphthalen-l-yl]-3-(2-phenoxy-
phenyl)-urea
73


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-(2-Methoxy-5-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea

1-(3,5-Bis-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea
1-(2-tert-Butyl-5-methyl-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea

1-(3-Methyl-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(3-tert-Butyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea

1-(4-Methyl-biphenyl-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea

1-(4-tert-Butyl-biphenyl-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea
1-(5-Chloro-2,4-dimethoxy-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen- I -yl] -urea

1-(5-Isopropyl-2-methyl-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea

1-(5-sec-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea

1-(5-tert-Butyl-2-methoxy-3-propyl-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea

1-(5-tert-Butyl-2-methoxymethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea
1-(5-tert-Butyl-2-methoxy-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-1 -yl]-urea

1-(5-tert-Butyl-2-methyl-phenyl)-3-(4- { 6-[(3-methoxy-propyl)-methyl-amino]-
pyridin-3 -
yl}-naphthalen-1-yl)-urea

74


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-(5-tert-Butyl-2-methyl-phenyl)-3 -[4-(4-morpholin-4-ylmethyl-imidazol-l-yl)-
naphthalen-l-yl]-urea

1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen- I -yl]-urea

1-(5-tert-Butyl-2-methyl-phenyl)-3-{4-[6-(3-methoxy-propylamino)-pyridin-3-yl]-

naphthalen-l-yl } -urea

I 0 1-(5-tert-Butyl-2-methyl-pyridin-3-yl)-3 -[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea

1-(5-tert-Butyl-2-morpholin-4-yl-phenyl)=3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea
1-(6-tert-Butyl-2-chloro-3-methyl-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(3-
trifluoromethyl-
phenyl)-urea

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(4-
trifluoromethoxy-
phenyl)-urea

1- [5-( l, l -Dimethyl-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea

1-[5-tert-Butyl-2-(1 H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea
1-[5-tert-Butyl-2-(2-methyl-pyrimidin-5-yl)-phenyl]-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea

1-[5-tert-Butyl-2-(3-hydroxy-propyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen- l -yl]-urea

1-[5-tert-Butyl-2-(3-morpholin-4-yl-3-oxo-propyl)-phenyl]-3-[4-(6-morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea
1-[5-tert-Butyl-2-(morpholine-4-carbonyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-

pyridin-3-yl)-naphthalen-l-yl]-urea

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-acetamide
and the pharmaceutically acceptable derivatives thereof.


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
In addtion to the abovementioned representative compounds the folloNN-ing
prophetic
compounds of the formula(II) may be made by the general methods described
hereinbelow:

1-[4-(6- { [Bis-(2-cyano-ethyl)-amino]-methyl } -pyridin-3-yl)-naphthalen-l-
yl]-3-(5-tert-
butyl-2-methoxy-phenyl)-urea
1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[4-(2-methyl-3-oxo-piperazin-l-
ylmethyl)-
pheny l ] -naphthal en-1-y l } -urea

1-[4-(6- { [Bis-(2-methoxy-ethyl)-amino]-methyl } -pyridin-3-yl)-naphthalen- I
-yl]-3-(5-
tert-butyl-2-methoxy-phenyl)-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(2-methyl-3-oxo-piperazin-l-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(1-oxo-114-thiomorpholin-4-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-thiomorpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea
1-(5-tert-Butyl-2-methyl-phenyl)-3- { 4-[6-(1-oxo-114-thiomorpholin-4-
ylmethyl)-pyridin-
3-yl]-naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-methyl-phenyl)-3-{4-[6-(2-methyl-3-oxo-piperazin-l-ylmethyl)-

pyridin-3-yl]-naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[4-(1-oxo-l1-thiomorpholin-4-ylmethyl)-
phenyl]-naphthalen-l-yl } -urea

1-[4-(4-{ [Bis-(2-cyano-ethyl)-amino]-methyl} -phenyl)-naphthalen-l-yl]-3-(5-
tert-butyl-
2-methoxy-phenyl)-urea

1-(2-Methoxy-5-pentafluoroethyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl-piperidin-
l-yl)-
naphthalen-l-yl]-urea

1-(2-Methoxy-5-trifluoromethyl-pyridin-3-yl)-3-{4-[2-(4-oxo-piperidin-l-
ylmethyl)-
pyrimidin-5-yl]-naphthalen-l-yl } -urea

1-(2-Methoxy-5-trimethylsilanyl-phenyl)-3- {4-[4-(tetrahydro-pyran-4-ylamino)-
phenyl]-
naphthalen-l-yl}-urea

76


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-(3-Methoxv-naphthalen-2-vl)-3-[4-(4-morpholin-4-ylmethvl-piperidin-l-vl)-
naphthalen-l-yl]-urea
1-(3-Methyl-naphthalen-2-yl)-3-[4-(4-morpholin-4-ylmethyl-phenyl)-naphthalen-l-
y1]-
urea

1-(3-tert-Butyl-5-methanesulfinyl-phenyl)-3-{4-[6-(1-methyl-piperidin-4-
vlmethyl)-
pyridin-3-yl]-naphthalen-I-yl}-urea

1-(3-tert-Butyl-phenyl)-3-[4-(3-pyridin-3-yl-propoxy)-naphthalen-l-yl]-urea
1-(3-tert-Butyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl-phenyl)-naphthalen-l-yl]-
urea
1-(4-Methoxy-biphenyl-3-yl)-3 - { 4- [4-(tetrahydro-pyran-4-ylmethyl)-imidazol-
l-yl]-
naphthalen-l-yl}-urea

1-(4-Methyl-biphenyl-3-yl)-3-{4-[4-(2-pyridin-4-yl-ethyl)-piperazin-l-vl]-
naphthalen-l-
yl}-urea

1-(4-tert-Butyl-biphenyl-2-yl)-3-[4-(pyridin-4-ylmethoxy)-naphthalen-l-yl]-
urea
1-(4-tert-Butyl-biphenyl-2-yl)-3-{4-[2-(1-oxo-114-thiomorpholin-4-ylmethyl)-3H-

imidazol-4-yl]-naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-hydroxy-phenyl)-3-[4-(5-morpholin-4-ylmethyl-pyrazin-2-yl)-
naphthalen-l-vl]-urea

1-(5-tert-Butyl-2-methoxy-3-propyl-phenyl)-3-{4-[4-(pyrrolidine-l-carbonyl)-
phenyl]-
naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-morpholin-4-ylmethyl-pyrimidin-5-yl)-

naphthalen-l-yl]-urea
1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(4-thiomorpholin-4-ylmethyl-phenyl)-
naphthalen-l-yl]-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-phenyl)-
naphthalen-l-
yl]-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3 - { 4- [4-(tetrahydro-pyran-4-ylamino)-
phenyl]-
naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3 - { 4-[6-(4-methyl-piperazin-l-ylmethyl)-
pyridin-3-
yl]-naphthalen-l-yl } -urea

77


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-(5-tert-Butyl-2-methoxy-pyridin-3-yl)-3- { 4-[6-(4-oxo-piperidin-l-ylmethyl)-
pyridin-3-
yl]-naphthalen- I -yl }-urea

1-(5-tert-Butyl-2-methyl-benzooxazol-7-yl)-3-[4-(6-pyridin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea

1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(4-morpholin-4-ylmethvl-phenyl)-
naphthalen-l-
yl]-urea
1-(5-tert-Butyl-2-phenoxy-phenyl)-3- {4-[6-(tetrahydro-pyran-4-yloxy)-pyridin-
3-yl]-
naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-pyrrolidin-l-vl-phenyl)-3-[4-(4-methoxy-6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea

1-(5-tert-Butyl-2-pyrrolidin-l-yl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl ] -urea

1-(5-tert-Butyl-3-cyano-2-methoxy-phenyl)-3- { 4-[2-(2,6-dimethyl-morpholin-4-
ylmethyl)-pyrimidin-5-yl]-naphthalen-l-yl } -urea
1-(5-tert-Butyl-4'-dimethylamino-biphenyl-3-yl)-3-[4-(2-morpholin-4-ylmethyl-
pyrimidin-5-yl)-naphthalen-l-yl]-urea
1-(6-Methoxy-3,3-dimethyl-indan-5-yl)-3- {4-[4-(morpholine-4-carbonyl)-phenyl]-

naphthalen-l-yl}-urea

1-(6-tert-Butyl-2-chloro-3-methyl-pyridin-4-yl)-3-[4-(6-thiomorpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea

1-(6-tert-Butyl-benzo [ 1,3 ] dioxol-4-yl)-3- { 4- [6-(morpholin-4-ylamino)-
pyridin-3-yl]-
naphthalen-l-yl}-urea

1-(7-Methoxy-1,4,4-trimethyl-1,2,3,4-tetrahydro-quinolin-6-yl)-3- {4- [6-
(tetrahydro-
pyran-4-yloxy)-pyridin-3-yl]-naphthalen-l-yl } -urea
1-(7-tert-Butyl-2,4-dimethyl-benzooxazol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea
1-[2-Methoxy-5-(1-methyl-l-phenyl-ethyl)-phenyl]-3-{4-[6-(2-pyridin-4-yl-
ethyl)-
pyridazin-3-yl]-naphthalen-l-yl}-urea

1-[2-Methoxy-5-(1-methyl-cyclohexyl)-phenyl]-3-{4-[4-(1-methyl-piperidin-4-
ylsulfanyl)-phenyl]-naphthalen-l-yl}-urea

78


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-[2-Methoxy-5-(1-methyl-cvcloprop~-l)-phenyl]-3-[4-(2-morpholin-4-ylmethyl-
pyrimidin-5-yl)-naphthalen-l-yl]-urea

1-[2-Methoxy-5-(2-methyl-tetrahvdro-furan-2-vl)-phenyl]-3-[4-(5-morpholin-4-
vlmethyl-
pyridin-2-yl)-naphthalen-l-yl]-urea

1-[2-Methoxy-5-(3-trifluoromethvl-bicN=clo[1.1.1 ]pent-l-yl)-phenyl]-3-[4-(4-
morpholin-
4-ylmethyl-phenyl)-naphthalen-l-yl]-urea

1-[3-tert-Butyl-5-(1-methyl-1 H-imidazol-4-yl)-phenyl]-3-[4-(5-morpholin-4-
ylmethyl-
pyridin-2-yl)-naphthalen-l-yl]-urea

1-[3-tert-Butyl-5-(2-pyrrolidin-l-yl-ethvl)-phenyl]-3-{4-[6-(1-methyl-
piperidin-4-yloxv)-
pyridin-3 -yl]-naphthalen-l-vl } -urea
1-[3-tert-Butyl-5-(3-pyrrolidin-l-vl-prop-l-ynyl)-phenyl]-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-vl]-urea

1-[4-(6-Imidazol-l-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-[2-methoxy-5-(1-
phenyl-
cyclopropyl)-phenyl]-urea

1-[5-(1,1-Dimethyl-propyl)-2-methoxv-phenyl]-3-[4-(4-thiomorpholin-4-ylmethyl-
phenyl)-naphthalen-l-yl]-urea

1-[5-(1-Cyano-cyclopropyl)-2-methoxy-phenyl]-3-[4-(2-morpholin-4-ylmethyl-
pyrimidin-5-yl)-naphthalen-l-yl]-urea
1-[5-(1-Hydroxymethyl-cyclopropyl)-2-methoxy-phenyl]-3-[4-(4-morpholin-4-
ylmethyl-
phenyl)-naphthalen- I -yl] -urea
1-[5-tert-Butyl-l-(2-diethylamino-ethyl)-2-oxo-1,2-dihydro-pyridin-3-yl]-3-{4-
[6-(1-
mmethyl-piperidin-4-yloxy)-pyridin-3 -y l] -naphthalen-l-yl } -urea

1-[5-tert-Butyl-2-(1 H-pyrazol-4-yl)-phenyl]-3-[4-(2-morpholin-4-yl-ethoxy)-
naphthalen-
1-yl]-urea

1-[5-tert-Butyl-2-(1 H-pyrazol-4-yl)-phenyl] -3- { 4- [4-(4-methyl-piperazine-
l-carbonyl)-
phenvl]-naphthalen-l-yl } -urea

]-[5-tert-Butyl-2-(2,5-dioxo-pyrrolidin-l-yl)-phenyl]-3-{4-[6-(1 H-imidazol-2-
ylmethyl)-
pyridin-3-yi]-naphthalen-l-yl}-urea

1- [5-tert-Butyl-2 - (2-methyl -pyrimi din- 5 -yl)-phenyl]-3- [4-(5-pyridin-4-
ylmethyl-pyridin-
2-yl)-naphthalen-l-yl]-urea

79


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-[5-tert-Butyl-2-(2-morpholin-4-yl-2-oxo-ethoxy)-phenyl]-3-{4-[6-(2-pvridin-4-
yl-
ethyl)-pyridazin-3-ti!1]-naphthalen-l-N-1 } -urea
1-[5-tert-Butyl-2-(2-morpholin-4-yl-2-oxo-ethylamino)-phenyl]-3- {4-[4-(1-
methyl-
piperidin-4-ylamino)-piperidin-l-yl]-naphthalen-l-yl}-urea
1-[5-tert-Butyl-2-(6-methyl-pyridin-3-}-1)-phenyl]-3-{4-[5-(2-pyrrolidin-l-yl-
ethyl)-
pyridin-2-yl]-naphthalen-l-yl }-urea

1-[5-tert-Butyl-2-methoxy-3-(3-morpholin-4-yl-3-oxo-propenyl)-phenyl]-3-[4-(6-
pyrrolidin-l-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea
1-[5-tert-Butyl-3-(2-diethylamino-ethoxy)-2-methoxy-phenyl]-3-{4-[4-
(tetrahydro-pyran-
4-yloxy)-phenyl]-naphthalen-l-yl } -urea
1-[5-tert-Butyl-3-(2-pyrrolidin-l-yl-ethyl)-benzofuran-7-yl]-3-[4-(4-morpholin-
4-
ylmethyl-phenyl )-naphthalen-l-vl]-urea

1-[6-tert-Butyl-4-(2-dimethylamino-ethvl)-3-oxo-3,4-dihydro-2H-benzo[
1,4]oxazin-8-
yl]-3- { 4-[6-(thiomorpholin-4-ylamino)-pyridin-3-yl]-naphthalen-l-yl } -urea

1-{ 5-tert-Butyl-2-methoxy-3-[2-(1-methyl-piperidin-4-yloxy)-ethyl]-phenyl }-3-
[4-(4-
morpholin-4-ylmethyl-phenyl)-naphthalen-l-yl]-urea
2-(4-tert-Butyl-2-{3-[4-(5-pyrrolidin-l-ylmethyl-pyridin-2-yl)-naphthalen-l-
yl]-ureido}-
phenoxy)-N-methyl-ac etamide

2-[4-tert-Butyl-2-(3- { 4- [6-(2,6-dimethvl-morpholin-4-ylmethyl)-pyridin-3-
yl]-
naphthalen-l-yi } -ureido)-phenoxy] -acetamide
3-(5-tert-Butyl-2-methoxy-3-{ 3-[4-(6-pyrrolidin-l-ylmethyl-pyridin-3-yl)-
naphthalen-I -
yl]-ureido}-phenyl)-acrylamide

3-{3-tert-Butyl-5-[3-(4-{4-[2-(1-oxo-114-thiazolidin-3-yl)-ethyl]-phenyl }-
naphthalen-l-
yl)-ureido]-phenyl } -N,N-dimethyl-propionamide

3- {4-[3 -(5-tert-Butyl-2-methoxy-pheny l)-ureido]-naphthalen-l-yl } -
benzamide
4-tert-Butyl-2- { 3-[4-(2-chloro-4-morpholin-4-ylmethyl-phenyl)-naphthalen-l-
yl]-
ureido}-benzamide

N-(4-tert-Butyl-2-{ 3-[4-(6-oxo-1,6-dihydro-pyridin-3-yl)-naphthalen-l-yl]-
ureido}-
phenyl)-2-morpholin-4-yl-acetamide

N-[3-tert-Butyl-5-(3- { 4-[5-(tetrahydro-pyran-4-ylamino)-pyridin-2-yl]-
naphthalen-l-yl } -
ureido)-phenyl]-2-morpholin-4-yl-acetamide


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
N-[4-tert-Butyl-2-(3- { 4-[4-(1-methyl-piperidin-4-v loxy)-phenyl]-naphthalen-
l-yl } -
ureido)-phenyl]-acetamide

and the pharmaceutically acceptable derivatives thereof.

In yet another embodiment of the invention. there is provided the followino
compounds
of the formula(Il): ~

1-(2-tert-Butyl-5-methyl-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;
1-(3-Methyl-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3 -yl)-
naphthalen-l-
yl]-urea;

1-(3-tert-Butyl-phenyl)-3- [4-(4-morpholin-4-ylmethyl-phenyl)-naphthalen-l-yl]-
urea;
1-(3-tert-Butyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3 -yl)-naphthalen-
l-yl]-
urea;

1-(4-Methyl-biphenyl-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-vl)-
naphthalen-l-
yl]-urea;

1-(4-tert-Butyl-biphenyl-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea;

1-(5-Chloro-2.4-dimethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(5-Isopropyl-2-methyl-phenyl)-3- [4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;
1-(5-sec-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl] -urea;

1-(5-tert-Butyl-2-methoxy-3 -propyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxymethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-morpholin-4-ylmethyl-pyrimidin-5-yl)-

naphthalen-l-yl]-urea;

81


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
I -(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(4-thiomorpholin-4-ylmethyl-phenyl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-phenvl)-
naphthalen-l-
yl]-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[4-(tetrahydro-pyran-4-ylamino)-phenyl]-

naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(4-methyl-piperazin-l-ylmethyl)-
pyridin-3-
yl]-naphthalen- I -yl } -urea;

1-(5-tert-Butyl-2-methyl-phenyl)-3-(4-{ 6-[(3-methoxy-propyl)-methyl-amino]-
pyridin-3-
yl}-naphthalen-l-yl)-urea;

1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl-imidazol-l-yl)-
naphthalen- I -yl] -urea;

1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl-phenyl)-
naphthalen-l-
yl]-urea;
1-(5-tert-Butyl-2-methyl-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methyl-phenyl)-3- {4-[6-(3-methoxy-propylamino)-pyridin-3-
yl]-
naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methyl-pyridin-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-morpholin-4-yl-phenyl)-3- [4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea;

1-(6-tert-Butyl-2-chloro-3-methyl-pyridin-4-y1)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-vl]-urea;
1-(6-tert-Butyl-2-chloro-3-methyl-pyridin-4-yl)-3 -[4-(6-thiomorpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen- I -yl]-urea;

1-[2-Methoxy-5-(1-methyl-cyclopropyl)-phenyl]-3-[4-(2-morpholin-4-ylmethyl-
pyrimidin-5-yl)-naphthalen-l-yl]-urea;

82


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-[4-(6-Morpholin-4-ylmethyl-pyridin- 3-yl)-naphthalen- I -_vl]-3-(3-
trifluoromethyl-
phenyl)-urea;

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(4-
trifluoromethoxy-
phenyl)-urea;

1-[5-(1,1-Dimethyl-propyl)-2-methoxy-phenyl]-3-[4-(4-thiomorpholin-4-ylmethyl-
phenyl)-naphthalen-l-yl]-urea;

1-[5-(1,1-Dimethyl-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea;

1-[5-(1-Cyano-cyclopropyl)-2-methoxy-phenyl]-3-[4-(2-morpholin-4-ylmethyl-
pyrimidin-5-yl)-naphthalen-l-yl]-urea;
1-[5-tert-Butyl-2-(1 H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-y1)-
naphthalen-l-yl]-urea;

1-[5-tert-Butyl-2-(2-methyl-pyrimidin-5-yl)-phenyl]-3-[4-(5-pyridin-4-ylmethyl-
pyridin-
2-yl)-naphthalen-l-yl]-urea;

1-[5-tert-Butyl-2-(2-methyl-pyrimidin-5-yl)-phenyl]-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl] -urea;

1-[5-tert-Butyl-2-(3-hydroxy-propyl)-phenyl]-3- [4-(6-morpholin-4-ylmethyl-
pyridin-3 -
yl)-naphthalen-l-yl]-urea;

1-[5-tert-Butyl-2-(3-morpholin-4-yl-3 -oxo-propyl)-phenyl]-3-[4-(6-morpholin-4-

ylmethyl-pyri din-3 -y l)-naphthal en-1-y l]-ure a;
1-[5-tert-Butyl-2-(morpholine-4-carbonyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-

pyridin-3-yl)-naphthalen-l-yl]-urea;

2-[4-tert-Butyl-2-(3- { 4- [6-(2,6-dimethyl-morpholin-4-ylmethyl)-pyridin-3-
yl]-
naphthalen-l-yl}-ureido)-phenoxy]-acetamide;
3-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-l-yl } -benzamide;
4-tert-Butyl-2- { 3-[4-(2-chloro-4-morpholin-4-ylmethyl-phenyl)-naphthalen-l-
yl] -
ureido } -benzamide;

and the pharmaceutically acceptable derivatives thereof.

83


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
In yet a ftirther another embodinlent of the invention there is provided the
following
compounds of the formula(II):

1-(2-tert-Butyl-5-methyl-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea:

1-(3-tert-Butyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-vl]-
urea;
1-(4-Methyl-biphenvl-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-vl)-
naphthalen-l-
yl]-urea;

1-(4-tert-Butyl-biphenyl-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea;

1-(5-Isopropyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl] -urea;

1-(5-sec-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxymethyl-pheny l)-3 - [4-(6-morpholin-4-ylmethyl-
pyridin-3 -yl)-
naphthalen-l-yl]-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-y1]-urea;

1-(5-tert-Butyl-2-methyl-phenyl)-3-(4-{ 6-[(3-methoxy-propyl)-methyl-amino]-
pyridin-3-
yl}-naphthalen-l-yl)-urea;

1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methyl-pyridin-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;

1-[5-(1,1-Dimethyl-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea;
1-[5-tert-Butyl-2-(1 H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-[5-tert-Butyl-2-(2-methyl-pyrimidin-5-vl)-phenyl]-3 -[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

84


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-[5-tei-t-Butyl-2-(3-hydroxy-propyl)-phenyl]-3-[4-(6-morpholin-4-vhnethyl-
pyridin-3-
yl)-naphthalen- I -yl )-urea;

1-[5-tert-Butyl-2-(morpholine-4-carbonyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-

pyridin-3-yl)-naphthalen-l-yl ]-urea;

N-(5-tert-Butyl-2-methoxy-3- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido} -phenyl)-acetamide

and the pharmaceutically acceptable derivatives thereof.

In yet still another generic aspect of the invention, there is provided
compounds of the
formula(III):

W
G~ Ar-X-Y-Z
E N
I
H
(III)

wherein:
E is carbon or a heteroatom group chosen from -0-, -NH- and -S-;
Gis:

an aromatic C6-io carbocycle or a nonaromatic C3_1ocarbocycle saturated or
unsaturated;
a 6-14 membered monocyclic, bicyclic or tricyclic heteroaryl containing 1 or
more
heteroatoms chosen from 0, N and S;



CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
a 6-8 membered monocvclic heterocycle containing one or more heteroatoms
chosen
from O. N and S:

or
an 8-11 membered bicyclic heterocycle, containing one or more heteroatoms
chosen
from O, N and S;
wherein G is optionally substituted by one or more Ri, R-) or R3;
Ar is:

phenyl, naphthyl, quinolinyl, isoquinolinyl, tetrahvdronaphthyl,
tetrahydroquinolinyl,
tetrahvdroisoquinolinyl, benzimidazolN-l. benzofuranyl, dihydrobenzofuranyl,
indolinyl,
benzothienyl, dihydrobenzothienyl, indanyl, indenyl or indolyl each being
optionally
substituted by one or more R4 or R5;


X is:
a C5_8 cycloalkyl or cycloalkenyl optionally substituted with one to two oxo
groups or one
to three C14 alkyl, C 1-4 alkoxy or C I_4 alkvlamino chains each being
branched or
unbranched;

aryl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, pyridinyl,
pyrimidinyl, pyridinonyl,
dihydropyridinonyl, maleimidyl, dihydromaleimidyl, piperdinyl, benzimidazole,
3H-
imidazo[4,5-b]pyridine, piperazinyl, pyridazinyl or pyrazinyl; each being
optionally
independently substituted with one to three C1_4 alkyl, C i_4alkoxy, hydroxy,
nitrile, amino,
mono- or di-(C 1_3 alkyl)amino, mono- or di-(C 1 _3 alkylamino)carbonyl,
NHZC(O), C 1_6
alkyl-S(O)m or halogen;

Y is:

a bond or a C1-4 saturated or unsaturated branched or unbranched carbon chain
optionally
partially or fully halogenated, wherein one or more C atoms are optionally
replaced by 0,
86


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
N, or S(O)1 ,, and wherein Y is optionally independently substituted with one
to two oxo
groups, nitrile, phenyl or one or more C. 1_4 alkyl optionally substituted by
one or more
halogen atoms;

Z is:

aryl, heteroaryl selected from pyridinyl, piperazinyl, pyrimidinyl,
pyridazinyl, pyrazinyl,
imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl. thienyl and pyranyl.
heterocycle
selected from tetrahydropyrimidonyl, cyclohexanonyl, cyclohexanolyl. 2-oxa- or
2-thia-
l0 5-aza-bicyclo[2.2.1 ]heptanyl, pentamethvlene sulfidyl, pentamethylene
sulfoxidyl,
pentamethylene sulfonyl, tetramethylene sulfidyl. tetramethylene sulfoxidyl or
tetramethylene sulfonyl, tetrahydropyranyl. tetrahydrofuranyl, 1,3-
dioxolanonyl, 1,3-
dioxanonyl, 1,4-dioxanyl, morpholino. thiomoipholino, thiomorpholino
sulfoxidyl,
thiomorpholino sulfonyl, piperidinyl, piperidinonyl, pyrrolidinyl and
dioxolanyl,
each of the aforementioned Z are optionally substituted with one to three
halogen, C1_6
alkyl, C i_6 alkoxy, CI_3 alkoxy-C I_3 alkyl, C i_6 alkoxycarbonyl, aroyl, C
1_3acyl, oxo,
hydroxy, pyridinyl-C1_3 alkyl, imidazolyl-C1_3 alkyl, tetrahydrofuranyl-C1_3
alkyl, nitrile-
C1_3 alkyl, nitrile, carboxy, phenyl wherein the phenyl ring is optionally
substituted with
one to two halogen, C 1_6 alkoxy, hydroxy or mono- or di-(C 1 _3 alkyl)amino,
C 1_6 alkyl-
S(O),,,, or phenyl-S(O),,, wherein the phenyl ring is optionally substituted
with one to two
halogen, C1_6 alkoxy, hydroxy, halogen or mono- or di-(C1_3 alkyl)amino;
or Z is optionally substituted with one to three amino or amino-C1_3 alkyl
wherein the N
atom is optionally independently mono- or di-substituted by aminoC1_6alkyl,
C1_3alkyl,
ary1C0_3alkyl, C1_; alkoxyC1_3 alkyl, Cj_; alkoxy, aroyl, C1_3acyl, C1_3alkyl-
S(O)",- or
ary1C0_3alkyl-S(O)nõ- each of the aforementioned alkyl and aryl attached to
the amino
group is optionally substituted with one to two halogen, C1_6 alkyl or CI_6
alkoxy;
or Z is optionally substituted with one to three aryl, heterocycle or
heteroaryl as
hereinabove described in this paragraph each in turn is optionally substituted
by halogen,
C' _b alkyl or C1 _6 alkoxy;


87


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
or Z is hvdroxy. halouen. nitrile. amino wherein the N atom is optionally
independently
mono- or di-substituted by C 1_3acyl. C1_6alkyl or C 1_3alkoxyC 1_3alkyl. C
i_6alkyl branched
or unbranched, Ci_6alkoxy, C1_3acylamino. nitrileC1_4alkyl. Ci_6 alkyl-
S(O),,,. and phenyl-
S(O),,,, wherein the phenyl ring is optionally substituted with one to two
halogen. Cl_6
alkoxy, hydroxy or mono- or di-(Ci_3 alkyl)amino;
each Ri is independently:

C1_1o alkyl branched or unbranched optionally partially or fully halogenated,
wherein one
lo or more C atoms are optionally independently replaced by O, N or S(O),,,,
and wherein
said CI_10 alkyl is optionally substituted with one to three C3_iocycloalkyl,
hydroxy. oxo,
phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl,
pyrrolidinyl,
imidazolyl, pyrazolyl, thienyl, furyl, dioxolanyl, isoxazolyl or isothiazolyl;
each of the
aforementioned being optionally substituted with one to five groups selected
from
halogen, C1_6 alkyl which is optionally partially or fully halogenated. C3_8
cycloalkanyl,
C5_8 cycloalkenyl, hydroxy, nitrile, C1_3 alkoxy which is optionally partially
or fully
halogenated or NHZC(O), mono- or di(C1_3alkyl)amino, and mono- or
di(C 1-3alkyl)aminocarbonyl;
or R, is

cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, or
cycloheptyloxy each
being optionally partially or fully halogenated and optionally substituted
with one to three
C1_3 alkyl groups optionally partially or fully halogenated, nitrile,
hydroxyC1_3alkyl or
aryl; or an analog of such cycloalkyl group wherein one to three ring
methylene groups
are independently replaced by 0, S(O),,,, CHOH, >C=O, >C=S or NH;
phenyloxy or benzyloxy each being optionally partially or fully halogenated
and
optionally substituted with one to three C1 _3 alkyl groups optionally
partially or fully
halogenated, nitrile, hydroxyC1_3alkvl or aryl; or an analog of such cvcloaryl
group
wherein one to two ring methyne groups are independently replaced by N;
88


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
cyclopropyl. cyclobutyl. cyclopentyl. cvclohexyl. cycloheptyl.
bicyclopentanyl,
bicyclohexanyl or bicycloheptanyl. each being optionally partially or fully
halogenated
and optionally substituted with one to three Ci_3 alkyl optionally partially
or fully
halogenated. nitrile, hydroxyCi_3alkyl or aryl: or an analoc, of such
cvcloalkyl group
wherein one to three ring methylene groups are independently replaced by O,
S(O),,,,
CHOH, >C=O, >C=S or NH;

C3_10 branched or unbranced alkenyl each being optionally partially or fully
halogenated,
and optionally substituted with one to three Ci_; branched or unbranched
alkyl, phenyl,
naphthyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl,
imidazolyl, pyrazolyl,
thienyl, furyl, isoxazolyl or isothiazolyl, each of the aforementioned being
substituted
with one to five halogen, C 1_6 alkyl which is optionally partially or fully
halogenated,
cyclopropanyl, cyclobutanyl, cyclopentanyl, cyclohexanyl, cycloheptanyl,
bicyclopentanyl, bicyclohexanyl and bicycloheptanyl, hydroxy, nitrile, C1_3
alkyloxy
which is optionally partially or fully halogenated, NH2C(O), mono- or di(CI _
3alkyl)aminocarbonyl; the C3_10 branched or unbranced alkenyl being optionally
interrupted by one or more heteroatoms chosen from 0, N and S(O),,,;
cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl,
bicyclohexenyl or bicycloheptenyl, wherein such cycloalkenyl group is
optionally
substituted with one to three C1_3 alkyl groups;

oxo, nitrile, halogen;

silyl containing three C1 _4 alkyl groups optionally partially or fully
halogenated; or
C3_6 alkynyl branched or unbranched carbon chain optionally partially or fully
halogenated, wherein one or more methylene groups are optionally replaced by
0, NH or
S(O),n and wherein said alkynyl group is optionally independently substituted
with one to
two oxo groups, hydroxy, pyrroldinyl, pyrrolyl, tetrahydropyranyl, one or more
C i_a alkyl
optionally substituted by one or more halogen atoms, nitrile, morpholino,
piperidinyl,

89


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
piperazinyl, imidazolyl, phenyl, pyridinyl. tetrazolyl. or mono- or
di(C1_3alkyl)amino
optionally substituted by one or more haloaen atoms:

each R,. R4. and R5 is
a C1_6 branched or unbranched alkyl optionally partially or fully halogenated,
C i_bacyl,
aroyl, CI_a branched or unbranched alkoxy. each being optionally partially or
fully
halogenated, halogen, methoxycarbonyl, CI_3 alkyl-S(O),,, optionally partially
or fully
halogenated, or phenyl-S(O),,,;

OR6. C1_6 alkoxy. hydroxy, nitrile, nitro. halogen;

or amino-S(O)n,- wherein the N atom is optionally independently mono- or di-
substituted
by C1.6alkyl or arylCo_3alkyl, or amino wherein the N atom is optionally
independently
mono- or di-substituted by C1_3alkyl, arylCo_3alkyl, Ci_6acyl, C1_6alkyl-
S(O),,,- or arylCo_
3alkyl-S(O),,,-, each of the aforementioned alkyl and aryl in this
subparagraph are
optionally partially or fully halogenated and optionally substituted with one
to two C1_6
alkyl or C1_6 alkoxy;

each R3 is independently:

phenyl, naphthyl, morpholino, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,
pyrrolyl,
pyrrolidinyl, imidazolyl, pyrazolyl, thiazolyl, oxazoyl, [1,3,4]oxadiazol,
triazolyl,
tetrazolyl, thienyl, furyl, tetrahydrofuryl, isoxazolyl, isothiazolyl,
quinolinyl,
isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl,
benzisoxazolyl,
benzpyrazolyl, benzothiofuranyl, cinnolinyl, pterindinyl, phthalazinyl,
naphthypyridinyl,
quinoxalinyl, quinazolinyl, purinyl or indazolyl, each of the aforementioned
is optionally
substituted with one to three phenyl, naphthyl, heterocycle or heteroaryl as
hereinabove
described in this paragraph, C1 _6 branched or unbranched alkyl which is
optionally
partially or fully halogenated, cyclopropanyl, cyclobutanyl, cyclopentanyl,
cyclohexanyl,
cycloheptanyl, bicyclopentanyl, bicyclohexanyl, bicycloheptanyl, phenyl CI_5
alkyl,



CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
naphthyl Ci_; alkyl, halogen, hydroxy. oxo, nitrile, Ci_3 alkoxy optionally
partially or fully
halogenated, phenyloxy, naphthyloxy. heteroaryloxy or heterocyclicoxy wherein
the
heterocyclic or heteroaryl moiety is as hereinabove described in this
paragraph, nitro,
amino, mono- or di-(Ci_3alky)lamino, phenylamino, naphthylamino, heteroaryl or
heterocyclic amino wherein the heteroaryl heterocyclic moiety is as
hereinabove
described in this paragraph. NH-)C(O), a mono- or di-(Ci_3alkyl)
aminocarbonyl, Ci_;
alkyl-C(O)-C 1_4 alkyl, amino-C 1 _; alkyl. mono- or di-(C 1 _;alkyl)amino,
mono- or di-(C I
3alkyl)amino-C1_5 alkyl, amino-S(O)2. di-(Ci_3alkyl)amino-S(O)2, R7-Ci_;
alkyl, Rg-CI _;
alkoxy, R9-C(O)-Ci_; alkyl, Rio-Ci_; alkyl(Ri i)N. carboxy-mono- or di-
(CI_;alkyl)-amino;
a fused aryl selected from benzocyclobutanyl, indanyl, indenyl,
dihydronaphthyl,
tetrahydronaphthyl, benzocycloheptanyl and benzocycloheptenyl, or a fused
heteroaryl
selected from cyclopentenopyridinyl, cyclohexanopyridinyl,
cyclopentanopyrimidinyl,
cyclohexanopyrimidinyl, cyclopentanopyrazinyl, cyclohexanopyrazinyl,
cyclopentanopyridazinyl, cyclohexanopyridazinyl, cyclopentanoquinolinyl,
cyclohexanoquinolinyl, cyclopentanoisoquinolinyl, cyclohexanoisoquinolinyl,
cyclopentanoindolyl, cyclohexanoindolyl, cyclopentanobenzimidazolyl,
cyclohexanobenzimidazolyl, cyclopentanobenzoxazolyl, cyclohexanobenzoxazolyl,
cyclopentanoimidazolyl, cyclohexanoimidazolyl, cyclopentanothienyl and
cyclohexanothienyl; wherein the fused aryl or fused heteroaryl ring is
independently
substituted with zero to three phenyl, naphthyl, pyridinyl, pyrimidinyl,
pyrazinyl,
pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl,
isothiazolyl, C1_6
alkyl which is optionally partially or fully halogenated, halogen, nitrile,
C1_3 alkyloxy
which is optionally partially or fully halogenated, phenyloxy, naphthyloxy,
heteroaryloxy
or heterocyclicoxy wherein the heteroaryl or heterocyclic moiety is as
hereinabove
described in this paragraph, nitro, amino, mono- or di-(C 1_3alkyl)amino,
phenylamino,
naphthylamino, heteroaryl or heterocyclic amino wherein the heteroaryl or
heterocyclic
moiety is as hereinabove described in this paragraph, NH2C(O), mono- or di-
(CI_
3alkyl)aminocarbonyl, CI_4 alkyl-OC(O), CI_; alkyl-C(O)-C1_4 alkyl, amino-Cl_5
alkyl,
mono- or di-(C1_3)alkylamino-C1_; alkyl, RIZ-CI_; alkyl, R13-CI_; alkoxy, R,4-
C(O)-CI_5
alkyl or Ri;-Cl_; alkyl(R16)N;

91


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
cyclopropanyl, cyclobutanyl. cyclopentanyl, cyclohexanyl, cycloheptanvl,
bicyclopentanyl, bicyclohexanyl or bicvcloheptanvl, each bein(y optionally be
partially or
fully halogenated and optionally substituted with one to three CI_3 alkyl
groups, or an
analog of such cycloalkyl group wherein one to three ring methylene aroups are
independently replaced by 0, S, CHOH, >C=O. >C=S or NH;

cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cvcloheptadienyl,
bicyclohexenyl or bicycloheptenyl, each optionally substituted with one to
three Ci_3 alkyl
groups;

C1_4 alkyl-phenyl-C(O)-C 1 _4 alkyl-, C 1_4 alkyl-C(O)-C 1_4 alkyl- or C1 _a
alkyl-phenyl-
S(O)m-CI_q alkyl-;

C1 _6 alkyl or C1_6 branched or unbranched alkoxy each of which is optionally
partially or
fully halogenated or optionally substituted with R17;

OR18 or CI_b alkyl optionally substituted with OR18;

amino or mono- or di-(CI_5alkyl)amino optionally substituted with R19;
R20C(O)N(R21)-, R220- or R23R24NC(O)-; R26(CH-,),,,C(O)N(R21)-, R23R)4NC(O)-
Ci_
3alkoxy or R26C(O)(CH2)mN(R21)-;

C2-6alkenyl substituted by R23R--)4NC(O)-;

C2_6 alkynyl branched or unbranched carbon chain, optionally partially or
fully
halogenated, wherein one or more methylene groups are optionally replaced by
0, NH,
S(O),,, and wherein said alkynyl group is optionally independently substituted
with one to
two oxo groups, pyrroldinyl, pyrrolyl, morpholino, piperidinyl, piperazinyl,
imidazolyl,
phenyl, pyridinyl, tetrazolyl one or more C1_a alkyl optionally substituted by
one or more
92


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
halogen atoms. nitrile. morpholino, piperidinyl, piperazinyl, imidazolyl.
phenyl,
pyridinyl. tetrazolyl. or mono- or di(Ci_4 alkyl)amino optionally substituted
by one or
more halogen atoms;

C1_6acyl or aroyl;
R6 is a:

C1_4 alkyl optionally partially or fully halogenated and optionally
substituted with R,6;

each R7, Rg, Rq, RIo, R12, R13. R14, R1;, R17, Riq, R~; and R26 is
independently:
nitrile, phenyl. morpholino, piperidinyl, piperazinyl, imidazolyl, pyridinyl,
tetrazolyl,
amino or mono- or di-(C1_4alkyl)amino optionally partially or fully
halogenated;

each R>> and R16 is independently:
hydrogen or CI_a alkyl optionally partially or fully halogenated;
R18 is independently:
hydrogen or a C1_4 alkyl optionally independently substituted with oxo or R25;
R?o is independently:
Cl-lo alkyl optionally partially or fully halogenated, phenyl, or pyridinyl;
R21 is independently:
hydrogen or C1_3 alkyl optionally partially or fully halogenated;
each Rx,, R23 and R24 is independently:

hydrogen, C1 _6 alkyl optionally partially or fully halogenated, said C1_6
alkyl is optionally
interrupted by one or more 0, N or S, said C1_6 alkyl also being independently
optionally
substituted by mono- or di-(C1_3alkyl)aminocarbonyl, phenyl, pyridinyl, amino
or mono-
93


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
or di-(Ci_4alkyl)amino each of which is optionally partially or fully
halogenated and
optionally substituted with mono- or di-(Ci_;alkvl)amino;
or R23 and R24 taken together optionally form a heterocyclic or heteroarvl
ring;
m=0. 1 or2:

WisOorSand
pharmaceutically acceptable derivatives thereof.

In another embodiment of the invention there is provided compounds of the
formula(III)
as described above and wherein:

E is -CHZ-, -NH- or -0-;
WisO;
and
G is:

phenyl, naphthyl, benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl,
benzocycloheptanyl, benzocycloheptenyl, indanyl, indenyl;

pyridinyl, pyridonyl, quinolinyl, dihydroquinolinyl, tetrahydroquinoyl,
isoquinolinyl,
tetrahydroisoquinoyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl,
benzthiazolyl, benzooxazolyl, benzofuranyl, benzothiophenyl, benzpyrazolyl,
dihydrobenzofuranyl, dibenzofuranyl, dihydrobenzothiophenyl, benzooxazolonyl,
benzo[1,4]oxazin-3-onyl, benzodioxolyl, benzo[1,3]dioxol-2-onyl, benzofuran-3-
onyl,
tetrahydrobenzopyranyl, indolyl, 2,3-dihydro-lH-indolyl, indolinyl, indolonyl,
indolinonyl, phthalimidyl, chromoyl;

oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl,
piperazinyl,
morpholino, tetrahydropyranyl, dioxanyl, tetramethylene sulfonyl,
tetramethylene

94


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
sulfoxidyl, oxazolinyl. 3.4-dihN~dro-2H-benzo[1,4]oxazinyl, thiazolinyl.
imidazolinyl,
tertrahydropyridinyl. homopiperidinyl. pvrrolinyl, tetrahydropyrimidinyl.
decahydroquinolinyl. decahydroisoquinolinyl, thiomorpholino, thiazolidinyl,
dihydrooxazinyl. dihydropyranvl. oxocanyl. heptacanyl, thioxanyl or dithianyl;
wherein G is optionally substituted by one or more Ri, R2 or R3.

In yet another embodiment there are provided compounds of the formula(III) as
described
immediately above and wherein:

E is -NH-:

G is phenyl, pyridinyl, pyridonyl, naphthyl, quinolinyl, isoquinolinyl,
pyrazinyl,
benzimidazolyl, benzooxazolyl, benzooxazolonyl, benzofuranyl, benzothiophenyl,
benzpyrazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, 3,4-dihvdro-2H-
benzo[1,4]oxazinyl, indanyl, indenyl, indolyl, indolinyl, indolonyl, 2,3-
dihydro-lH-
indolyl or indolinonyl, wherein G is optionally substituted by one or more RI,
R2 or R3;
Ar is:

naphthyl, quinolinyl, isoquinolinyl, tetrahydronaphthyl, tetrahydroquinolinyl,
tetrahydroisoquinolinyl, indanyl, indenyl or indolyl each being optionally
substituted by
one or more R4 or R; groups;

X is:

phenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, pyridinyl,
pyrimidinyl,
pyridinonyl, dihydropyridinonyl, maleimidyl, dihydromaleimidyl, piperdinyl,
piperazinyl, pyridazinyl or pyrazinyl; each being optionally independently
substituted
with one to three C1_4 alkyl, C1_4alkoxy, hydroxy, nitrile, amino, mono- or di-
(C 1 _3


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
alkyl)amino, mono- or di-(Ci_3 alkylanlino)carbonyl, NH-2C(O). Ci_6 alkvl-
S(O),,, or
halogen;

Y is:
a bond or

a CI_4 saturated or unsaturated carbon chain wherein one or more of the C
atoms is
optionally replaced by 0, N. or S(O)1 ,, and wherein Y is optionally
independently
substituted with one to two oxo groups. nitrile, phenyl or one or more C1_a
alkyl
t o optionally substituted by one or more halogen atoms;
Z is:

phenyl, heteroaryl selected from pyridinyl, piperazinyl, pyrimidinyl,
pvridazinyl,
pyrazinyl, imidazolyl, furanyl, thienyl and pyranyl, heterocycle selected from
2-oxa-5-
aza-bicyclo[2.2.1 ]heptanyl, tetrahydropyrimidonyl, pentamethylene sulfidyl,
pentamethylene sulfoxidyl, pentamethylene sulfonyl, tetramethylene sulfidyl,
tetramethylene sulfoxidyl tetramethylene sulfonyl, tetrahydropyranyl.
tetrahvdrofuranyl,
1,3-dioxolanonyl, 1,3-dioxanonyl, 1,4-dioxanyl, morpholino, thiomorpholino,
thiomorpholino sulfoxidyl, piperidinyl, piperidinonyl, dihydrothiazolvl,
dihydrothiazolyl
sulfoxidyl, pyrrolidinyl and dioxolanyl which are optionally substituted with
one to three
nitrile, C1-3 alkyl, C1_3 alkoxy, amino, mono- or di-(CI_3 alkyl)amino. CONHz
or OH;
or Z is optionally substituted by phenyl, heterocycle or heteroaryl as
hereinabove
described in this paragraph each in turn is optionally substituted by halogen,
C1_3 alkyl or
C 1 _3 alkoxy;

or Z is nitrile, nitrileC 1_3 alkyl, C1 _6 alkyl-S(O)n,, halogen, hydroxy,
C1_3 alkyl, C 1_3
acylamino, Ci_4 alkoxy, amino, mono- or di-(C1_3 alkyl)aminocarbonyl. or amino
mono or
di-substituted by aminoC1_6 alkyl or C1_3alkoxyC1_3alkyl;

each R, is independently:

96


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
C1_6 alkyl branched or unbranched optionally partially or ftillv halogenated.
wherein one
or more C atoms are optionally independently replaced by O. N or S(O)1,,, and
wherein
said C1_6 alkyl is optionally substituted with one to three C3_6cvcloalkyl.
oxo, phenyl,
dioxolanyl, pyrrolidinyl. furyl. isoxazolyl or isothiazolyl; each of the
aforementioned
being optionally substituted with one to three groups selected from halogen,
C1 _3 alkyl
which is optionally partially or ftllly halogenated, hydroxy, nitrile and
Cl_;alkoxy which
is optionally partially or fully halogenated;

cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl, bicyclopentanyl or
bicyclohexanyl, each being optionally partially or fully halogenated and
optionally
substituted with one to three C1_3 alkyl groups optionally partially or fully
halogenated,
nitrile, hydroxyC i_3alkyl or phenyl; or an analog of such cycloalkyl group
wherein one to
three ring methylene groups are independently replaced by 0, S, CHOH, >C=O,
>C=S or
NH;

oxo;
C3_6 alkynyl branched or unbranched carbon chain optionally partially or fully
halogenated, wherein one or more methylene groups are optionally replaced by
0, NH or
S(O),,, and wherein said alkynyl group is optionally independently substituted
with one to
two oxo groups, hydroxy, pyrroldinyl, pyrrolyl, tetrahydropyranyl, C i_4 alkyl
optionally
substituted by one or more halogen atoms, nitrile, morpholino, piperidinyl,
piperazinyl,
imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono- or di(C1_3alkyl)amino
optionally
substituted by one or more halogen atoms;
or

silyl containing three Ci_4 alkyl groups optionally partially or fully
halogenated;
R, is independently:

97


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
a Ci_; branched or unbranched alkyl optionally partially or fully halogenated.
acetyl,
aroyl, CI_a branched or unbranched alkoxy. each beinQ optionally partially or
fully
halogenated, halogen. methoxvcarbonyl. Ci_2 alkyl-S(O),,, optionally partially
or fully
halogenated, or phenyl-S(O),,,;

C i_3 alkoxy, hydroxy, nitrile, nitro, halogen;

or amino-S(O),,,- wherein the N atom is optionally independently mono- or di-
substituted
by C1_3alkyl or arylCO_3alkyl, or amino wherein the N atom is optionally
independently
]0 mono- or di-substituted by CI_3alkyl, arvlCo_3alkyl, Ci_3acy1, CI_aalkyl-
S(O),,,- or arylCo_
3alkyl-S(O),,,-, each of the aforementioned alkyl and aryl in this
subparagraph are
optionally partially or fully halogenated and optionally substituted with one
to two C1_3
alkyl or C I_3 alkoxy;

R3 is independently:

phenyl, morpholino, pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, pyrrolidinyl,
imidazolyl,
[1,3,4]oxadiazol, pyrazolyl, each is optionally substituted with one to three
phenyl,
naphthyl, heterocycle or heteroaryl as hereinabove described in this
paragraph, C1 _b alkyl
which is optionally partially or fully halogenated, cyclopropanyl,
cyclobutanyl,
cyclopentanyl, cyclohexanyl, cycloheptanyl, bicyclopentanyl, bicyclohexanyl.
bicycloheptanyl, phenyl C i_; alkyl, naphthyl CI _; alkyl, halogen, oxo,
hydroxy, nitrile, C1_3
alkoxy optionally partially or fully halogenated, phenyloxy, naphthyloxy,
heteroaryloxy
or heterocyclicoxy wherein the heteroaryl or heterocyclic moiety is as
hereinabove
described in this paragraph, nitro, amino, mono- or di-(C1_3alkyl)amino,
phenylamino,
naphthylamino, heteroaryl or heterocyclic amino wherein the heteroaryl or
heterocyclic
moiety is as hereinabove described in this paragraph, NH2C(O), a mono- or di-
(CI _
3alkyl)aminocarbonyl, C i_; alkyl-C(O)-C 1 _4 alkyl, mono- or di-(C
1_3alkyl)amino, mono- or
di-(C1_3)alkylamino-Ci_; alkyl, mono- or di-(CI_3alkyl)amino-S(O)z, R7-Ci_;
alkyl, R8-Ci_5
alkoxy, R9-C(O)-Ci_; alkyl, Rio-Ci_; alkyl(Rii)N, carboxy-mono- or di-(C1_5)-
alkyl-
amino;

98


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865

Ci_3 alkyl or CI-4 alkoxy each being optionally partially or fully
halog,enated or optionally
substituted with R17;

OR18 or Ci_6 alkyl optionally substituted with OR18;

amino or mono- or di- (Ci-5 alkyl)amino optionally substituted with R19;
R'?oC(O)N(R21)-, R220- ; R23R24NC(O)-: R,6CH2C(O)N(R,I)-, R--)3R?4NC(O)-
C1_2alkoxy
or R26C(O)CH2N(R21)-;

C?_4alkenyl substituted by R23R?4NC(O)-; or

C24 alkynyl branched or unbranched carbon chain optionally partially or fully
halogenated wherein one of the methylene groups is optionally replaced by 0,
and
optionally independently substituted with one to two oxo groups, pyrroldinyl,
pyrrolyl,
morpholino, piperidinyl, piperazinyl, imidazolyl, phenyl, pyridinyl,
tetrazolyl or one or
more C1_4 alkyl optionally substituted by one or more halogen atoms;

C I_3acy1; and

R23 and R24 taken together optionally form imidazolyl, piperidinyl,
morpholino,
piperazinyl or a pyridinyl ring.


In yet still another embodiment of the invention there is provided compounds
of the
formula(III) as described immediately above and wherein:

G is phenyl, pyridinyl, pyridonyl, naphthyl, quinolinyl, isoquinolinyl,
pyrazinyl, 3,4-
dihydro-2H-benzo[1,4]oxazinyl, benzothiophenyl, dihydrobenzofuranyl,

99


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
dihydrobenzothiophenyl, benzooxazolyl, indanyl, indolyl, indolinyl, indolonyl
or
indolinonyl, wherein G is optionally substituted by one or more Ri. R-) or R3;

Ar is naphthyl:
Xis
phenyl, imidazolyl, pyridinyl, pyrimidinyl, piperdinyl, piperazinyl,
pyridazinyl or
pyrazinyl each being optionally independently substituted with one to three
CI_4 alkvl, Ci
4alkoxy, hydroxy, nitrile, amino, mono- or di-(C1 _3 alkyl)amino, mono- or di-
(Ci_3
lo alkylamino)carbonyl. NHzC(O), C1_6 alkyl-S(O),,, or halogen;
Y is:
a bond or
a C1_4 saturated carbon chain wherein one or more of the C atoms is optionally
replaced
by 0, N or S and wherein Y is optionally independently substituted with
nitrile or oxo;
Z is:

phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, imidazolyl,
dihydrothiazolyl,
dihydrothiazolyl sulfoxide, pyranyl, pyrrolidinyl, phenylpiperazinyl,
tetrahydropyranyl,
tetrahydrofuranyl, dioxolanyl, 2-oxa-5-aza-bicyclo[2.2.1]heptanyl, morpholino,
thiomorpholino, thiomorpholino sulfoxidyl, piperidinyl, piperidinonyl,
piperazinyl or
tetrahydropyrimidonyl each of which are optionally substituted with one to two
C 1_2 alkyl
or C1_Z alkoxy; or


Z is hydroxy, C1_3 alkyl, C1_3 alkoxy, C1_3 acylamino, C1_3 alkylsulfonyl,
nitrile C1_3 alkyl
or amino mono or di-substituted by C1_3 alkoxyC1_3 alkyl;

each R, is independently:

100


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
Ci_; alkyl branched or unbranched optionallv partially or fully halo-enated.
Nvherein one
or more C atoms are optionally independently replaced by O. N or S(O)11,. and
wherein
said CI_; alkyl is optionally substituted with oxo. dioxolanyl, pyrrolidinyl,
furyl or
phenyl each optionally substituted with one to three halogen. CI_3 alkvl which
is
optionally partially or fully halogenated. hydroxy, nitrile and C1_3alkoxv
which is
optionally partially or fully halogenated;

cyclopropyl, cyclobutyl, cyclopentanyl. cyclohexanyl, bicyclopentanyl or
bicyclohexanyl, each being optionally partially or fully halogenated and
optionally
1o substituted with one to three C1_3 alkyl groups optionally partially or
fully halogenated,
nitrile, hydroxyC1_3alkyl or phenyl; and an analog of cyclopropyl, cyclobutyl,
cyclopentanyl, cyclohexanyl, bicyclopentanyl or bicyclohexanyl wherein one
ring
methylene group is replaced by 0;

oxo;

C24 alkynyl optionally partially or fully halogenated wherein one or more
methylene
groups are optionally replaced by O, and optionally independently substituted
with one to
two oxo groups, hydroxy, pyrroldinyl, pyrrolyl, tetrahydropyranyl, C 1_4 alkyl
optionally
substituted by one or more halogen atoms, nitrile, morpholino, piperidinyl,
piperazinyl,
imidazolyl, phenyl, pyridinyl, tetrazolyl, or mono- or di(C1_3alkyl)amino
optionally
substituted by one or more halogen atoms;

or

silyl containing three CI_Z alkyl groups optionally partially or fully
halogenated;
each R2 is independently:

101


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
a Ci_:, alkyl optionally partially or fully halo~~enated, C1_, alkoxy
optionally partially or
fully halogenated, bromo, chloro. fluoro. methoxycarbonyl, methyl-S(O),,,,
ethyl-S(O),,,
each optionally partially or ftilly halogenated or phenyl-S(O),,,;

or R, is mono- or di-C1_3acylamino, amino-S(O),,, or S(O),,,amino wherein the
N atom is
mono- or di-substituted by C,_3alkyl or phenyl, nitrile, nitro or amino;

each R3 is independently:

phenyl, morpholino, pyridinyl, pyrimidinyl, p_vrrolidinyl, 2,5-pyrrolidin-
dionyl,
lo imidazolyl, [1,3,4]oxadiazol, pyrazolyl, each of the aforementioned is
optionally
substituted with one to three Ci_3 alkyl which is optionally partially or
fiilly halogenated,
halogen, oxo, hydroxy, nitrile and Cl_; alkoxy optionally partially or fullv
halogenated;
C1_3 alkyl or C1_3 alkoxy optionally partially or fully halogenated or
optionally substituted
with R ;

OR18 or C1_3 alkyl optionally substituted with OR18;
amino or mono- or di-(C1 -3 alkyl)amino optionally substituted with R19;

R20C(O)N(R21)-, R220- ; R,3R24NC(O)-; R-)6CH2C(O)N(R2I)-, NH2C(O)methoxy or
R26C(O)CH-)N(R21)-;

C24 alkenyl substituted by R23R24NC(O)-; or

C2-4alkynyl substituted with pyrroldinyl or pyrrolyl;
C1-3acyl and

R23 and R24 taken together optionally form morpholino.

102


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
In yet a further embodiment of the invention there is provided compounds of
the
formula(III) as described immediately above and wherein:

G is phenyl, pyridinyl. pyridonyl, 2-naphthyl. quinolinyl. isoquinolinyl.
dihydrobenzofuranyl. indanyl, 5-indolyl. 3-oxo-3.4-dihydro-2H-benzo[1,4]oxazin-
8-yl,
benzooxalolyl, 2.3-dihydrobenzooxazol-7-y1. 2-oxo-2,3-dihydro-lH-indol-5-yl,
indolinyl,
indolonyl, or indolinonyl , wherein G is optionally substituted by one or more
RI, R-, or
R3;

Ar is 1-naphthyl;
X is:

phenyl, imidazolyl, pyridinyl, pyrimidinyl, piperdinyl, piperazinyl,
pyridazinyl or
pyrazinyl;

Y is:
a bond or
-CH2-, -CH2CH2-, -C(O)-, -0-, -S-, -NH-CH,CH,CHZ- , -N(CH3)-,
CH2(CN)CH2-NH-CH2 or -NH-;

Z is

morpholino, dioxolanyl, tetrahydrofuranyl, pyridinyl, 2-oxa-5-aza-
bicyclo[2.2.1]heptanyl, C1_3alkoxyphenylpiperazinyl, hydroxy, C1_3alkyl,
N,N-diC1-3alkoxyC1_3alkylamino, C1_3acylamino, Ci_3alkylsulfonyl or
nitrileC1_3alkyl;
each Ri is independently:

Ci-; alkyl optionally partially or fully halogenated wherein one or more C
atoms are
optionally independently replaced by 0 or N. and wherein said CI_; alkyl is
optionally
103


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
substituted with oxo. dioxolanvl, pyrrolidinyl. furyl or phenyl optionally
substituted by
C i _3alkoxy;

cyclopropyl, cyclopentanyl, cvclohexanyl and bicyclopentanyl optionally
substituted with
one to three methyl groups optionally partially or fully halogenated. nitrile,
hydroxymethyl or phenyl; or 2-tetrahydrofuranyl substituted by methyl; or
trimethyl silyl;

propynyl substituted hydroxy or tetrahvdropyran-2-yloxy;
RZis
is mono- or di-C1_3acylamino. amino-S(O),õ or S(O)~õ amino wherein the N atom
is mono-
or di-substituted by C1_3alkyl or phenyl, bromo, chloro, fluoro, nitrile,
nitro, amino,
methylsulfonyl optionally partially or fully halogenated or phenylsulfonyl;

each R3 is independently:

phenyl, morpholino, pyridinyl, pyrimidinyl, pyrrolidinyl, 2,5-pyrrolidin-
dionyl,
imidazolyl, [1,3,4]oxadiazol or pyrazolyl, each is optionally substituted with
CI_, alkyl
which is optionally partially or fully halogenated;

C1_3 alkyl or C1_3 alkoxy each being optionally partially or fully halogenated
or optionally
substituted with diethylamino;

OR18 or C1_3 alkyl optionally substituted with OR18;

amino or mono- or di-(C1_3 alkyl)amino optionally substituted with R19;
CH3C(O)NH-, R220- ; R23R24NC(O)-; R26CH-,C(O)N(R21)-, NH?C(O)methoxy or
R26C(O)CH2N(RZ])-;

104


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
C-2-4alkenyl substituted by R-'3R--14NC(O)-; or

C2_4 alkynyl substituted with pyrroldinyl or pyrrolyl:
C1_2acyl; and

R23 and R-24 are H or R23 and R24 taken together optionally form morpholino;
and
R26 is morpholino.


In yet still a further embodiment of the invention there are provided
compounds of the
formula(III) as described immediately above and wherein:

G is

phenyl, pyridinyl, 5-indolyl, 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl,
benzooxalolyl, 2,3-dihydrobenzooxazol-7-yl, 2-oxo-2,3-dihydro-IH-indol-5-yl or
2-
naphthyl wherein G is optionally substituted by one or more R, , R2 or R3;

X is:

imidazolyl, pyridinyl, pyrimidinyl or pyrazinyl;
Y is:

a bond, CH2(CN)CH2-NH-CH2, -CH2-, -NH-CH7CH2CH--)- or -NH-;

Z is morpholin-4y1, dioxolan-2y1, tetrahydrofuranyl, pyridinyl, 2-oxa-5-aza-
bicyclo[2.2.1]hept-5y1, methoxyphenylpiperazinyl, hydroxy, methyl, N,N-
dimethoxyethylamino, acetylamino. methylsulfonyl or cyanoethyl;

each Ri is independently:

105


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
tert-butyl, sec-butyl. tert-amyl, phenyl, tetrahydropyran-2-yloxypropynyl,
hydroxypropynyl, trihalomethyl, 2,2-diethylpropionyl or cyclohexanyl;

R-) is chloro, nitro, amino, nitrile, methylsulfonylamino, diacetylamino.
phenylsulfonylamino, N,N-di(methylsulfonyl)amino, methylsulfonyl or
trihalomethylsulfonyl;

R3 is independently:

methyl, Ci_3 alkoxy, methoxymethyl, hydroxypropyl, dimethylamino,
CI_4alkylamino,
NH2C(O)methoxy. acetyl, pyrrolidinyl. imidazolyl, pyrazolyl, morpholino or
morpholinocarbonyl.

In yet still even a further embodiment of the invention there is provided
compounds of
the formula(III) as described immediately above and wherein:

X is pyridinyl.

In still even a further embodiment of the invention there is provided
compounds of the
formula(III) as provided immediately above and wherein:

the pyridinyl is attached to Ar via the 3-pyridinyl position.
The following are representative compounds of the formula(III):
1-(4-tert-Butyl-phenyl)-3 - [4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-1-yl]-
urea;

1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(4-morpholin-4-ylmethyl-piperidin-1-yl)-
naphthalen-l-yl]-urea;

1-(6-Chloro-4-trifluoromethyl-pyridin-2-yl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea;

106


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-(4-Difluoromethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-
1-yl]-urea;

1-(3-Methyl-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylnlethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea;

1-[2-Methoxy-5-(1-methyl-l-phenyl-ethyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;
(5-tert-Butyl-2-methyl-phenyl)-carbamic acid 3-(5-{4-[3-(5-tert-butyl-2-methyl-
phenyl)-
ureido]-naphthalen-l-yl } -pyridin-2-ylamino)-propyl ester;

1-(6-tert-Butyl-benzo[ 1,3]dioxol-5-yl)-3- [4-(6-morpholin-4-ylmethyl-pvridin-
3-yl)-
naphthalen-1-yl]-urea;

N-(5-tert-Butyl-2-methoxy-3- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-acetamide;

1,3-Bis-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-Butyl-3-(2,2-dimethyl-[ 1,3]dioxolan-4-ylmethyl)-2-hydroxy-phenyl]-3-
[4-(6-
morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen- l -yl] -urea;

1-[5-tert-Butyl-2-(2-pyrrolidin-l-yl-ethoxy)-phenyl]-3- [4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

1-[5-tert-Butyl-3 -(2,3-dihydroxy-propyl)-2-hydroxy-phenyl]-3- [4-(6-morpholin-
4-
ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;
1-(23-Dimethyl-1 H-indol-5-yl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-
1-yl]-urea;

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-vl)-naphthalen-l-yl]-3-(2-p-tolyloxy-5-
trifluoromethyl-phenyl)-urea;

1-[2-(2-Methoxy-phenoxy)-5-trifluoromethyl-phenyl]-3 -[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-naphthalen-l-yl-
urea;
1- { 5-tert-Butyl-2-methyl-3- [3 -(tetrahydro-pyran-2-yloxy)-prop-l-ynyl] -
phenyl } -3-[4-(6-
morpholin-4-ylmethyl-pyridin-3 -yl)-naphthalen-l-yl]-urea;

1-{ 5-tert-Butyl-2-[3-(tetrahydro-pyran-2-yloxy)-prop-l-ynyl]-phenyl } -3-[4-
(6-
morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;
107


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-(5-Hydroxymethyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-vl)-

naphthalen-l-y 1] -urea;

1-(2-Methoxy-dibenzofuran-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-v1)-
naphthalen-l-vl ] -urea;

1-(2,5-Di-tert-butvl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea;
1-[3-(4-Bromo-l-methyl-1 H-pyrazol-3-yl)-phenvl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

1-(3-Hydroxy-5.6,7,8-tetrahydro-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-naphthalen-1-yl]-urea;

1-(1-Acetyl-2,3-dihydro-1 H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl ] -urea;

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-3-(3-oxazol-5-yl-
phenyl)-
urea;

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(3-[
1,3,4]oxadiazol-2-yl-
phenyl)-urea;
1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pvridin-3-
yl)-
naphthalen-l-yl]-urea;

Furan-2-carboxylic acid (4-tert-butyl-2- { 3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-ureido}-phenyl)-amide;

1-(2-Methoxy-4-phenylamino-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3 -yl)-

naphthalen-l-y1] -urea;

1-(5-Methoxy-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3 -yl)-
naphthalen-
1-yl]-urea;

1-(3-Hydroxy-naphthalen-2-y1)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-
1-yl]-urea;
N,N-Diethyl-4-methoxy-3- { 3-[4-(6-morpholin-4-vlmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -benzenesulfonamide;

1-(2,2-Difluoro-benzo [ 1,3 ]dioxol-5-yl)-3- [4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea;

108


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-[5-(1,1-Dimethyl-propyl)-2-phenoxv-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen- I -yl]-urea;

1-[5-(2,2-Dimethyl-propionyl)-2-methyl-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-
3-y])-naphthalen-l-yl]-urea;

2-Chloro--'-)- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
ureido } -
benzoic acid isopropyl ester;

1-(4-Amino-3,5-dibromo-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pvridin-3-yl)-
naphthalen-l-yl]-urea;

1-[5-tert-Butyl-3-(3-hydroxy-prop-l-ynyl)-2-methyl-phenyl]-3-[4-(6-morpholin-4-

ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-Butyl-2-(3-hydroxy-prop-l-vnvl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-

pyridin-3-yl)-naphthalen-l-yl]-urea;

1-[5-tert-Butyl-3-(2,2-dimethyl-[ 1,3]dioxolan-4-ylmethyl)-2-methoxy-phenyl]-3-
[4-(6-
morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-Butyl-3-(2,3-dihydroxy-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-

ylmethy l-pyri din-3 -y l)-naphthal en-1-y 1]-ure a;

1-(5-tert-Butoxy-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-[5-(1-Cyano-cyclopropyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-
3-yl)-naphthalen-1-yl]-urea;
1-[5-tert-Butyl-3-(2-diethylamino-ethyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-

ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-[1,3]dioxolan-2-yl-pyridin-3-yl)-
naphthalen-
1-yl]-urea;

1-(5-tert-Butyl-2-pyrrolidin-l-yl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-dimethylamino-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-propoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen- I -yl]-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3 -[4-(6-hydroxymethyl-pyridin-3-yl)-
naphthalen-l-
109


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2.6-dimethyl-morpholin-4-ylmethyl)-
pyridin-3-yl]-naphthalen-I -yl}-urea;
2-(5-tert-Butvl-2-methoxy-phenyl)-N-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-acetamide;

1-(2-Methoxy-5 -phenoxy-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen- l -yl]-urea;

1-(3,3-Dimethyl-2-oxo-2,3-dihydro-1 H-indol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-

pyridin-3-yl)-naphthalen-l-yl]-urea; 15 1-(5-tert-Butyl-2-cyclopentyloxy-
phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-

naphthalen-l-yl]-urea;
l -(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(3-pyridin-3-yl-pyrrolidin-l-
ylmethyl)-
pyridin-3 -yl]-naphthalen-l-yl } -urea;
I -(5-Cyclohexyl-2-methoxy-phenyl)-3 - [4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;

1-(2,4-Dimethoxy-5-trifluoromethyl-phenyl)-3- [4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea;

1-(6-tert-Butyl-3-oxo-3,4-dihydro-2H-benzo[ 1,4]oxazin-7-yl)-3-[4-(6-morpholin-
4-
ylmethyl-pyridin-3-yl)-naphthalen-l-vl]-urea;
1-(5-tert-Butyl-2-methoxy-3-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea;

1-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-3-[4-(6-methyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea;
N-Acetyl-N-(5-tert-butyl-2-methoxy-3- { 3- [4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-ureido } -phenyl)-acetamide;
1-(6-tert-Butyl-4-methyl-3-oxo-3,4-dihydro-2H-benzo [ 1,4] oxazin-8-yl)-3-[4-
(6-
morpholin-4-vimethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[6-tert-Butyl-4-(2-morpholin-4-yl-ethyl)-3 -oxo-3,4-dihydro-2H-benzo [
1,4]oxazin-8-
yl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-ethoxy-phenyl)-3- [4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

110


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-(5-tert-Butyl-2-isopropoxy-phenyl)-3-[4-(6-morpholin-4-ylmethvl-pvridin-3-
yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-imidazol-l-yl-pheny1)-3-[4-(6-morpholin-4-ylmethy 1-pyridin-
3-yl)-
naphthalen-I -yl]-urea;

N-(5-tert-Butyl-2-methoxy-4- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3 -yl)-
naphthalen-l-
yl]-ureido}-phenyl)-methanesulfonamide;
1-(5-tert-Butyl-3-ethylamino-2-methoxv-phenyl)-3-[4-(6-morpholin-4-vlmethyl-
pyridin-
3-yl)-naphthalen-l-yl]-urea;

N-(5-tert-Butyl-2-methoxy-3-{ 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido}-phenyl)-bis(methanesulfon)amide;

1-[5-tert-Butyl-2-(1-methyl-1 H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

1-(2-Methanesulfinyl-5-trifluoromethyl-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea;

1-(2-Ethanesulfonyl-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea;
1-[4-(6-{ [Bis-(2-methoxy-ethyl)-amino]-methyl}-pyridin-3-yl)-naphthalen-l-yl]-
3-(5-
tert-butyl-2-methoxy-phenyl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(3-dimethylamino-pyrrolidin-l-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea;

N-[1-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-l-vl }-
pyridin-2-
ylmethyl)-pyrrolidin-3 -yl] -acetamide;

1-(1-Acetyl-3,3-dimethyl-2,3-dihydro-1 H-indol-5-yl)-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-propionamide;
1-(5-tert-Butyl-2-methyl-benzooxazol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(3-
trifluoromethanesulfonyl-phenyl)-urea:

111


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
N-(5-tert-Butyl-2-methoxy-3- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido} -phenyl)-isobutyramide;

2-(4-tert-Butyl-2- k )-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl )-naphthalen-l-
yl]-ureido } -
phenoxy)-acetamide;

1-(5-tert-Butyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

1-(6-tert-Butyl-3-cyano-2-methoxymethoxy-pyridin-4-yl)-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

1-(6-tert-Butyl-3-cyano-2-hydroxy-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-
3-yl)-naphthalen-l-yl]-urea;
1-(5-tert-Butyl-3-cyano-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea;

1-[4-(6-Morpholiii-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(1,3.3-
trimethyl-2,3-
dihydro-1 H-indol-5-yl)-urea;

1-(5-tert-Butyl-benzooxazol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen- I -yl]-urea;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-benzenesulfonamide;

Ethanesulfonic acid (5-tert-butyl-2-methoxy-3- { 3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-ureido } -phenyl)-amide;
1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(4-morpholin-4-ylmethyl-piperidin-l-yl)-

naphthalen-l-yl]-urea;

1-[5-tert-Butyl-2-(1-methyl-1 H-pyrazol-4-yl)-phenyl]-3-[4-(4-morpholin-4-
ylmethyl-
piperidin-l-yl)-naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-morpholin-4-ylmethyl-pyrimidin-5-yl)-

naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methylsulfanyl-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxy-pyridin-3-yl)-3-[4-(6-inorpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-I -yl]-urea;
2,2,2-Trifluoro-ethanesulfonic acid (5-tert-butyl-2-methoxy-3-{3-[4-(6-
morpholin-4-
112


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-ureido}-phenyl)-amide;
N-(5-{4-[3-(5-tert-Butyl-2-methyl-phenvl)-ureido]-naphthalen-l-yl}-pvrazin-2-
yl)-
methanesulfonamide:
1-[4-(6- { [Bis-(2-cyano-ethyl)-amino]-methyl }-pyridin-3-yl)-naphthalen-l-yl]-
3-(5-tert-
butyl-2-methoxy-phenyl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(4-methyl-piperazin-l-ylmethyl)-
pyridin-3-
1 o yl]-naphthalen-l-y] } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-thiomorpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(2,6-dimethyl-piperidin-l-vlmethyl)-
pyridin-
3-yl]-naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(1-oxo-tetrahydro-thiopyran-4-
ylamino)-
pyridin-3-yl]-naphthalen-l-yl } -urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(tetrahydro-pyran-4-ylamino)-
pyridin-3-yl]-
naphthalen-l-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6- { [(2-cyano-ethyl)-(tetrahydro-
furan-2-
ylmethyl)-amino]-methyl } -pyridin-3-yl)-naphthalen-l-yl]-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3 - { 4-[6-(2-methoxymethyl-morpholin-4-N-
lmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4- { 6-[(2-morpholin-4-yl-ethylamino)-
methyl]-
pyridin-3-yl } -naphthalen- l -yl)-urea;

1-(5-tert-Butyl-2-m ethoxy-phenyl)-3 - { 4- [6-(2-methyl-3 -oxo-piperazin-l-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea;
1-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-l-yl } -pyridin-
2-
ylmethyl)-piperidine-3-carboxylic acid amide;

1-(5- { 4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-l-yl } -
pyridin-2-
ylmethyl)-piperidine-4-carboxylic acid amide;
1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(1-oxo-114-thiomorpholin-4-ylmethyl)-

pyridin-3-yl]-naphthalen-l-yl } -urea;

1-(3,)-Dimethyl-2-oxo-2,3-dihydro-1 H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-

pyridin-3-yl)-naphthalen-l-yl]-urea;

113


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
1 -(5-tert-Butyl-2-methoxy-phenyl )-3- { 4-[6-(3-oxo-piperazin- I -ylmethv l)-
pyridin-3-yl]-
naphthalen-l-v 1 } -urea;

1-{4-[6-(4-Acetyl-piperazin-l-ylmethyl)-pvridin-3-yl]-naphthalen-l-yl 1-3 -(5-
tert-butyl-
2-methoxy-phenyl)-urea;

4-(5-{4-[3-(5-tert-Butyl-2-methoxv-phenvl)-ureido]-naphthalen-l-yl} -pyridin-2-

ylmethyl)-piperazine-l-carboxylic acid ethyl ester;
1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[(2-pyridin-3-yl-ethylamino)-methyl]-

pyridin-3-yl } -naphthalen- l -yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[(tetrahydro-furan-3-ylamino)-
methyl]-
pyridin-3 -yl } -naphthalen- l -yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-{ [(2-cyano-ethyl)-pyridin-3-
ylmethyl-amino]-
methyl } -pyridin-3 -y l)-naphthalen-l-yl ] -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4- { 6-[(2-methylsulfanyl-ethylamino)-
methyl]-
pyridin-3-yl } -naphthalen- l -yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(2-oxa-5-aza-bicyclo [2.2.1 ]hept-5-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3 - { 4- [6-(2,6-dimethyl-morpholin-4-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-[(2-piperazin-l-yl-ethylamino)-
methyl]-
pyridin-3-yl } -naphthalen- l -yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(4-pyrimidin-2-yl-piperazin-l-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3 - {4- [6-(4-pyridin-2-yl-piperazin-l-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4- { 6- [4-(3-methoxy-phenyl)-piperazin-l-

ylmethyl]-pyridin-3-yl } -naphthalen- l -yl)-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3 - { 4-[6-(morpholine-4-carbonyl)-pyridin-3-
yl]-
naphthalen-l-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2-thia-5-aza-bicyclo[2.2.1 ]hept-5-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl}-urea;

114


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(5-morpholin-4-ylmethyl-pyrazin-2-yl)-
naphthalen-l-yl]-urea;

1-(6-tert-Butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl)-3-[4-(6-morpholin-
4-
ylmethyl-pyridin-3-yl)-naphthalen-l-\-l]-urea;
1-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-3-[4-(6-rnorpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea;

to N-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-l-yl}-pyridin-
2-yl)-
acetamide;

N-(5-tert-Butyl-2-methoxy-3- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-N-methyl-acetamide;
N-(5-tert-Butyl-2-methoxy-3-{ 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido}-phenyl)-2,2,2-trifluoro-acetamide;
1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(pyridin-3-yloxy)-pyridin-3-yl]-
naphthalen-l-
yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(pyridin-3-ylamino)-pyridin-3-yl]-
naphthalen-l-yl } -urea;

[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-carbamic acid 3-tert-
butyl-
phenyl ester;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-methanesulfonamide and
and the pharmaceutically acceptable derivatives thereof.

In yet another embodiment of the invention there is provided the following
compounds of
the formula(III):

1-(3-Methyl-naphthalen-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-urea;
N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-acetamide;

1-[5-tert-Butyl-3-(2,3-dihydroxy-propyl)-2-hydroxy-phenyl]-3-[4-(6-morpholin-4-

ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;

115


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-(2,3-Dimethyl-1 H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-
1-yl]-urea;

1- { 5-tert-Butyl-2-methyl-3-[3-(tetrahydro-pyran-2-yloxy)-prop-I -ynyl]-
phenyl }-3-[4-(6-
morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;
1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethvl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;
1- [5-(2,2-Dimethyl-propionyl)-2-methyl-phenyl]-3 -[4-(6-morpholin-4-vlmethyl-
pyridin-
3-yl)-naphthalen- I -yl]-urea;

1-[5-tert-Butyl-3-(3-hydroxy-prop-l-ynyl)-2-methyl-phenyl]-3-[4-(6-morpholin-4-

ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;
1-[5-tert-Butyl-2-(3-hydroxy-prop-l-ynyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-

pyridin-3-yl)-naphthalen-l-yl]-urea;

1-[5-tert-Butyl-3-(2,2-dimethyl- [ 1,3 ]dioxolan-4-ylmethyl)-2-methoxy-phenyl]
-3-[4-(6-
morpholin-4-ylmethyl-pyridin-3 -yl)-naphthalen-l-yl] -urea;
1-[5-tert-Butyl-3-(2,3-dihydroxy-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-

ylmethyl-pyridin-3 -yl)-naphthalen-l-yl] -urea;
1-(5-tert-Butoxy-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pvridin-3-yl)-
naphthalen-l-yl] -urea;

1-[5-(1-Cyano-cyclopropyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-
3o 3-yl)-naphthalen-l-yl]-urea;

1-[5-tert-Butyl-3-(2-diethylarnino-ethyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-
4-
ylmethyl-pyridin-3-yl)-naphthalen-l-yl] -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-[ 1,3]dioxolan-2-yl-pyridin-3-yl)-
naphthalen-
1-yl]-urea;

1-(5-tert-Butyl-2-pyrrolidin-l-yl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea;
1-(5-tert-Butyl-2-dimethylamino-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-propoxy-phenyl)-3- [4-(6-morpholin-4-ylmethyl-p_yridin-3-yl)-

naphthalen-l-yl]-urea;

116


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-hydroxvmethvl-pyridin-3-yl)-
naphthalen-l-
yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2.6-dimethyl-morpholin-4-ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea;

1-(5-Cyclohexyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(2,4-Dimethoxy-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxy-3-nitro-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl] -urea;
1-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-3-[4-(6-methyl-pyridin-3-vl)-
naphthalen-l-
yl]-urea;

N-Acetyl-N-(5-tert-butyl-2-methoxy-3- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-ureido}-phenyl)-acetamide;
1-(6-tert-Butyl-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl)-3-[4-(6-
morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-ethoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-isopropoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;
1-(5-tert-Butyl-2-imidazol-l-yl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-3-ethylamino-2-methoxy-phenyl)-3- [4-(6-morpholin-4-ylmethyl-
pyridin-
)-yl)-naphthalen-l-yl]-urea;

N-(5-tert-Butyl-2-methoxy-3-{ 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-bis(methanesulfon)amide;

1-[5-tert-Butyl-2-(1-methyl-1 H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

1-(2-Methanesulfinyl-5-trifluoromethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea;
1-[4-(6-{ [Bis-(2-methoxy-ethyl)-amino]-methyl }-pyridin-3-yl)-naphthalen-l-
yl]-3-(5-
117


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
tert-butyl-2-methoxy-phenyl)-urea;

N-[1-(5- { 4-[3-(5-tert-Butyl-2-methoxv-phenyl)-ureido]-naphthalen-l-yl } -
pyridin-2-
ylmethyl)-pyrrolidin-3-yl]-acetamide:
1-(1-Acetyl-3.3-dimethyl-2,3-dihydro-1 H-indol-5-yl)-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

N-(5-tert-Butyl-2-methoxy-3- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido}-phenyl)-propionamide;

1-(5-tert-Butyl-2-methyl-benzooxazol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-3-(3-
trifluoromethanesulfonyl-phenyl)-urea;
N-(5-tert-Butyl-2-methoxy-3- { 3-[4-(6-morpholin-4-vlmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-isobutyramide;
2-(4-tert-Butyl-2- { 3-[4-(6-morpholin-4-vlmethy l-pyridin-3 -yl)-naphthalen-l-
yl]-ureido } -
phenoxy)-acetamide;

1-(5-tert-Butyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

I -(5-tert-Butyl-3-cyano-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-benzooxazol-7-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

N-(5-tert-Butyl-2-methoxy-3 - { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-benzenesulfonamide;
Ethanesulfonic acid (5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-ureido } -phenyl)-amide;

1-(5-tert-Butyl-2-methoxy-phenyl)-3 - [4-(2-morpholin-4-ylmethyl-pyrimidin-5 -
yl)-
naphthal en-l-yl ] -ure a;

1-(5-tert-Butyl-2-methylsulfanyl-phenyl)-3 -[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxy-pyridin-3-vl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;

118


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
2.2,2-Trifluoro-ethanesulfonic acid (5-tert-butyl-2-methoxy-3-{3-[4-(6-
morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-l-vl]-ureido}-phenyl)-amide;

N-(5-{4-[3-(5-tert-Butyl-2-methyl-phenyl)-ureido]-naphthalen-l-N-l}-pyrazin-2-
vl)-
methanesulfonamide:

1-[4-(6-{ [Bis-(2-cyano-ethyl)-amino]-methyl}-pyridin-3-yl)-naphthalen-l-yl]-3-
(5-tert-
butyl-2-methoxy-phenyl)-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(4-methyl-piperazin-l-ylmethyl)-
pvridin-3-
yl]-naphthalen-l-vl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-thiomorpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen- l -yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenvl)-3- { 4-[6-(2,6-dimethyl-piperidin-l-
ylmethyl)-pyridin-
3-yl]-naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(1-oxo-tetrahydro-thiopyran-4-
ylamino)-
pyridin-3-yl]-naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(tetrahydro-pyran-4-vlamino)-
pyridin-3-yl]-
naphthalen-l-yl}-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3 - [4-(6- { [(2-cyano-ethyl)-(tetrahydro-
furan-2-
ylmethyl)-amino] -methyl } -pyridin-3-yl)-naphthalen-l-yl]-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3 - { 4-[6-(2-methoxymethyl-morpholin-4-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2-methyl-3-oxo-piperazin-l-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea;

1-(5- { 4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-l-yl } -
pyridin-2-
ylmethyl)-piperidine-3-carboxylic acid amide;
1-(5-tert-Butyl-2-methoxy-phenyl)-3- { 4- [6-(1-oxo-114-thiomorpholin-4-
ylmethyl)-
pyridin-3 -yl]-naphthalen- l -yl } -urea;
1-(3,3-Dimethyl-2-oxo-2,3-dihydro-1 H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-

pyridin-3-yl)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenvl)-3-{4-[6-(3-oxo-piperazin-1-ylmethyl)-pyridin-
3-yl]-
naphthalen-l-yl}-urea;

119


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{ 6-[(tetrahydro-furan-3-ylamino)-
methyl]-
pyridin-3-yl } -naphthalen-l-yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-1 [(2-cyano-ethyl)-pyridin-3-
ylmethyl-amino]-
methyl}-pyridin-3-yl)-naphthalen-l-yl]-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3-i4-[6-(2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-
ylmethyl)-
pyridin-3-yl]-naphthalen-1-yl }-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2,6-dimethyl-morpholin-4-ylmethyl)-
pyri din-3 -y l]-n aphthal en-1-y l}-ure a;

1 -(5-tert-Butyl-2-methoxy-phenyl)-3 -(4- { 6-[4-(3-methoxy-phenyl)-piperazin-
l-
ylmethyl]-pyridin-3-yl }-naphthalen-l-yl)-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(morpholine-4-carbonyl)-pyridin-3-
yl]-
naphthalen-l-yl } -urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(5-morpholin-4-ylmethyl-pyrazin-2-yl)-
naphthalen-1-yl]-urea;

1-(6-tert-Butyl-3-oxo-3,4-dihydro-2H-benzo[ 1,4]oxazin-8-yl)-3-[4-(6-morpholin-
4-
ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea;
1-(3 -Amino- 5 -tert-butyl-2-methoxy-phenyl)-3 - [4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea;

N-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-l-yl } -pyridin-
2-yl)-
acetamide;
N-(5-tert-Butyl-2-methoxy-3- 13 -[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-N-methyl-acetamide;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido}-phenyl)-2,2,2-trifluoro-acetamide;
1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(pyridin-3-yloxy)-pyridin-3-yl]-
naphthalen-l-
yl}-urea;

[4-(6-Morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-carbamic acid 3-tert-
butyl-
phenyl ester;

N-(5-tert-Butyl-2-methoxy-3- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-methanesulfonamide and
and the pharmaceutically acceptable derivatives thereof.
120


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
In addtion to the abovementioned compounds the following prophetic compounds
of the
formula(III) may be made by the general methods described hereinbelow:

1-(5-tert-Butyl-2-methylsulfanyl-pyridin-3 -y 1)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-chloro-pyridin-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methylamino-pyridin-3-yl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea;
N-(5-tert-Butyl-3- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-
ureido}-2-oxo-2H-pyridin-l-yl)-methanesulfonamide;
5-tert-Butyl-7- { 3- [4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-
ureido } -
benzooxazole-2-carboxylic acid amide;

2-(5-tert-Butyl-7- { 3- [4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-l-
yl]-ureido } -
benzooxazol-2-yl)-ac etamide;

5-tert-Butyl-2-methoxy-3- { 3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-
ureido}-benzamide and

and the pharmaceutically acceptable derivatives thereof.

Any compounds of this invention containing one or more asymmetric carbon atoms
may
occur as racemates and racemic mixtures, single enantiomers, diastereomeric
mixtures
and individual diastereomers. All such isomeric forms of these compounds are
expressly
included in the present invention. Each stereogenic carbon may be in the R or
S
configuration, or a combination of configurations.

Some of the compounds of formulas (I), (la), (II) and (III) can exist in more
than one
tautomeric form. The invention includes all such tautomers.


121


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
All terms as used herein in this specification. unless otherwise stated, shall
be understood
in their ordinary nleaning as known in the art. For example, "C I 4alkoxy" is
a C1_4alkyl
with a terminal oxygen, such as methoxy, ethoxy. propoxy, pentoxy and hexoxy.
All
alkyl, alkenyl and alkynyl groups shall be understood as being branched or
unbranched
where structurally possible and unless otherwise specified. Other more
specific
definitions are as follows:

The term "aroyl" as used in the present specification shall be understood to
mean
"benzoyl" or "naphthoyl".

The term "carbocycle" shall be understood to mean an aliphatic hydrocarbon
radical
containing from three to twelve carbon atoms. Carbocycles include hydrocarbon
rings
containing from three to ten carbon atoms. These carbocycles may be either
aromatic
and non-aromatic ring systems. The non-aromatic ring systems may be mono- or
polyunsaturated. Preferred carbocycles include but are not limited to
cyclopropyl,
cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl,
cycloheptanyl,
cycloheptenyl, phenyl, indanyl, indenyl, benzocyclobutanyl, dihydronaphthyl,
tetrahydronaphthyl, naphthyl, decahydronaphthyl, benzocycloheptanyl and
benzocycloheptenyl. Certain terms for cycloalkyl such as cyclobutanyl and
cyclobutyl
shall be used inerchangeably.

The term "heterocycle" refers to a stable nonaromatic 4-8 membered (but
preferably, 5 or
6 membered) monocyclic or nonaromatic 8-11 membered bicyclic heterocycle
radical
which may be either saturated or unsaturated. Each heterocycle consists of
carbon atoms
and one or more, preferably from I to 4 heteroatoms selected from nitrogen,
oxygen and
sulfur. The heterocycle may be attached by any atom of the cycle, which
results in the
creation of a stable structure. Unless otherwise stated, heterocycles include
but are not
limited to, for example oxetanyl, pyrrolidinyl, tetrahydrofuranyl,
tetrahydrothiophenyl,
piperidinyl, piperazinyl, moipholinyl. tetrahydropyranyl, dioxanyl,
tetramethylene
sulfonyl, tetramethylene sulfoxidyl, oxazolinyl, thiazolinyl, imidazolinyl,
tertrahydropyridinyl, homopiperidinyl, pyrrolinyl, tetrahydropyrimidinyl,
122


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
decahydroquinolinyl. decahydroisoquinolinyl, thiomorpholinyl. thiazolidinvl,
dihydrooxazinyl. dihydropyranyl. oxocanyl, heptacanyl, thioxanyl, dithianvl or
2-oxa- or
2-thia-5-aza-bicyclo[2.2.1]heptanyl.

The term "heteroaryl" shall be understood to mean an aromatic 5-8 membered
monocyclic or 8-11 membered bicyclic ring containing 1-4 heteroatoms such as
N,O and
S. Unless otherwise stated, such heteroarvls include: pyridinyl, pyridonyl.
quinolinyl,
dihydroquinolinyl, tetrahydroquinoyl. isoquinolinyl, tetrahydroisoquinoyl,
pyridazinyl,
pyrimidinyl, pyrazinyl. benzimidazolyl. benzthiazolyl, benzoxazolyl,
benzofiiranyl,
] o benzothiophenyl, benzpyrazolyl, dihydrobenzofuranyl,
dihydrobenzothiophenyl,
benzooxazolonyl, benzo[l,4]oxazin-3-onyl, benzodioxolyl, benzo[1,3]dioxol-2-
onyl,
tetrahydrobenzopyranyl, indolyl, indolinyl, indolonyl, indolinonyl,
phthalimidyl.
The term "heteroatom" as used herein shall be understood to mean atoms other
than
carbon such as 0, N, S and P.

The term "aryl" as used herein shall be understood to mean aromatic carbocycle
or
heteroaryl as defined herein.

2o Terms which are analogs of the above cyclic moieties such as aryloxy or
heteroaryl
amine shall be understood to mean an aryl, heteroaryl, heterocycle as defined
above
attached to it's respective group.

As used herein, "nitrogen" and "sulfur" include any oxidized form of nitrogen
and sulfur
and the quaternized form of any basic nitrogen.

The term "halogen" as used in the present specification shall be understood to
mean
bromine, chlorine, fluorine or iodine.

3o The compounds of the invention are only those which are contemplated to be
'chemically
stable' as will be appreciated by those skilled in the art. For example, a
compound which
123


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
would have a'danaling valency'. or a'carbanion' are not conipounds
contemplated by
the invention.

The invention includes pharmaceutically acceptable derivatives of compounds of
formula
(I), (la), (II) and (III) . A"pharmaceutically acceptable derivative" refers
to any
pharmaceutically acceptable salt or ester of a compound of this invention, or
any other
compound which, upon administration to a patient, is capable of providing
(directly or
indirectly) a compound of this invention, a pharmacologically active
metabolite or
pharmacologically active residue thereof. A pharmacologically active
metabolite shall be
l0 understood to mean any compound of the invention capable of being
metabolized
enzymatically or chemically. This includes, for example, hydroxylated or
oxidized
derivative compounds of the formulas(I), (Ia), (II) or (III).

Pharmaceutically acceptable salts of the compounds of this invention include
those
derived from pharmaceutically acceptable inorganic and organic acids and
bases.
Examples of suitable acids include hydrochloric, hydrobromic, sulfuric,
nitric, perchloric,
fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-
sulfuric,
tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic,
naphthalene-2-sulfuric
and benzenesulfonic acids. Other acids, such as oxalic acid, while not
themselves
pharmaceutically acceptable, may be employed in the preparation of salts
useful as
intermediates in obtaining the compounds of this invention and their
pharmaceutically
acceptable acid addition salts. Salts derived from appropriate bases include
alkali metal
(e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(C1-C4

alkyl)4+ salts.

In addition, the compounds of this invention include prodrugs of compounds of
the
formula (I), (Ia), (II) and (III). Prodrugs include those compounds that, upon
simple
chemical transformation, are modified to produce compounds of the invention.
Simple
chemical transformations include hydrolysis, oxidation and reduction.
Specifically, when
a prodrug of this invention is administered to a patient, the prodrug may be
transformed
into a compound of the invention, thereby imparting the desired
pharmacological effect.
124


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
METHODS OF USE


In accordance with the invention, there are provided methods of using the
compounds of
the formulas (I), (Ia), (II) and (III). The compounds of the invention
effectively block
inflammatory cytokine production from cells. The inhibition of cytokine
production is an
lo attractive means for preventing and treating a variety of disorders
associated with excess
cytokine production, e.g., diseases and pathological conditions involving
inflammation.
Thus, the compounds of the invention are useful for the treatment of such
conditions.
These encompass chronic inflammatory diseases including, but not limited to.
osteoarthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease,
ulcerative
colitis, psoriasis, graft versus host disease, systemic lupus erythematosus
and insulin-
dependent diabetes mellitus. The compounds of the invention can also be used
to treat
other disorders associated with the activity of elevated levels of
proinflammatory
cytokines such as responses to various infectious agents and a number of
diseases of
autoimmunity such as rheumatoid arthritis, toxic shock syndrome, diabetes and
inflammatory bowel diseases unrelated to those listed above are discussed in
the
Background of the Invention.

In addition, the compounds of the invention being inhibitors of cytokine
production are
expected to block inducible cyclooxygenase (COX-2) expression. COX-2
expression has
been shown to be increased by cytokines and it is believed to be the isoform
of
cyclooxygenase responsible for inflammation (M.K. O'Banion et al., Proc. Natl.
Acad.
Sci. U.S.A, 1992, 89, 4888.) Accordingly, the present novel compounds would be
expected to exhibit efficacy against those disorders currently treated with
COX inhibitors
such as the familiar NSAIDs. These disorders include acute and chronic pain as
well as
symptoms of inflammation and cardiovascular disease.

As discussed in the Background of the Invention, IL-8 plays a role in the
influx of
neutrophils into sites of inflammation or injury. Therefore, in a yet further
aspect of the
125


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
invention, the compounds of the invention may be useful in the treatment of
diseases
mediated predominantly by neutrophils such as stroke and myocardial
infarction, alone or
following thrombolytic therapy, thermal injury, adult respiratory distress
syndrome
(ARDS), multiple organ injury secondary to traunla, acute glomerulonephritis,
dermatoses with acute inflammatory components, acute purulent meningitis or
other
central nervous system disorders. hemodialysis, leukopherisis, granulocyte
transfusion
associated syndromes, and necrotizing entrerocolitis.

For therapeutic use, the compounds of the invention may be administered in any
1 o conventional dosage form in any conventional manner. Routes of
administration include,
but are not limited to, intravenously, intramuscularly, subcutaneously,
intrasynovially, by
infusion, sublingually, transdermally, orally, topically or by inhalation. The
preferred
modes of administration are oral and intravenous.

The compounds of this invention may be administered alone or in combination
with
adjuvants that enhance stability of the inhibitors, facilitate administration
of pharmaceutic
compositions containing them in certain embodiments, provide increased
dissolution or
dispersion, increase inhibitory activity, provide adjunct therapy, and the
like, including
other active ingredients. Advantageously, such combination therapies utilize
lower
2o dosages of the conventional therapeutics, thus avoiding possible toxicity
and adverse side
effects incurred when those agents are used as monotherapies. Compounds of the
invention may be physically combined with the conventional therapeutics or
other
adjuvants into a single pharmaceutical composition. Advantageously, the
compounds
may then be administered together in a single dosage form. In some
embodiments, the
pharmaceutical compositions comprising such combinations of compounds contain
at
least about 5%, but more preferably at least about 20%, of a compound of
formulas (I),
(Ia), (II) or (III) (w/w) or a combination thereof. The optimum percentage
(w/w) of a
compound of the invention may vary and is within the purview of those skilled
in the art.
Alternatively, the compounds may be administered separately (either serially
or in
parallel). Separate dosing allows for greater flexibility in the dosing
regime.
126


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
As mentioned above. dosage forms of the compounds of this invention include
pharmaceutically acceptable carriers and adjuvants known to those of ordinary
skill in the
art. These carriers and adjuvants include, for example, ion exchangers.
alumina,
aluminum stearate, lecithin, serum proteins. buffer substances, water, salts
or electrolytes
and cellulose-based substances. Preferred dosage forms include, tablet,
capsule, caplet.
liquid, solution, suspension, emulsion. lozenges. syrup, reconstitutable
powder, granule,
suppository and transdermal patch. Methods for preparing such dosage forms are
known
(see, for example, H.C. Ansel and N.G. Popovish, Pharmaceutical Dosage Fornzs
afid
Drug Delivery Systenzs, 5th ed., Lea and Febiger (1990)). Dosage levels and
requirements are well-recognized in the art and may be selected by those of
ordinary skill
in the art from available methods and techniques suitable for a particular
patient. In some
embodiments, dosage levels range from about 1-1000 mg/dose for a 70 kg
patient.
Although one dose per day may be sufficient, up to 5 doses per day may be
given. For
oral doses, up to 2000 mg/day may be required. As the skilled artisan will
appreciate,
lower or higher doses may be required depending on particular factors. For
instance,
specific dosage and treatment regimens will depend on factors such as the
patient's
general health profile, the severity and course of the patient's disorder or
disposition
thereto, and the judgment of the treating physician.

In order that this invention be more fully understood, the following examples
are set
forth. These examples are for the purpose of illustrating preferred
embodiments of this
invention, and are not to be construed as limiting the scope of the invention
in any way.
The examples which follow are illustrative and, as recognized by one skilled
in the art,
particular reagents or conditions could be modified as needed for individual
compounds.
Starting materials used in the scheme below are either commercially available
or easily
prepared from commercially available materials by those skilled in the art.

GENERAL SYNTHETIC METHODS

127


CA 02362003 2008-01-24
25771-701

The compounds of the invention may be prepared by Method A, B, or C as
illustrated in
Scheme I, preferably method C. Further reference in this regard may be made to
PCT
Publication WO 2000/043 384.


Method A

D'-NCO 0
D~NH2 V D.NA, N.D'
- ~
H H
I, Ia, II, or
IV III(E=NH)
Method B

1 phosgene 0
p" D. ~ .D'
NH2 N N
2. D' -NH2 H H

1, la, Il, or
IV VI III (E = NH)
Method C

O D'-NH2 0
CICO Ph ~ ,p
p~NH2 2 D,N O.Ph VI p,N N'
H H H
IV Vll I, Ia, II, or
III (E = NH)

In the above Methods, D Ar, (for formula I and la compounds) or G
(for formula II or I II compounds); D' = Ar2-X-Y-Z (or its precursor) for
formula I and la compounds or Ar-X-Y-Z (or its precursor) for formula II
or III compounds

128


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
In Method A. a mixture of an amine of formula IV and an isocyanate of formula
V is
dissolved in a non-protic, anhydrous solvent such as THF, ether, toluene,
dioxane or ethyl
acetate. The preferred solvent is THF. The mixture is stirred at between 0 -
45 C,
preferably at 25 C, for 2-24 hr, and the volatiles are removed. Purification
of the residue
by recrystallization from an appropriate solvent such as ethyl
acetate/hexanes, ethyl
acetate/methanol. THF/petroleum ether, ethanol/water or by silica gel
chromatography,
using for example, hexanes and ethvl acetate as eluents, provides the product
of formula
I, la, II or III (E = NH).

In Method B. an amine of formula IV is dissolved in a halogenated solvent.
such as
methylene chloride, chloroform or dichloroethane. The preferred solvent is
methylene
chloride. The mixture is diluted with aqueous alkali, such as sodium
bicarbonate or
potassium carbonate, cooled in an ice bath and phosgene is added. The mixture
is
vigorously stirred for 5- 30 min, with 10 min being preferable. The organic
layer is
dried, with agents such as MgSO4 or Na2SO4, and the volatiles removed to
provide the
corresponding isocyanate, D-N=C=O. The isocyanate and amine VI are mixed in a
non-
protic, anhydrous solvent such as THF, ether, toluene, dioxane, methylene
chloride or
ethyl acetate. The preferred solvent is THF. The mixture is stirred at between
0 - 45 C,
preferably at 25 C, for 2 - 24 hr, and the volatiles are removed.
Purification of the
residue by recrystallization or by silica gel chromatography, as above,
provides the
product of formula I, Ia, II or III (E = NH).

The required isocyanate may also be prepared from the carboxylic acid D-CO2H
by
reaction with a chloroformate, such as ethyl chloroformate, in the presence of
a suitable
base, such as triethylamine, in a suitable solvent, such as THF at about 0 C.
The
resulting mixed anhydride is treated with an aqueous solution of sodium azide.
Heating a
solution of the resulting acyl azide in a suitable solvent, such as toluene,
at about reflux,
results in a Curtius rearrangement, providing the isocyanate D-N=C=O in situ.

129


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
In Method C. an amine of formula IV is dissolved in a suitable solvent such as
a
halogenated solvent such as methylene chloride, chloroform or dichloroethane.
The
preferred solvent is methylene chloride. A suitable base such as triethylamine
mav be
added, followed by phenyl chloroformate. The mixture is stirred at between 0 -
85 C.
preferably at reflux temperature, for ?- 24 hr, and the volatiles are removed
providing
carbamate VII. The carbamate and amine VI are mixed in a non-protic, anhydrous
solvent such as THF, ether, toluene. dioxane, methylene chloride or ethyl
acetate. The
preferred solvent is THF. The mixture is stirred at between 0 - 110 C,
preferably at
reflux temperature, for 2 - 24 hr, and the volatiles are removed. Purification
of the
t o residue as above provides the product of formula I, Ia, II or III (E =
NH). This Method
may also be employed in the reverse sense, that is one may form the carbamate
from
D'NH2 and react this carbamate with amine D-NH,. Example 37 illustrates the
synthesis
of a compound of formula III in which E is -0-, and Example 38 illustrates the
synthesis
of a compound of formula III in which E is -CH2-.

The method used to produce amines of formula IV will depend on the nature of
the
desired group D. In general, intermediates of formula IV can be made by
methods
known to those skilled in the art. Some general methods are illustrated in the
schemes
below. Compounds D'-NCO or D'-NH2 in Scheme I may be commercially available,
or
may be prepared by methods known to those skilled in the art. If D' is a
precursor of
Ar2-X-Y-Z or Ar-X-Y-Z , the desired final product of formula I, Ia, II or III
may be
constructed by methods known to those skilled in the art. Illustrative
examples are
contained in the Synthetic Examples section below.

Desired aminopyrazoles of formula XV, for use in preparation of compounds of
formula I
or Ia, can be prepared as described in Scheme II. A hydrazine of formula X,
bearing
substituent R3, may be prepared by Method D or E. In Method D. an aryl bromide
of
formula VIII is dissolved in a non-protic, inert solvent, such as THF, 1,4-
dioxane or
diethyl ether, and cooled to low temperature under an inert atmosphere. The
preferred
temperature for the solution is -77 C. A strong base dissolved in a non-
protic, inert
solvent, such as hexanes, THF or ether, is added dropwise while maintaing a
reaction
temperature below 0 C and preferrably below -60 C. The preferred bases are
alkyl
130


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
lithium reagents and the most preferred is sec-butyl lithium. After the
addition of the
base, the reaction mixture is stirred for a period of time between thirty and
ninety min or
until all the starting aryl bromide has been consumed. An excess of dialkyl
azodicarboxylate is added while maintaining a reaction temperature below 0 C
and
preferrably below -60 C. The preferred dialkyl azodicarboxylate is di-tej=t-
butyl
azodicarboxylate. The reaction is stirred at cold temperatures and warmed to
room
temperature after 0.5hto 2 hr. The reaction is quenched with the addition of
water and the
product extracted into a non-protic solvent, such as ethyl acetate, diethvl
ether or
chloroform. The organic layers are dried with agents such as MgSO4 or Na?SO4
and the
volatiles removed. The residue is dissolved in protic solvents, such as
methanol or iso-
propanol, cooled, preferably to 0-5 C and treated with acid. Preferred acids
are
hydrochloric, hydrobromic, sulfuric and trifluoroacetic. The most preferred is
hydrochloric acid in gaseous form. After the addition of excess acid the
mixture is heated
at the reflux temperature of the solvent until all starting material has been
consumed.
After cooling the product aryl-hydrazine salt of formula X is filtered and
dried.
Scheme II

131


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
Method D
1. base

R3-Br 2. t-BuOzCN=NCOZt-Bu
VIII

Method E R3 NHNH2
X
R3 NH2 1. NaNOz
IX
2. reduce
Method F 1. base
CH3CN 2. R1CO2Me
XI 0
Method G R~CN
1
HO2CCN XIV
RjC(O)CI
XII XIII
R1
Method H ~
X + XIV N
Method I N NH2
I
R3 xv

In Method E. an aryl amine bearing R3 (IX) is dissolved in a concentrated
aqueous acid
such as hydrochloric, hydrobromic or sulfuric and cooled to ice bath
temperatures. The
most preferred acid is hydrochloric with concentrations between 3-8 N with the
most
preferred concentration of 6 N. A nitrosating reagent in water is added
dropwise while
maintaining a cold temperature. The preferred temperature is 0-5 C. The
preferred
reagent is sodium nitrite. The reaction is stirred between 10 -90 min and a
reducing
agent is added while maintaing cold temperatures. The preferred temperature is
0-5 C.

132


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
Reducing agents include zinc, iron. samarium iodide and tin(II) chloride. The
most
preferred agent is tin(II) chloride dissolved in aqueous hydrochloric acid
with a
concentration of 3-8 N with a most preferred concentration of 6 N. The
reaction is stirred
between 0.5 - 3hand quenched with alkali to a pH between 12-14. Alkali
reagents
include sodium hvdroxide, potassium hydroxide, lithium hydroxide and calcium
hydroxide. The most preferred alkali reaaent is potassium hydroxide. The
aqueous
solution is extracted with a non-protic organic solvent, such as diethyl
ether, chloroform,
ethyl acetate and methylene chloride. The organic layers are dried with agents
such as
MgSO4 and Na-)SOa and the volatiles removed to provide the aryl hydrazine (X),
which
l0 can be carried forward without further purification.

A(3-ketonitrile bearing Ri (XIV) may be prepared by Method F or G. In Method
F, a
metal hydride, such as sodium hydride, potassium hydride or lithium hydride,
is
suspended in an anhydrous, inert, non-protic solvent, such as diethyl ether,
THF and
dioxane, at temperatures between 35-85 C. The most preferred metal hydride is
sodium
hydride and the most preferred solvent is THF at a temperature of 75 C. An
alkyl ester,
preferably a methyl ester (XI), and acetonitrile is dissolved in an anhydrous,
inert, non-
protic solvent, such as diethyl ether, THF or dioxane and added dropwise to
the metal
hydride suspension. The preferred solvent is THF. The mixture is kept at
elevated
temperatures between 3-24 h, cooled to room temperature and diluted with a non-
protic
solvent and aqueous acid. The organic layer is washed with water and brine,
dried, with
agents such as MgSOa and Na2SO4, and the volatiles removed to provide the (3-
ketonitrile
(XIV), which could be used without further purification.

Alternatively, following Method G, a solution of a strong base, such as alkyl
lithium
reagents and metal amide reagents, such as n-butyl lithium, sec-butyl lithium,
methyl
lithium and lithium diisopropylamide, in an anhydrous, inert, non-protic
solvent, such as
diethyl ether, THF and dioxane, is cooled below 0 C. The preferred base is n-
butyl
lithium, the preferred solvent is THF and the preferred temperature is -77 C.
A solution
of cyanoacetic acid (XII) in an anhydrous, inert, non-protic solvent, such as
diethyl ether,
133


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
THF and dioxane, and most preferrably THF. is added dropwise while maintaining
a
reaction temperature below 0 C and preferrably at -77 C. The reaction is
stirred
between 10 - 45 min while warming to 0 C. The solution of the dianion of
cyanoacetic
acid is cooled to temperatures below -25 C and preferrably at -77 C. An alkyl
acid
chloride (XIII) dissolved in an anhydrous, inert, non-protic solvent, such as
diethyl ether.
THF and dioxane, and most preferrablv THF, is added. The reaction mixture is
warmed
to 0 C betweeen 10 - 30 min and quenched with aqueous acid. The product is
extracted
with an organic solvent, such as chloroform, ethyl acetate, ether and
methylene chloride.
The combined organic extracts are dried, with agents such as MgSO4 and Na2SO4,
and

the volatiles removed to provide the (3-ketonitrile (XIV), which could be used
without
further purification.

The desired aminopyrazole (XV) may then be prepared by Method H or I. In
Method H,
aryl hydrazine X and (3-ketonitrile XIV are mixed in an organic solvent, such
as toluene,
ethanol, iso-propanol or t-butanol. The preferred solvent is ethanol. An acid,
such as
hydrochloric acid, p-toluene sulfonic acid or sulfuric acid, is added, The
preferred acid is
concentrated hydrochloric acid. The mixture is heated to temperatures between
50 - 100
C, preferably at 80 C, for 10 - 24hand cooled to room temperature. The
mixture is
diluted with non-protic organic solvent. such as ethyl acetate, ether,
chloroform and
methylene chloride, and washed with aqueous alkali, such as sodium bicarbonate
and
potassium carbonate. The organic layer is dried, with agents such as MgSO4 and
Na2SO4, and the volatiles removed to provide a residue which is purified by
recrystallization or silica gel chromatography using hexanes and ethyl acetate
as eluents.
The product-rich fractions are collected and the volatiles removed to provide
the desired
aminopyrazole (XV).

Alternatively, using Method I, aryl hydrazine X and (3-ketonitrile XIV are
mixed in an
organic solvent, such as toluene, ethanol, iso-propanol or t-butanol. The
preferred
solvent is toluene. The mixture is heated at reflux temperatures for 3-
24hwith

134


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
azeotropic removal of water and worked up as described above providing the
aminopyrazole XV.

The synthesis of other desired aminoheterocycles that may be used in
preparation of
compounds of formula I or Ia can be prepared by methods known in the art and
described
in the literature. The examples that follow in Schemes III-XV are illustrative
and, as
recognized by one skilled in the art, particular reagents or conditions could
be modified
as needed for individual compounds. Intermediates used in the schemes below
are either
commercially available or easily prepared from commercially available
materials by
those skilled in the art.

A general synthesis for desired aminothiophenes is illustrated in Scheme III,
Method J.
Scheme III

Method J

0 Lawesson's R1
reagent
R R3 S
1
O R
XVi 3 XVii
R1
1. nitrate
S
2. reduce Z NH2
R3
XVIII
A mixture of 1-aryl-5-alkyl-butane-1,4-dione (XVI) and a sulfating reagent,
such as
Lawesson's reagent or phosphorous (V) sulfide, preferably Lawesson's reagent,
is
135


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
dissolved in a non-protic. anhydrous solvent , such as toluene. THF and
dioxane. The
preferred solvent is toluene. The mixture is heated at elevated temperatures
and
preferably at a solvent-refluxing temperature for 1-10 hr. The volatiles are
removed and
the residue is purified by silica gel chromatography using hexanes and ethyl
acetate as
eluent. The product-rich fractions are collected and the volatiles removed to
provide the
substituted thiophene XVII.

A mixture of substituted thiophene XVII is dissolved in a solvent such as
acetic
anhydride or acetic acid. The preferred solvent is acetic anhydride. The
mixture is
cooled to 0-30 C and preferrably to -10 C. A solution of concentrated nitric
acid in a
solvent such as acetic anhydride or acetic acid, with the preferred solvent
being acetic
anhydride is added while cooling to 0-30 C and preferably to -10 C. The
mixture is
stirred between 10 -120 min, poured onto ice and extracted with a non-protic
solvent
such as diethyl ether, chloroform, ethyl acetate or methylene chloride. The
organic
extracts are washed with aqueous alkali, dried with agents such as MgSO4 and
Na-)SO4
and the volatiles removed. The residue is purified by silica gel
chromatography using
hexanes and ethyl acetate as eluents. The product-rich fractions are collected
and the
volatiles removed to provide the 2-aryl-5-alkyl-3-nitrothiophene. The 2-aryl-5-
alkyl-3-
nitrothiophene is reduced by metals, such as iron, tin and zinc or catalytic
hydrogenation.
The preferred reduction conditions are iron in acetic acid at temperatures
between 50-
110 C and preferrably at 100 C for 5-30 min. After cooling to room
temperature the
reaction is diluted with water, neutralized with alkali, such as sodium
hydroxide,
potassium hydroxide, potassium carbonate or sodium bicarbonate, and extracted
with a
non-protic solvent such as diethyl ether, ethyl acetate or methylene chloride.
The organic
extracts are dried with agents such as MgSO4 and Na2SO4 and the volatiles
removed to
provide the desired aminothiophene XVIII.

Scheme IV outlines a general scheme for desired aminofurans as described by
Stevenson
et al. (J. Am. Chenz. Soc., 1937. 59, 2525). An ethyl aroylacetate (XIX) is
dissolved in a
136


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
non-protic solvent, such as ether or THF. and treated with a strong base, such
as sodium,
sodium ethoxide or sodium hydride, and the anion is reacted with a bromomethyl
alkylketone (XX) at low temperatures. such as 00 C. After stirring the
reaction until no
starting material remains, it is poured onto cold water and extracted with a
non-protic
solvent. The combined extracts are dried with agents such as MgSOa or Na?SO4.
The
diketo-ester (XXI) may be carried forward without further purification or
purified by
distillation or silica gel chromatography. The diketo-ester in a protic
solvent, such as
ethanol, is heated in the presence of a mineral acid, such as sulfuric or
hydrochloric, for
5-l Ohand extracted with a non-protic solvent. The combined extracts are dried
with
agents such as MgSO4 or Na2SO4. The furan-ester (XXII) may be carried forward
without further purification or purified by distillation or silica gel
chromatography. The
furan-ester in a protic solvent, such as ethanol, is treated with hydrazine
hydrate and the
mixture heated for 2-5 days. The hydrazide is isolated as above and treated
with hot
formic acid and the resulting furan-amine (XXIII) purified by distillation or
silica gel
chromatography.
Scheme IV

0 0
O O base
R3I'-A OEt + R' "C Br R3 OEt
O Ri
XIX XX XXI

R' hydrazine R'
acid O hydrate O Z ~

heat R. CO2Et acid R~ NH2
3 3

XXii XXiii

137


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
The synthesis of substituted 4-aminooxazoles may be achieved analogous to a
procedure
described by Lakhan et al. (J. Het. Chent.. 1988, 25, 1413) and illustrated in
Scheme V.
A mixture of aroyl cyanide (XXIV), aldehvde (XXV) and anhydrous ammonium
acetate
in acetic acid is heated at 100-110 C for 3-6 hr, cooled to room temperature
and
quenched with water. Extraction by a non-protic solvent provides the product
XXVI
which can be carried forward without further purification or purified by
recrystallization
or silica gel chromatography.

Scheme V

0 0 R'
N H4OAc ~-, N
R CN + RAH HOAc O '
3 NH2
R3
XXIV XXV XXVI

The synthesis of substituted 3-aminopyrroles (XXX) may be achieved in a manner
analogous to Aiello et al., J. Chem. Soc. Perkins Trans. I, 1981, 1. This is
outlined in
Scheme VI. A mixture of aryldioxoalkane (XXVII) and amine (XXVIII) in acetic
acid is
heated at 100-110 C for 3-6hand worked up in the usual manner. The product
(XXIX)
in acetic acid is treated with a nitrating agent, such as nitric acid and
potassium nitrate in
concentrated sulfuric acid. The mixture is poured onto cold water and
extracted with a
non-protic solvent. The combined extracts are dried with agents such as MgS04
and
Na2SO4. Removal of the volatiles provides the nitro-pyrrole which which may be
carried
forward without further purification or purified by recrystallization or
silica gel
chromatography. The nitro-pyrrole is reduced to the amine with iron in acetic
acid or by
catalytic hydrogenation using palladium on activated carbon. The aminopyrrole
(XXX)
may be carried forward without further purification or purified by
recrystallization or
silica gel chromatography.


138


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
Scheme VI

0
R Ri + R2 NHz HOAc
3 heat
O

XXVII XXVI II

Ri Ri
1. HNO3
R2 N~ 31 R2 N
2. Reduce Z NH2
R3 R3
XXIX XXX

In an analogous fashion, a mixture of amine XXXI and 3-aryl-2,5-dioxoalkane
(XXXII)
in acetic acid is heated between 80-110 C for 2-24 hr. The reaction is
diluted with water
and extracted with an organic solvent. The combined extracts are dried with
agents such
as MgSO4 or Na2SO4 and the volatiles removed. The resulting pyrrole is treated
with a
nitrating agent and subsequently reduced to XXXIII as described above. The
product
may be carried forward without further purification or purified by
recrystallization or
silica gel chromatography. This process is illustrated in Scheme VII.

139


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
Scheme VII

R
'N
R-NH2 + R H
O ::::
2 ~ R2 NH
2
3 O 3. Reduce R3
R
XXX I XXX I I XXX I I I

Substituted 5-aminothiazoles (XXXVII) may be prepared in a manner analogous to
Gerwald et al., J. Prakt. Chem. 1973, 315, 539. As illustrated in Scheme VIII,
to a
mixture of aminocyanide XXXIV, aldehyde XXXV and sulfur in an anhydrous
solvent,
such as ethanol and methanol, is added dropwise a base, such as triethylamine.
The
mixture is heated at 500 C for 1-3 hr. The mixture is cooled and the excess
sulfur
removed. Acetic acid is added to neutralize the mixture and the solid
collected. The
imine XXXVI is treated with acid, such as hydrochloric and toluenesulfonic
acid, in
water and an organic solvent. After the starting material is consumed the
reaction is
worked up and the product XXXVII may be carried forward without further
purification
or purified by recrystallization or silica gel chromatography.

Scheme VIII

R1
CN O ~S
+ S /CHR
Rl'~NH RAH - N~ N 1
3 2 , Base
R3
XXXIV XXXV XXXVI
RI
Acid \ -S

Water N ?-- NH2
R3
XXXVI I

140


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
A synthesis of substituted 2-aminothiophenes (XXXIX), analogous to a procedure
described by Gewald et al. (J. Prakt. Chen7.. 1973, 315. 539) is illustrated
in Scheme IX.
A mixture of disubstituted thiophene-3-carboxylic acid (XXXVIII) in a protic
solvent,
such as acetic acid, at a temperature of 0-50 C is treated with a nitrating
agent, such as
nitric acid or potassium nitrate in concentrated sulfuric acid. After the
startina material
has been consumed the reaction is poured onto ice and the product extracted
with a non-
protic solvent. The combined extracts are dried with agents such as MgSOa and
Na-'SO4
and the volatiles removed. The nitrothiophene is reduced to the amine with
iron in acetic
acid or by catalytic hydrogenation using palladium on activated carbon. The
amino-
1o thiophene may be carried forward without further purification or purified
by
^recrystallization or silica gel chromatography.

Scheme IX
Ri CO2H 1. Acid Ri

HNO3 / ~SNH2
R2 s 2. Reduction R2 XXXVI I I XXXIX

1,5-Disubstituted-3-aminopyrazoles (XLII) may be prepared as shown in Scheme
X, in a
fashion analogous to the procedure described by Ege et al. (J. Het. Chem.,
1982, 19,
1267). Potassium is added to anhydrous t-butanol and the mixture cooled to 5
C.
Hydrazine XL is added, followed by cyanodibromoalkane XLI. The mixture is
heated at
refluxing temperatures for 3-10 hr. The mixture is cooled to room temperature
and
poured onto ice water. The product is extracted with an organic solvent. The
combined
extracts are dried with agents such as MgSO4 or Na2SO4 and the volatiles
removed. The
product XLII may be carried forward without further purification or purified
by
recrystallization or silica gel chromatography.

141


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
Scheme X

Br Potassium Ri
R2 NHNH2 + R~ i:d
w- ~ uOH RZ N,

Br 2XL XLI XLII

The synthesis of 2-amino-3,5-disubstituted thiophenes shown in Scheme XI, is
done in a
fashion analogous to Knoll et al., J. Prakt. Chem., 1985, 327, 463. A mixture
of
substituted N-(3-aminothioacryloyl)-formamidine (XLIII) and substituted
bromide
(XLIV) in a protic solvent, such as methanol or ethanol, is heated, preferably
at a reflux
temperature, for 5-30 min and cooled below room temperature. The product
thiophene-
imine is filtered and dried. The thiophene-imine XLV is converted to the
thiophene-
amine (XLVI) by treatment with aqueous acid.

Scheme XI
SH
RHN N~NHR + RBr Heat
Ri
XLIII XLIV
Ri Ri
S Aqueous S

Z~ N~NR Acid NH2
R3 R3
XLV XLVI

142


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
The synthesis of 1,4-disubstituted-2-aminopyrroles (L) may be accomplished in
a manner
analogous to Brodrick et al. (J. Chem. Soc. Per=kin Trcins. 1, 1975, 1910).
and as
illustrated in Scheme XII. The potassium salt of formylnitrile XLVII in -
Vvater is treated
with amine XLVIII and acetic acid and the mixture heated at 50-90 C for 5-30
min. The
aminonitrile XLIX is collected by filtration upon cooling and then is stirred
at room
temperature with a base such as ethanolic potassium ethoxide for 2-5hand the
volatiles
removed. The residue is diluted with Nvater and extracted with an organic
solvent. The
combined extracts are dried with agents such as MgSO4 and Na->SO4 and the
volatiles
removed. The product (L) may be carried forward without further purification
or purified
by recrystallization or silica gel chromatography.
Scheme XII
R
Acid ~ CN
R~\ ^CN + R3 NHz

CHO Heat NH
XLVII XLVIII R3
XLIX

R~
KOEt / ~NNH2
30 EtOH I
R3
L
The preparation of 1,2-disubstituted-4-aminoimidazoles (LII) by reduction of
the
corresponding nitro compound (LI), for example with iron in acetic acid or
catalytic
hydrogenation may be accomplished as described by Al-Shaar et al. (J. Chem.
Soc.
Perkin Trans. 1, 1992, 2779) and illustrated in Scheme XIII.


143


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
Scheme XIII

R1\ R1\
N ~~N02 Reduction N ~ \~
R2 N R2 N NH2
LI LII
2,4-Disubstituted 5-aminooxazoles (LVII) may be prepared in a manner analogous
to the
procedure described by Poupaert et al. (Synthesis, 1972, 622) and illustrated
in Scheme
XIV. Acid chloride LIII is added to a cold mixture of 2-aminonitrile LIV and a
base such
as triethylamine in a non-protic solvent, such as THF, benzene, toluene or
ether. The
preferred temperature is 00 C. The mixture is stirred for 12-24hand washed
with water.
The volatiles are removed and the product LV treated with ethylmercaptan and
dry
hydrogen chloride in dry methylene chloride for 5-30 min. The solid 5-imino-
l,3-
oxazole hydrochloride (LVI) is collected by filtration, dissolved in dry
pyridine and the
solution saturated with hydrogen sulfide during 4hat 00 C. The mixture is
diluted with an
organic solvent and washed with water and dried. Removal of the volatiles
provides the
5-amino-1,3-oxazole product (LVII) which may be carried forward without
further
purification or be purified by silica gel chromatography.

Scheme XIV

144


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
0 NHz Base 0 R3
Rl-'CI + R CN 30 R1 N CN
3 H
LIII LIV LV
R R
EtSH ~O Pyridine // O
~ N Y'-1-- N H H S N/ N Hz
z
R3 R3
LVI LVI I

The synthesis of 1,4-disubstituted-2-aminopyrazoles may be accomplished as
illustrated
in Scheme XV and described in Lancini et al., J. Het. Chen2., 1966, 3, 152. To
a mixture
of substituted aminoketone (LVIII) and cyanamide in water and acetic acid was
added
aqueous sodium hydroxide until pH 4.5 is reached. The mixture is heated at 50-
90 C for
1-5 hr, cooled and basicified with ammonium hydroxide. The product LIX is
collected
by filtration and dried.

lo Scheme XV

Water R1
O N
~NHR3 + H2N-CN pH 4.5 ~NH
R Heat N z
R3
LVIII LIX

Aryl amine and heteroaryl amine intermediates IV (G-NH2) for the synthesis of
compounds of formulas II and III are either commercially available or easily
prepared by
methods known to those skilled in the art. For example, one may obtain desired
aryl
amines and heteroaryl amines by nitration and reduction of a substituted aryl
or

145


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
heteroaryl ring as illustrated in the synthesis of several 5-membered
heterocycle amines
(Arl-NH2) in the above schemes. Alternatively, one may convert a substituted
aryl ester
to an aryl amine as illustrated for the substituted furan in Scheme IV above,
and
exemplified in synthetic example 17 belmv. Several additional syntheses of G-
NH2 and
Ari-NH2 are provided in the Synthetic Examples section.

Methods by which intermediates V and VI (Scheme I. D' = Ar-X-Y-Z or Ar-~-X-Y-
Z)
may be prepared are described below. In Method K (Scheme XVI), a
bromoarylamine
LX, which may be commercially available or easily prepared by one skilled in
the art, is
1 o reacted with a cycloalkenone LXI in the presence of a transition metal
catalyst, for
example a palladium(II) catalyst such as bis(triphenylphosphine)palladium(II)
chloride,
in the presence of a bis(triphenylphosphine) chelator, such as 1,2-

Scheme XVI

146


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
Method K

0 Pd(Ph3)2CI2 0
DPPP
H2NAr'Br + I
6), NaHCO3 H N
DMF z ~Ar' n
150 oC
LX LXI LXII
n = 1-4
Ar' = Ar or Ar2 Method B or C

0
phosgene O
LXI I CH2CI2 Method A I

aq NaHCO3 OCN~ I D~Ny NAr' )n
0 C Ar' )n O

LXIII LXIV
Method L

1. t-BuLi LX
Br-X-Q Bu3Sn-X-Q H2NAr'-X-Q
LXV 2. Bu3SnCI LXVI Pd(PPh3)4 LXVII
Q= Y-Z or Ar' = Ar or Ar2
a precursor

bis(diphenylphosphino)ethane (DPPE), 1, 1 ' -bis(diphenylphosphino)ferrocene
(DPPF)
and 1,3-bis(diphenylphosphino)propane (DPPP), preferably DPPP, and a base,
preferably sodium bicarbonate, in a suitable solvent, preferably DMF at a
temperature of
about 150 C to provide LXII. LXII may then be used (as VI) in Method B
(Scheme I),
or converted to isocyanate LXIII by reaction with phosgene or a phosgene
equivalent in
the presence of a base, such as sodium bicarbonate in a suitable solvent such
as
dichloromethane, at a temperature of about 0 C, and used (as V) in Method A.
The
resulting product LXIV may be modified further by methods known by one skilled
in the
art to obtain desired compounds of formula I, as described in synthetic
examples below.
147


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
In Method L. bromide LXV is reacted -~vith a strong base. such as t-btrty1
lithium, in a
suitable solvent. such as THF. with tributyltin chloride at a temperature of
about -50 C
to -100 C, preferably about -78 C to give LXVI. LXVI is then reacted with LX
in a
suitable solvent. such as THF or 1,4-dioxane, in the presence of a transition
metal
catalyst, preferably tetrakis(triphenylphosphine)palladium(0), at a
temperature of about
50 C to 150 C, preferably about 100 C and in a sealed tube, providing
LXVII. LXVII
may then be used (as VI) in Method B or C (Scheme I), or converted to the
corresponding
isocyanate as described in Method K, and used (as V) in Method A.

Methods by which Y and Z may be joined to X are illustrated in Scheme XVII. As
illustrated by Method M, if one desires a product in which Y includes an amino
nitrogen
bonded to X, an X containing a ketone may be reacted with a Y-Z containing a
terminal
primary or secondary amine under reductive amination conditions. For example,
ketone
LXIV is combined with a primary or secondary amine, in a suitable solvent such
as THF.
An acid, such as acetic acid, is added, followed by a suitable reducing agent,
preferably
sodium cyanoborohydride or sodium (triacetoxy)borohydride, to provide the
desired
product LXVIII.

Method N, illustrates a procedure for obtaining a methylene group for Y and a
primary or
secondary amine for Z. An X group bearing an aldehyde and a halogen,
preferably
bromine (LXIX), may be reacted with a primary or secondary amine under
reductive
amination conditions as described in Method M to provide LXX. This
intermediate may
then be used as described in Method L.


Scheme XVII

148


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
Method M

0 N(R)R'
RNHR' I
~ H H
p"' N y N"Ar' )n D~N y N~Ar' )n
reductive
0 amination 0
LXIV LXVIII
n = 1-4 -N(R)R' = -Y-Z
Ar'=ArorAr2 n= 1-4
Method N

RNHR'
Br-X-CHO 30 Br-X-CH2-N(R)R'
reductive
LXIX amination LXX
-CH2N(R)R' = -Y-Z

As in the cases described above, the synthesis of additional intermediates
corresponding
to V, VI and VII may be accomplished by methods similar to those described in
the
literature or known to those skilled in the art. Several examples are provided
in the
Synthetic Examples section below.

SYNTHETIC EXAMPLES

EXAMPLE 1

1-[5-tert-Butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-[4-(2-cyclohexenon-3-
yl)naphthalen-1-yl]
urea:

149


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
0
Br O Pd(PPh3)2C'2
H, DPPP, NaHC03
N ~ I + ~ -- ~
H DMF, 150 oC N
H
LXXI LXX I I
cicoci
O CH2C12
N satd. NaHCO3 aq.
I 0 C
N O
N_H
N N N LXXIV o
H H -~N
THF, RT

~ LXXIII
As outlined in Method K, a 350 mL sealed tube under inert atmosphere was
charged with
4-bromo-l-naphthylamine (LXXI) (1.97 g; 8.9 mmol; I equiv.), 2-cyclohexenone
(1.65
g; 17.2 mmol; 1.9 equiv.), sodium bicarbonate powder (2.17 g; 25.8 mmol; 2.9
equiv.),
1,3-bis(diphenylphosphino)propane (177 mg; 0.43 mmol; 0.05 equiv.),
bis(triphenylphosphine)palladium(II) chloride (302 mg; 0.43 mmol; 0.05 equiv.)
and
DMF (degassed, 100 mL). The mixture was heated at 150 C for 8 h. After
cooling back
io to ambient temperature, the mixture was diluted with 100 mL EtOAc and
filtered through
diatomaceous earth. The solution was then transferred to a separatory funnel
and washed
with water (100 mL) and saturated brine (100 mL). After drying with MgSO4 the
volatiles were removed in vaczto. The product was then purified by column
chromatography using EtOAc (10 to 50 %) in hexanes as eluent to provide 1.3 g
material
which was recrystallized from hot EtOAc/Hexanes to afford 800 mg LXXII (3.4
mmol;
38% yield) as a dark brown solid.

150


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
LXXII (100 mg; 0.42 mmol; I equiv.) was dissolved in methylene chloride (20
mL) and
saturated aqueous sodium bicarbonate (20 mL) was added. The mixture was
vigorously
stirred at 0 C for 15 min. The stirring was then stopped and phosgene (-2.0 M
in
toluene; 0.63 mL: 1.26 mmol: 3.0 equiv.) was added via syringe to the organic
layer in
one portion. Stirring was immediately resumed and continued at 0 C for 20 min.
The
layers were then separated and the aqueous phase was extracted further with
nlethylene
chloride (1 x 25 mL). The combined organics were dried (Na)SO4), filtered and
3/4 of the
solvent removed in vacuo. This solution of isocyanate LXXIII was then
immediately
to diluted with anhydrous THF (8 mL) and treated with LXXIV at room
temperature
(Method A). The mixture was left stirring under nitrogen overnight then MeOH
(2 mL)
was added and the volatiles removed in vacuo. The title compound 1 was thus
obtained as
an orange/red foam (200 mg; 0.41mmol; 74%). This was recrystallized overnight
from
EtOAc twice to afford 49 mg of yellow crystals (mp: 168-170 C).

EXAMPLE 2

1-[5-tert-Butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-{4-[3-(morpholin-4-yl)cyclohexen-
1-
yl]naphthalen-1-yl} urea:

O co)
H N
O CN)

N N NN O O
N~ ~ (\
~ H H NaB(OAc)3H N N N I
I THF, AcOH ~ H H
~ ~ ~
1 2

As described in Method M, the product from Example 1(1) (93 mg; 0.19 mmol; I
equiv.)
and morpholine (30 uL; 0.34 mmol; 1.8 equiv.) were dissolved in 1.0 mL
anhydrous THF
151


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
and treated with acetic acid (16 uL; 0.28 mmol; 1.5 equiv.) and sodium
(triacetoxy)borohydride (80 mg; 0.39 mmol; 2 equiv.). The reaction was stii-
red at room
temperature for 2 days. then 5% aqueous NaOH solution (3 mL) was added and the
reaction then extracted with EtOAc (3 x 3 mL). The combined organics were
washed
once with water. then brine, dried (Na.7SOa), filtered and the solvents
removed in vacuo.
Column chromatography using EtOAc/hexanes as eluent afforded 64 mg of a tan
foam
(0.11 mmol; 60%). This was chromatographed a second time with 5% MeOH in
methylene chloride to provide the title compound 2 as a light purple foam (50
mg).

EXAMPLE 3

1-[5-tert-Butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-{4-[5-(morpholin-4-ylmethyl)fur-2-

yl]naphthalen-1-yl} urea:

152


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
HN~
1) t BuLi
O O N

0 0 O 2) B I
u3SnC
gr Br
AcOH, Na[HB(OAc)3]
LXXV Br LXXVI

I H2N \ N~
/ \ O 0
N LXXI
Bu Sn O O H2N
3 [Pd(PPh3)a]
LXXVI I LXXVI I I

N
N N \ O 0
NH2 1) Ph(CO)CI O ~
2) LXXVIII N \
\
(Method C) N H H
\ ~ I
LXXIV 3
As described in Method N, to a mixture of 5-bromo-2-furaldehyde (LXXV) (1.76
g) and
morpholine (1.00 ml) in 40 mL anhydrous THF at room temperature was added
acetic
acid (0.60 mL) followed by sodium triacetoxyborohydride (3.28 g). The mixture
was
stirred at room temperature for 3h and then poured into a saturated solution
of sodium
bicarbonate (100 mL). After stirring vigorously for 5 min the layers were
separated and
the aqueous layer was extracted with EtOAc. The combined organic layers were
washed
to with brine, dried (Na2SO4), filtered and evaporated to dryness.
Purification of the residue
by flash chromatography afforded 2.09 g (8.49 mmol, 84% yield) of LXXVI.

As illustrated by Method L, LXXVI (0.678 g, 2.76 mmol) was dissolved in 10 mL
anhydrous THF under inert gas atmosphere and the solution was cooled to at -78
C. t-
Butyllithium (4.0 mL of a 1.7 M solution in pentane) was added dropwise and
the

153


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
solution was stirred at -78 C for 30 min. Tributyltinchioride (0.60 mL. 0.72g.
2.2 mmol)
was added and the solution was stirred for another 30 min at -78 C. pH7 Buffer
(NaHzPO4/Na-)HPO4 sat.) was added (10 mL) and the mixture was warnled to room
temperature. The layers were separated and the aqueous laver was extracted
with EtOAc.
The combined organic layers were washed with brine, dried (Na2SO4). filtered
and
evaporated to dryness. Purification of the residue by flash chromatography
afforded
0.526 g(1.15 mmol, 42% yield) of LXXVII.

As outlined in Method L, LXXVII (0.399 g, 0.874 mmol) and LXXI (0.200(Y. 0.901
lo mmol) were dissolved in 10 mL anhydrous 1,4-dioxane in a sealable tube
under inert gas
atmosphere. The solution was degassed and purged with nitrogen (2x).
Tetrakis(triphenylphosphine)palladium(0) (0.057g, 0.049 mmol) was added and
the
solution was degassed and purged with nitrogen again (2x). The tube was sealed
and
heated to 100 C for 24 h. After cooling to room temperature the mixture was
diluted with
EtOAc, saturated aqueous potassium carbonate solution (10 mL) was added and
the
mixture was stirred for 1 h at room temperature. The mixture was filtered over
diatomaceous earth and the layers were separated. The aqueous layer was
extracted, with
EtOAc. The combined organic layers were washed with brine, dried (NazSO4),
filtered an
evaporated to dryness. Purification of the residue by flash chromatography
afforded
0.3 14 g of a yellow oil, which contained LXXVIII along with tributyltin
bromide. This
mixture was used for the next step without further purification.

LXXVIII (0.283g, 0.917 mmol) was reacted with the phenylcarbamate of LXXIV
(0.395 g, 1.13 mmol) according to Method C. The product was purified by flash

chromatography to give the title compound 3 as a yellow solid (0.338 g,0.600
nunol,
65 %o yield) that was further purified by recrystallization to give 0.131g of
title
compound 3 (mp. 144-146 C).

EXAMPLE 4

1-j5-tert-Butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-{4-[6-(morpholin-4-
ylmethyl)pyridin-3-
yl]naphthalen-1-yl} urea:

154


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865

O O
Br Pd(dppf)2C12 ZN OMe DIBALH I\
/ N CO/MeOH/Et3N / N
Br Br Br
LXXIX LXXX LXXXI
HN~
~O N ~O "~ 1) tert. BuLi N
2) Bu3SnCl N ~,O
AcOH/Na[HB(OAc)3)] Br ~ Bu3Sn

LXXXI I LXXXI I I
Br

H2"
O
I
LXI

HZN [Pd(PPh3)4] XXIV

N
N O
O
"~N NH2 Ph(CO)CI N ~
2 2)LXXXIV N N N
H H
(Method C)
\~ \I

LXIV 4
As described by R.J. Chambers and A. Marfat, (Synthetic Communications, 1997,
27,
515) a mixture of 2,5-dibromopyridine (LXXIX) (9.90 g, 41.78 mmol),
Pd(dppf)C12 (1.51
g, 1.85 mmol), anhydrous MeOH (40 mL), anhydrous DMF (40 mL) and anhydrous
triethylamine (12 mL) was purged in a Parr apparatus with a stream of carbon
monoxide
for 10 min and then stirred under 80 psi carbon monoxide at 50 C for 4 h. The
mixture
was diluted with EtOAc (600 mL) and washed with water (2x100 mL) and brine
(1x100

155


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
mL), dried (sodium sulfate), filtered and evaporated to dryness. The residue
was purified
by flash chromatographv on silica gel (40% EtOAc in hexanes) to give LXXX as a
light
orange solid (3.733 g. 17.28 mmol, 41%).

To a solution of compound LXXX (165.9 mg. 0.7679 mmol) in anhydrous THF (10
mL)
at -78 C was added dropwise diisobutylaluminum hydride (1.0 M in THF) (2.0
mL. 2.0
mmol). The mixture was stirred at -78 C for 2 h. then saturated potassium
carbonate
(0.6 mL) solution was added, the mixture was warmed to room temperature and
stirred
for another 30 min. Sodium sulfate was added and the mixture was stirred for
10 min.
The solids were removed by filtration and the filtrate was evaporated to
dryness. The
residue was purified by flash chromatography on silica gel (20% EtOAc in
hexanes) to
give aldehyde LXXXI as a white solid (80 mg. 0.43 mmol, 56%).

To a solution of LXXXI (367.7 mg, 2.0 mmol) in anhydrous 1,2-dichloroethane
(10 mL)
was added morpholine (0.20 mL, 0.20 g, 2.3 mmol), followed by glacial acetic
acid (0.12
mL, 0.13 g, 2.1 mmol) and sodium triacetoxyborohydride (625 mg, 2.95 mmol).
The
mixture was stirred at room temperature for 30 min. A saturated solution of
sodium
bicarbonate (10 mL) was added and the mixture was stirred vigorously for
another 30
min. The layers were separated and the aqueous layer was extracted with EtOAc
(3x20
mL). The combined organic layers were washed with brine, dried (sodium
sulfate),
filtered and evaporated to dryness. Flash chromatography (1 % triethylamine in
EtOAc) of
the residue gave LXXXII as a light yellow oil (460.8 mg, 1.79 mmol, 91 %).

To a solution of tert-butyllithium (1.42 M in pentane) (2.80 mL, 3.98 mmol) in
anhydrous THF (20 mL) at -78 C was added dropwise a solution of LXXXII (460.8
mg,
1.792 mmol) in anhydrous THF (10 mL) and the mixture was stirred at -78 C for
10 min.
Tributyltin chloride (0.49 mL, 0.59 g, 1.8 mmol) was added and the mixture was
stirred
at-78 C for another 15 min. pH 7 Buffer (Na2HPO4/NaH2PO4 sat.) (10 mL) was
added
and the mixture was warmed to room temperature. The layers were separated and
the
aqueous layer was extracted with EtOAc (3x20 mL). The combined organic layers
were
washed with brine, dried (sodium sulfate), filtered and evaporated to dryness.
Flash
156


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
chromatography (EtOAc) of the residue gave LXXXIII as colorless oil (548.8 mg,
1.17
mmol, 65%).

A degassed solution of LXXXIII (302 m-. 0.646 mmol), LXXI (177 mg, 0.797 mmol)
and Pd(PPh3)4 (55 mg, 0.48 mmol) in anhvdrous 1,4-dioxane (10 mL) was heated
to 100
C in a sealed tube for 16 h. The black precipitate was removed by filtration
and the tube
was washed with EtOAc. The combined filtrates were stirred with potassium
fluoride
solution (40%) (10 mL) for 30 min. Water and brine were added, the layers were
separated and the aqueous layer was extracted with EtOAc (4x50 mL). The
combined
1 o organic layers were washed with brine. dried (sodium sulfate), filtered
and evaporated to
dryness. Flash chromatography (5% MeOH and 1% triethylamine in EtOAc) of the
residue gave LXXXIV as a light bro,,vn solid (157.6 mg, 0.49 mmol. 76%).

LXXXIV and the phenyl carbamate of LXIV were reacted according to Method C.
Purification by flash chromatography using 5% MeOH and 1% triethylamine in
EtOAc as
the eluent followed by recrystallization from EtOAc/hexanes gave the title
compound 4
as a white solid (mp. 169-170 C).

EXAMPLE 5

1-[5-tert-Butyl-2 p-tolyl-2H-pyrazol-3-yl]-3-{4-[3-(morpholin-4-
yl)phenyl]naphthalen-1-yl} urea:

157


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
0

BrfBr) / 1) t-BuLi

~ \ ( 2) Bu3SnCl
N~
/ NHZ i-PrNEt2 Br
Br \
LXXXVI ~~
Br

H2N
/
I \ a
BuaSn \ ( N LXXI H2N [Pd(PPh3)a] I /

LXXXVII LXXXVI I I
1) Ph(CO)CI
N~N NHZ 2) LXXXVIII N.N H H O
(Method C)
I I
LXIV 5
3-Bromoaniline (3.0 mL, 4.7 g, 28 mmol), 2-bromoethylether (4.2 mL, 7.7 g, 33
mmol)
and diisopropylethylamine (15 mL, 11 g, 86 mmol) were dissolved in anhydrous
DMF
(20 mL) under inert gas atmosphere and heated to 100 C for 6 h. After cooling
to room
temperature the mixture was poured into water (300 mL) and extracted with
EtOAc. The
combined organic layers were washed with brine, dried (Na2SO4), filtered and
evaporated
to dryness. Purification of the residue by flash chromatography afforded 2.9 g
(12 mmol,
43% yield) of LXXXVI

LXXXVI (1.73 g, 7.13 mmol) was dissolved in anhydrous THF (30 mL) and cooled
to -
78 C. t-Butyllithium (10.0 mL of a 1.7 M solution in pentane) was added
dropwise and
the solution was stirred at -78 C for 30 min. Tributyltinchloride (1.90 mL,
2.28 g, 7.00
mmol) was added and the solution was stirred for another 45 min at -78 C. pH
7 Buffer
(NaH2PO4/Na-)HPO4 sat.) was added (10 mL) and the mixture was warmed to room

158


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
temperature. The layers were separated and the aqueous layer was extracted
with EtOAc.
The combined organic layers were ~vashed with brine, dried (Na)SO4), filtered
an
evaporated to dryness. Purification of the residue by flash chromatographv
afforded 2.28
g(5.36 mmol, 77% yield) of LXXXVII.


LXXXVII (1.49 g, 3.51 mmol) and LXXI (0.69 g. 3.11 mmol) were dissolved in 20
mL
anhydrous 1.4-dioxane in a sealable tube under inert gas atmosphere. The
solution was
degased and purged with nitrogen (2x).
Tetrakis(triphenylphosphine)palladilun(0) (0.21
g, 0.18 mmol) was added and the solution was degassed and purged with nitrogen
again
to (2x). The tube was sealed and heated to 100 C for 17 h. After cooling to
room
temperature the mixture was diluted with EtOAc, saturated aqueous potassium
carbonate
solution (10 mL) was added and the mixture was stirred for I h at room
temperature. The
mixture was filtered over diatomaceous earth and the layers were separated.
The aqueous
layer was extracted with EtOAc. The combined organic layers were washed with
brine,
dried (Na2SO4), filtered and evaporated to dryness. Purification of the
residue by flash
chromatography afforded 0.363 g (1.19 mmol, 38%) of LXXXVIII.

LXXXVIII (0.360 g, 1.18 mmol) was reacted with the phenylcarbamate of LXIV
(0.69 g,
1.97 mmol) according to Method C. The product was purified by flash
chromatography
to give a colorless solid (0.433 g, 0.77 mmol, 66% yield) that was further
purified by
recrystallization from EtOAc - hexanes to give 0.344 g of the title compound 5
(mp. 188-
190 C).


Table 1 illustrates additional compounds of the invention, which were prepared
by
methods analogous to those described above.


159


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
TABLE 1

O
Ar1NN,.Ar2~ Y
I I X Z
H H

R
1
/ . I
Ar1 Ar2
N~ .
N
I
R3
Ex. R, R3 Xa Y Z` M.P. C
No.
6 t-Bu 4-MePh Phenyl 4-CH2 4-morpholinyl 146-148
7 t-Bu 4-MePh Phenyl 3-CH2 4-morpholinyl 120-122
8 t-Bu 4-MePh Phenyl Bond 4-(4- >230
morpholinyl)
9 t-Bu 4-MePh Phenyl 4-CH2 4-morpholinvl 183-186
t-Bu 4-MePh Phenyl 4-CH2 NMe2 108-114
11 t-Bu 4-MePh 2-pyridyl 5-CH2 4-morpholinyl foam
12 t-Bu 4-MePh 1- Bond 3"-(4- 133-135
cycloheptenyl morpholinyl)
13 t-Bu 6-Me-3- 3-pyridyl 6-(CH2) 4-morpholinyl 162-165
pyridyl
14 t-Bu Me 3-pyridyl 6-(CH2) 4-morpholinyl foam
t-Bu 6-Me-3- 1-cyclohexenyl 3-[NH- 4-morpholinyl
pyridyl (CHZ)Z]
5
a number refers to position on X that is bonded to napthalene ring (Ar2). b
number
refers to position on X that Y is bonded to. ` number refers to position on Z
that
is bonded to Y (or X if Y is a bond). d refers to position on X that Z is
bonded to.

160


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
EXAMPLE 16

1- [4-(6- {[Bis- (2-cyanoethyl)amino]methyl} pyridin-3-yl)naphthalen-l-yl]-3-
(5-tert-
butyl-2-methylphenyl)urea

NO2BF4 H2, Pd/C O

CH3CN NO di-t-butyl dicarbonate N~,Oj<
2 1
H
D

O
N D
~
H2N LXXXIX fN O
IO HCI BCI3, NEt3 N N Method C H H XC

0
I N H ~CN
O I\ \ HN
NN CN
H H I / Na(AcO)3BH
CICH2CHzCl
\ N ~ CN
I \ ~ I \
CN
N N
H H

16
161


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
To a solution of 4-tert-butyl toluene (33.7 mmol) in acetonitrile (150 mL) at
0 C was
added nitronium tetrafluoroborate (40.5 mmol). After 30 min at room
temperature, the
reaction was diluted with water (50 mL) and extracted with EtOAc (3x30 mL).
The
combined organic extracts were washed with brine and dried (MgSO4). Removal of
the
volatiles in vacuo left a residue; flash chromatographv using 10 % methylene
chloride /
petroleum ether as eluent provided 4-tert-butyl-2-nitrotoluene.
4-tert-Butyl-2-nitrotoluene (1.1 mmol) was dissolved in DMF (10 mL). The
catalyst
(10% Pd/C, 5 mg) was added followed by the addition of di-tert-butyl
dicarbonate (1.4
lo mmol). The system was purged with argon then exposed to H, (1 atm) for 12
h. The
mixture was filtered over a pad of diatomaceous earth; the filtrate was
diluted with water
and extracted with EtOAc (3x10mL). The combined organic extracts were washed
with
brine and dried (MgSOa). N-Boc-5-tert-butyl-2-methylaniline was obtained as a
crystalline solid, 265 mg, after the evaporation of volatiles.

To a mixture of N-boc-5-tert-butyl-2-methylaniline (0.8 mmol) and
triethylamine (0.22
mol) in benzene (10 mL) at room temperature was added via syringe boron
trichloride
(0.4 mmol). The resulting heterogenous mixture was stirred at 80 C for 30 min.
The
heat source was removed, and aminonaphthalene LXXXIX was added (0.7 mmol). The

reaction mixture was stirred at room temperature for 16 h. The reaction
mixture was
diluted with water (10 mL) and extracted with EtOAc (3x10 mL). The combined
organic extracts were washed with brine and dried (MgSO4). Removal of the
volatiles
in vacuo left a residue; flash chromatography using 10% MeOH / EtOAc as eluent
provided 300 mg of the desired urea XC.


This urea was subjected to acidic conditions to remove the acetal which
exposed the
aldehyde functionality. In 1,2-dichloroethane, 1.25 equivalents of bis(2-
cyanoethyl)amine were added to this aldehyde followed by the addition of
sodium
triacetoxyborohydride (1.5 equivalents). After column chromatography (5%

MeOH/EtOAc), the title compound 16 was obtained.
162


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
EXAMPLE 17
1-(6-tert-Butyl-2-chloro-3-methylpyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-naphthalen-1-yl] urea:


0
Br
H1O, B1O, H
1. 3 eq. n BuLi
2. B(OMe)3 N
3. 5% HCI
--- I / / I /
ON, H O N Br
O
0 Pd(PPh3)4
XCI 2 M NazCO3, DME
C C
N
~ N
11
HCI, dioxane

I \ \ NaOH I \ \
_~Oy N, H HN, H
O
Xcii Xciii

To a stirred solution of N-Boc-l-amino-4-bromo naphthalene (15.5 mmol) in
anhydrous
THF (40 mL) at -78 C was added n-BuLi (47 mmol). The resultant yellow-green
solution was stirred at -78 C for two h then was transferred to a solution of
trimethylborate (5.64 grams, 54.2 mmol) in anhydrous THF (25 mL) at -42 C.
The
reaction was allowed to warm to room temperature overnight as the bath warmed.
After
stirring for 16 h, 5% aqueous HC1 was added (25 mL) and the mixture was
stirred for 15
163


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
min. The aqueous laver was saturated with NaC1 and the layers were separated.
The
aqueous portion was extracted with diethyl ether (3 x 60 mL) and the combined
or-anics
were extracted with 0.5 M NaOH (6 x 30 mL). The combined basic extracts were
acidified to -pH 2 with 3 M HC1 (-30 mL) and the suspension was extracted with
diethyl
ether (3 x 100 mL). The combined ethereal extracts were dried (M6O4), filtered
and the
solvent was removed to afford the boronic acid XCI as a beige solid (2.3 g)
which was
used without further purification.

5-Bromo-2-(morpholin-4-ylmethyl)pyridine (0.70 mmol) and XCI (0.70 mmol) were
dissolved in a biphasic mixture of dimethoxyethane (2 mL) and 2 M aq. Na')CO3
(1 mL).
The reaction was purged with a stream of N2 for 15 min, the Pd catalyst was
added, and
the mixture was heated at 85 C for 16 h. The reaction was cooled to room
temperature
and was partitioned between water (10 mL) and EtOAc (75 mL). The layers were
separated and the organic portion was washed with brine (20 mL), dried
(MgSO4),

filtered and the solvent was removed to afford a brown solid. Column
chromatography
afforded the product XCII as a beige solid.

XCII (0.50 mmol) was dissolved in 2 mL anhydrous dioxane and HCl was added
(2.5
mmol). The solution was stirred at room temperature for 16 h. To the resultant

suspension was added diethyl ether (5 mL) and the mixture was chilled to 0 C.
Neutralization with aq. NaOH and filtration afforded 4-[6-(morpholin-4-
ylmethyl)pyridin-3-yl]-1-aminonaphthalene (XCIII) as a light brown solid (100
mg).

164


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
N LiOH
I N
CI / COOMe CI I COOH
Method B I
1) Ethyl chloroformate N
!irazde iN O CI

~
~

17
A mixture of 2-t-butyl-6-chloro-5-methylpyridine-4-carboxylic acid methyl
ester (2.27 g,
9.39 mmol) and LiOH monohydrate (2.36 g, 56.3 mmol) in MeOH (30 mL) and water
(10 mL) was stirred at room temperature for 24 h. The reaction was then
concentrated
and purified by chromatography on silica gel (eluent: 5 % TFA in
dichloromethane) to
give the corresponding carboxylic acid (1.41 g, 66.3 %).

lo To a stirred solution of the above carboxylic acid (0.54 g, 2.36 mmol) and
triethylamine
(0.66 mL, 4.75 mmol) in THF (6 mL) at -10 C was added dropwise ethyl
chloroformate
(0.34 mL, 3.51 mmol). The resulting mixture was stirred at 0 C for 1 h. A
solution of
sodium azide (0.40 g, 6.0 mmol) in water (2 mL) was added and stirring was
continued
for another 1 h. The mixture was extracted with toluene. The organic phase was
separated, dried with sodium sulfate, and concentrated to 15 mL. It was then
heated at
reflux for 2 h forming the isocyanate in situ, before a solution of XCIII
(0.39 g, 1.23
mmol) in dichloromethane (5 mL) was added. The reaction was stirred at room
temperature overnight. Concentration and chromatography on silica gel (eluent:
EtOAc)
afforded the title compound 17 (0.60 g, 89.9 %).


165


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
EXAMPLE 18
1-(5-tert-Butyl-2-methylphenyl)-3-(4-{6-((3-methoxypropyl)methylamino]pyridin-
3-
yl}naphthalen-1-yl)urea
Br
115 C
I~ N H - Br N
Br N
XCIV O

O N
H~O, B~O, H N
1) Pd(PPh3)4
I\ \ N 2 M Na2CO3, DME
O N ~ N 2) HCI
yH
O Br H'N~H
XCI XCV
ly
XCVI \ N
0

NH2 phosgene N N Method B H H 18

2,5-Dibromopyridine (100 mg) was heated to 115 C in a sealed tube in the
presence of
to 3-methoxypropyl-l-methylamine (2 mL) for 48 h to give XCIV. A Suzuki
coupling of
XCIV with XCI and removal of the tert-butyl carbamate (analogous to the
procedures
in Example 17) afforded the desired naphthylamine XCV.

166


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
5-tert-Butyl-2-methylaniline (0.56 mmol) was dissolved in dichloromethane (20
mL).
An equal volume of sat. aqueous sodium bicarbonate was added, and the biphasic
solution was cooled to 0 C. During the addition of phosgene (1.93 M in
toluene, 0.80
mL), stirring was stopped. Immediately afterward, stirring was resumed for 15
min

with the reaction mixture at 0 C. The layers were separated, the organics were
dried
over solid magnesium sulfate, and concentrated to approximately 5 mL of
solution.
The desired naphthylamine (XCVI, 0.47 mmol) in 5 mL dichloromethane was added.
The reaction mixture was stirred at room temperature for 16 h. Flash
chromatography
using 7 % MeOH / EtOAc as eluent followed with trituration with ether provided
the

i o title compound 18.

EXAMPLE 19
1-[4-(6-Morpholin-4-ylmethylpyridin-3-yl)naphthalen-l-ylJ-3-(3-trifluoromethyl-

phenyl)urea:

F F
F F F F
PhOCOCI
O
NH2 HOPh
XCVI
F
F F
N
XCIII O N O
Method D N N
H H

19
A stirred solution of 3-trifluoromethylaniline (4.7 mmol) in dry THF (30 mL)
at 0 C was
treated with phenyl chloroformate (4.8 mmol). After 2h, the reaction mixture
was
quenched with aqueous, saturated sodium bicarbonate solution and extracted
with EtOAc.
The combined organic layers were washed with aqueous, saturated sodium
bicarbonate
167


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
solution and brine, and were dried over solid MgSO4. Concentration afforded
the
carbamate XCVI (97%). A mixture of XCIII (Example 17) (0.06mmo1) and the above-

mentioned carbamate (0.05mmol) was heated in a sealed tube for 2 days. The
reaction
mixture was cooled to room temperature. PS-trisamine (100 mg, Argonaut) and PS-

isocynate resins (150 mg, Argonaut) were added, and the reaction mixture was
shaken for
3 days. The reaction mixture was filtered and concentrated to provide the
title compound
19.

Examples 20-25 exemplify the synthesis of aryl and heteroaryl amines which may
be
used as intermediate IV in Methods A-C (General Synthetic Methods) to prepare
compounds of formula II or III.

EXAMPLE 20
1-[5-tert-Butyl-2-(1 H-pyrazol-4-yl)-phenyl] amine

LiOH 1) DMF, POCI3 ",, NH2NHZ, EtOH
MeOH/H20 I 2) NaPF6, H20 ,~.

MezN NMez
Co2Me COzH PFs
XCVII
NOzBF4 Pd/C
MeCN NH4CO2H
/ NOz EtOH NH
2
H-N H-N H-N

Methyl 4-t-butylphenylacetate (20 mmol) was dissolved in MeOH (160 mL) and
treated
with water (40 mL) and LiOH monohydrate (30 mmol). The reaction was allowed to
stir
20 at room temperature overnight. Volatiles were removed under reduced
pressure; the

168


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
remaining residue was diluted with water and neutralized to pH 4 with 1 N
sulfuric acid.
The resulting solids were filtered, washed with water and dried to leave 4-t-
butylphenylacetic acid as an off-white solid (3.8 g, 99%).

Anhydrous DMF (139 mmol) was cooled to 0 C and treated with POC13 (79.6 mmol).
After 5 min, 4-t-butylphenylacetic acid (19.9 mmol) was added and the reaction
vessel
was transferred to a 110 C oil bath. The reaction mixture was stirred for 2 h,
during
which all solids dissolved. After cooling to room temperature, the reaction
mixture was
poured into a stirred solution of NaPF6 (19.8 mmol) in water (200 mL). When
t o precipitation of solids was complete, they were filtered, washed with
water, and dried to
give XCVII (7.8 g. 97%).

XCVII (5 mmol) was taken up in EtOH (50 mL), and the resulting suspension was
treated
with hydrazine hydrate (5 mmol). The reaction vessel was transferred to a 90 C
oil bath,
and the reaction mixture was stirred at reflux for 2 h. Volatiles were removed
under
reduced pressure after allowing the reaction mixture to cool to room
temperature. The
residue was taken up in ice water, solids were filtered, washed with water and
dried,
giving 4-(4-t-butylphenyl)pyrazole (973 mg, 97%).

2o 4-(4-t-butylphenyl)pyrazole (0.5 mmol) was suspended in MeCN (2 mL), cooled
to 0 C,
and treated with NO2BF4 (0.6 mmol). The reaction mixture was allowed to warm
slowly
to room temperature and was stirred at RT for 2 h. Volatiles were removed
under
reduced pressure after the reaction was quenched with aqueous NaHCO3. The
residue
was taken up in water and extracted with CH2C12. The organics were combined,
dried
over MgSO4, and concentrated to leave a yellow oil which was chromatographed
on
silica gel (eluent: CH2C12/EtOAc, 6:4) to give 4-(4-t-butyl-2-
nitrophenyl)pyrazole as a
yellow crystalline solid (71 mg, 58%).

4-(4-t-butyl-2-nitrophenyl)pyrazole (0.27 mmol) was dissolved in EtOH (3 mL)
and
treated with 10 % Pd/C (0.2 eq by weight of nitro compound), followed by
NH4CO2H
(2.7 mmol). After 30 min, the catalyst was filtered through a bed of
diatomaceous earth,

169


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
and the filtrate ~vas concentrated undei- reduced pressure. The residue was
taken up in
water, the resulting solids were filtered. washed with water and dried (54 mg.
93%).
giving the title compound 20.

EXAMPLE 21
3-Amino-2-methoxy-5-tert-butylpyridine
O NH4OH O

Et0" v NOz H N~NOz
z
DIBAL, hexane,
NC\ ~ AIC13, NO2Me, 0OC -70 OC - rt
> +
NC CI NC CN
O
OH O H N)t'~INOz PC15, POC13
H H 2 I ~ I
piperidine, EtOH HN 110 OC N
NOz NOz
0 CI
NaOMe, MeOH Pd/C, HCO2NH4,

65 0C N~ I NO EtOH, 50 OC N~ I NH
z 2
OMe OMe

21
Ethyl nitroacetate (3.3 mL, 4.0 g, 29.7 mmol) was added to ammonium hydroxide
(25
mL, 11 %) and stirred overnight as described by A.V. Amet et al., Russian
Clrenzical
Bulletin, 1996, 45(2), 393-398. The reaction was basified with 4 N
hydrochloric acid,
extracted into ether (3x25 mL), then into EtOAc (3x100 mL). The combined EtOAc
extracts were dried (magnesium sulfate), filtered and evaporated to dryness to
afford
nitroacetamide as a pale yellow solid (1.7 g, 16.3 mmol, 55%).

170


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
Trichloroaluminurn (45.5 g, 341 mnlol) was added slowly to 100 mL of ice cold
nitromethane under nitrogen. This was followed by a solution of malononitrile
(21.5 mL,
22.6 g, 341 mmol) in 50 mL of nitromethane added dropwise over one hour,
keeping the
temperature below 10 C. Next, a solution of tert-butyl chloride (88 mL, 74.9
g, 809
mmol) in 25 mL of nitromethane was added slowly over 2.5 h, keeping the
temperature
under 10 C. The reaction was capped and stored in the freezer for 60 h. The
reaction
was quenched by adding saturated aqueous sodium bicarbonate (500 mL) dropwise
over
4 h, keeping the temperature below 10 C. The heterogeneous mixture was
neutralized
further with solid sodium bicarbonate (50 g). The layers were separated and
the aqueous
layer extracted with methylene chloride (3x250 mL). The combined organic
extracts
were dried (magnesium sulfate) and concentrated in vacuo to afford 42 g of a
partially
crystalline brown oil. The residue was vacuum distilled at 100 C. The first
fraction was
collected and then a solid began to form in the condenser. The cooling water
was turned
off and the condenser heated with a heat gun to melt the solid. This fraction
was
collected until no more solid formed in the condenser when cool water was run
through it
to afford the desired dinitrile as a low melting cream solid (19 g, 155 mmol,
46%).

A solution of the above dinitrile (961 mg, 7.9 mmol) in anhydrous hexanes (50
mL) was
cooled to -70 C in a dry ice/acetone bath under nitrogen. DIBAL-H (17.5 mL,
1.0 M in
cyclohexane) was added dropwise over 20 min. The mixture was stirred at -70 C
for 45
min, then at room temperature for 5 h. The reaction was cooled to 0 C, 2 M
aqueous
hydrochloric acid (45 mL) was added slowly, keeping the temperature below 10
C. The
mixture was stirred at room temperature for 15 h. The layers were separated
and the
aqueous layer extracted with ether (3 x 25 mL). The combined organic extracts
were
dried (magnesium sulfate), filtered and evaporated to dryness to afford the
desired
dialdehyde as a viscous yellow oil (600 mg, 4.68 mmol, 60%).

A solution of the above aldehyde (271 mg, 2.11 mmol), nitroacetamide (223 mg,
2.14
mmol), and piperidine (20% in EtOH) (250 uL, 0.51 mmol) in absolute EtOH (3
mL) was
heated at 65 C for 3 h. After cooling to room temperature, the reaction
mixture was
171


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
concentrated in vacuo. The residue was purified by flash chromatoo-raphy on
silica gel
(EtOAc) to give the desired nitropyridone as a yellow solid (280 mg, 1.43
mmol, 67%).
A mixture of the nitropyridone (150 mg. 0.76 mmol), phosphorous pentachloride
(199
mg, 0.96 mmol) and phosphorous oxychloride (1 drop) was heated to reflux in a
sealed
tube. After 2 h, the phosphorous oxychloride was removed in vacuo and the
residue
stirred in ice water (10 mL) for 18 h. The desired product was collected as a
brown solid
(95 mg, 0.44 mmol, 58%).

1o To a solution of 2-chloro-3-nitro-5-tei-t-butyl pyridine (30 mg, 0.14 mmol)
in anhydrous
MeOH (1.5 mL) under nitrogen NA-as added a solution of sodium methoxide (1.57
g
sodium in 40 mL anhydrous MeOH) (85 uL, 0.14 mmol). The reaction was heated in
a
sealed tube in an oil bath set at 80-90 C overnight. The volatiles were
removed in
vacuo, the residue taken up in EtOAc (15 mL), washed with water (10 mL), brine
(10
mL), dried (magnesium sulfate). filtered and evaporated to dryness. Flash
chromatography of the residue on silica gel (10% EtOAc in hexanes) gave the
desired 2-
methoxy-3 -nitro- 5 -tert-butyl pyridine as a glassy yellow solid (12 mg,
0.057 mmol,
41%).

To a suspension of the above intermediate (12 mg, 0.057 mmol) and Pd/C (10%,
14 mg)
in absolute EtOH (1 mL) was added ammonium formate (22 mg, 0.35 mmol) and the
mixture was heated to 50 C for 1 hour. The cooled reaction mixture was
filtered through
diatomaceous earth and rinsed with MeOH. The filtrate was evaporated to
dryness to
afford the title compound 21 as a brown solid (10 mg, 0.055 mmol, 100%).


EXAMPLE 22
N-Acetyl-5-amino-3.3-dimethylindoline

172


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
Mel
p Ac20 O:N p K2C03 H N

O-
3N H2SO4 Red-Al AcCI
p Et3N
I -~
/ H N I / N

H /~-- O
HNO3 (fuming) O2N Pd/C H N
HCOzNH4 z IC- N ' N

p ~O
22
A solution of oxindole (5.0 g, 37.5 mmol) in acetic anhydride (7.1 mL, 75.1
mmol) and
acetic acid (25 mL) was refluxed for 20 h. After cooling to room temperature,
the
reaction mixture was diluted with water (200 mL). The resulting solids were
filtered,
washed with water and dried to give N-acetyl oxindole as a white solid (5.2 g,
79%).

A mixture of N-acetyl oxindole (2.0 g. 11.4 mmol), iodomethane (1.56 mL, 25.1
mmol)
and potassium carbonate (3.1 g, 22.8 mmol) in DMSO (20 mL) was stirred at room
t o temperature for 20 h. The reaction mixture was diluted with water. The
resulting solids
were filtered, washed with water and dried to give N-acetyl dimethyl oxindole
as an
orange solid (1.9 g, 84%).

A solution of N-acetyl dimethyl oxindole (500 mg, 2.5 mmol) in 3 N sulfuric
acid
solution (7 mL) and THF (7 mL) was refluxed for 4 h. After cooling to room
temperature,
the reaction mixture was diluted with ether. The ethereal layer was washed
with water
and brine, dried (magnesium sulfate), filtered and concentrated in vacuo. The
residue

173


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
was purified by flash chromatography on silica gel (eluent: 30% EtOAc in
hexanes) to
give dimethyl oxindole as a red solid (228 mg, 57%).

A solution of dimethyl oxindole (220 mg. 1.4 mmol) in toluene (5 mL) was
treated with
65% Red-Al solution in toluene (0.64 mL. 2.05 mmol) at 80 C. After stirring
at 100 C
for 4 h, the reaction mixture was quenched with IN sodium hydroxide solution.
The
organic layer was separated, washed xvith water and brine, dried (sodium
sulfate), filtered
and concentrated in vacuo. The residue was purified by flash chromatography on
silica
gel (eluent: 25% EtOAc in hexanes) to Qive dimethyl indoline as a light blue
oil (121 mg,
60%).

A solution of dimethyl indoline (65 mg. 0.44 mmol) and triethylamine (0.12 mL,
0.88
mmol) in dry dichloromethane (3 mL) was treated with acetyl chloride (0.05 mL,
0.66
mmol) at 0 C. The mixture was allowed to warm to room temperature and was
stirred
for 16 h. Then the reaction mixture was quenched with water and the product
was
extracted into ether. The organic layer was washed with water and brine, dried
(sodium
sulfate) filtered and concentrated in vacuo. The residue was purified by flash
chromatography on silica gel (eluent: 30% EtOAc in hexanes) to give N-acetyl
dimethyl
indoline as a light yellow oil (68 mg. 82%).

A solution of N-acetyl dimethyl indoline (65 mg, 0.34 mmol) in acetic acid (2
mL) was
treated with fuming nitric acid (24 L, 0.57 mmol) at room temperature and the
resulting
mixture was stirred for 1 h. The reaction mixture was quenched with sat.
sodium
bicarbonate solution and the product was extracted into EtOAc. The organic
layer was
washed with water and brine, dried (sodium sulfate), filtered and concentrated
in vacuo.
The residue was purified by flash chromatography in silica gel (eluent: 50%
EtOAc in
hexanes) to give the desired nitrated indoline as a light orange solid (66 mg,
67%).

A mixture of N-acetyl-3,3-dimethyl-5-nitroindoline (64 mg, 0.27 mmol),
ammonium
formate (86 mg, 1.36 mmol) and 10% palladium on carbon (5 mg) in MeOH (5 mL)
was
stirred at room temperature for 2 h. The reaction mixture was filtered through
a short
174


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
plug of diatomaceous earth. The filtrate was concentrated in vaciio. The
residue was
purified bv flash chromatography on silica gel (eluent: 50% EtOAc in hexanes)
to give
the title compound 22 as a white solid (48 mg, 87%).

EXAMPLE 23
8-Amino-6-tert-butvl-3-oxo-4-N-methvlbenzoxazine

0
ci"~AO ci
TEBA
o, + +.o Pd-C H,N N o NaHCO H, N N+.o
o,o o CH3CN H o o CHC13 3 0 0
H reflux H~ 0-55OC o

NaH Mel O
DMF

N / N+ o Pd-C N NH
CH3CN ~ 1
0 0 o reflux 0 o H
23
To a solution of 4-tert-butyl-2,6-dinitrophenol (3.15 g, 13.13 mmol) dissolved
in 100 mL
acetonitrile was added ammonium formate (5.0 g, 78.8 mmol) and 10% palladium
on
carbon (1.0 g). The mixture was refluxed for 20 min, then allowed to cool and
filtered
through diatomaceous earth. The residues were washed with EtOAc and the
combined
organics were evaporated in vacuo. The residue was taken up in dichloromethane
and
filtered through a short plug of silica gel. After removal of solvent in vacuo
2-amino-4-
tert-butyl-6-nitro-phenol was obtained as a rust-red solid (4.86 mmol; 37%
yield).

To a solution of 2-amino-4-tert-butvl-6-nitrophenol (258 mg, 1.23 mmol) and
benzyltriethylammonium chloride (280 mg, 1.23 mmol) in 5 mL chloroform was
added
175


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
finely powdered NaHCO3 (413 mg, 4.92 mmol). The mixture was cooled to 0 C and
a-
chloroacetyl chloride (0.12 mL. 1.47 mmol) in 1.5 n1L chloroform was added
dropwise
via syringe over 15 min. Once the addition was complete, the mixture "vas
allowed to stir
at 0 C for 1 h. It was then allowed to warm to ambient temperature and finally
was
gently refluxed for 6 h. The resulting crude orange mixture was allowed to
cool, then was
filtered through diatomaceous earth to remove a white precipitate, which was
washed
generously with more chloroform. After removal of the solvent in vaczto. the
oily residue
was treated with water (40 mL) and aQitated with a spatula, whereupon a vellow
precipitate formed. This pure 6-tert-butvl-8-nitro-3-oxo-benzoxazine was
filtered, dried
first under a stream of air, then in vacuo (1.05 mmol; 85 %).

To a solution of 6-tert-butyl-8-nitro-3-oxo-benzoxazine (51 mg, 0.20 mmol) in
3.5 mL
DMF at 0 C was added sodium hydride (10 mg. 60% in mineral oil; 0.24 mmol) in
one
portion. After 20 min, methyl iodide (20 uL, 0.24 mmol) was added via syringe.
The
mixture was allowed to warm slowly to ambient temperature overnight. The crude
mixture was quenched with saturated aqueous ammonium chloride solution and
extracted
with EtOAc (3x10 mL). The combined organics were washed with water, then
brine, then
dried over sodium sulfate. Filtration and removal of the solvents in vacuo
afforded 6-tert-
butyl-8-nitro-3-oxo-4-N-methylbenzoxazine (100%).

6-tert-Butyl-8-nitro-3-oxo-4-N-methvl-benzoxazine (53 mg, 0.2 mmol) was
dissolved in
12.5 mL acetonitrile. Cyclohexene (0.20 mL. 2.0 mmol) and 10% palladium-on-
carbon
(75 mg) were added. The mixture was refluxed for 1 h, then cooled to ambient
temperature and filtered through diatomaceous earth. The residues were washed
with
EtOAc and the combined organics were evaporated in vacuo to afford the title
compound
23 (100%).

EXAMPLE 24
7-Amino-5-tert-butyl-3H-benzoxazol-2-one
176


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
/
OzN O
~ ~I
I\
OCI O
H N NO pyridine NO Pd C NH
z z HN z HN z
H~O ~O ~O
24
To a solution of 2-amino-4-tert-butyl-6-nitrophenol (300 mg, 1.43 mmol) and
pyridine
(0.30 mL) in methylene chloride (30 mL) was added 4-nitrophenylchloroformate
(280
mg, 1.39 mmol). The mixture was stirred for 24 h. The resulting solution was
washed
with aqueous sodium bicarbonate (2x20 mL). dried over solid magnesium sulfate
and
concentrated to an orange solid. Column chromatography (silica gel, eluant =
40%
EtOAc/petroleum ether) afforded 5-tert-butyl-7-nitro-3H-benzoxazol-2-one
(70%).

1 o 5-tert-Butyl-7-nitro-3H-benzoxazol-2-one (200 mg, 0.9 mmol) was dissolved
in EtOH
(10 mL). Cyclohexene (4 mL) and 10% palladium on carbon (50 mg) were added.
The
mixture was refluxed for 3 h, then cooled to ambient temperature and filtered
through
diatomaceous earth. Column chromatography (silica gel, eluant = 25%
EtOAc/petroleum
ether) afforded the title compound 24 (70%).


EXAMPLE 25
7-Amino-5-tert-butyl-2-methylbenzoxazole

HCO2NH4
triethyl orthoacetate Pd-C EtOH

H2N NO N NO A NH
z z N z
OH X0 XO

25
177


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
2-Amino-4-tert-butyl-6-nitrophenol was dissolved in triethyl orthoacetate (10
mL). The
reaction mixture was stirred overnight at 100 C. EN-aporation of volatiles in
vacuo
afforded 5-tert-butyl-2-methyl-7-nitrobenzoxazole (110 mg).

5-tert-Butyl-2-methyl-7-nitrobenzoxazole (100 mg, 0.4 mmol) was dissolved in
EtOH
(20 mL). The catalyst (10% Pd/C, 100 mg) was added followed by ammonium
formate
(160 mg, 0.3 mmol). The resulting heterogenous mixture was stirred at 100 C
for 1 h.
Filtration followed by evaporation provided the title compound 25 (85 mg).

lo Examples 26-29 exemplify the synthesis of four heteroaryl amines which may
be used as
intermediate IV in Methods A-C (General Svnthetic Methods) to prepare
compounds of
formula I or Ia.

EXAMPLE 26
5-(5-Amino-3-tert-butylpyrazol-lyl)-2-methylbenzamide
NH2 HN" NH2

NaNO2, HCI CN N N NH2

SnCi2, HCI EtOH, HCI
0

I
Zn(CN)2, Pdo N. 10 N NaOH N~
N NH2 N NH2
DMF A A

~ CN NH 2

O
26

178


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
3-Iodo-4-methylphenyl amine (10 g. 43 mmol) was dissolved in 6 N HCI (40 mL),
cooled
to 0 C, and vigorously stirred throughout the procedure. Sodium nitrite (2.9
g, 1.03
equiv.) was dissolved in water (5 mL) and this solution was added to the
reaction in a
dropwise fashion. After 30 min, tin (II) chloride dihydrate (22.8 g. 1 mol) in
6 N HC1
(100 mL) was added via addition funnel, and the reaction slurry was stirred at
0 C for 3h.
The pH was adjusted to 14 with 40% aqueous sodium hydroxide solution and the
aqueous
mixture was extracted with EtOAc. (6x50 mL), dried (MgSO4), and concentrated
to give
3-iodo-4-methylphenylhydrazine (7 g, 57%). This material was used directly
without
further purification.

A solution of the above phenylhydrazine (5.08 g. 22 mmol) and 4.4-dimethyl-3-
oxopentanenitrile (3.06 g, 1.1 equiv.) in EtOH (100 mL) containing conc. HC1
(3 mL)
was refluxed for 17 h, then cooled to room temperature. The pH was adjusted to
14 with
40% aqueous sodium hydroxide solution. The aqueous mixture was extracted with
EtOAc, (3x50 mL), dried (MgSO4). and concentrated to give 5-tert-butyl-2-(3-
iodo-4-
methyl-phenyl)-2H-pyrazol-3-ylamine (6.3 g, 86 %). This material was used
directly
without further purification.

2o 5-tert-Butyl-2-(3-iodo-4-methyl-phenyl)-2H-pyrazol-3-ylamine (2 g, 5.6
mmol) was
combined with zinc cyanide (397 mg. 0.6 eq.) and tetrakis(triphenylphosphine)-
palladium(0) (325 mg, 5 mol %) in deoxygenated dimethylformamide (10 mL). The
resulting yellow slurry was heated at 100 C for 4 h, cooled to room
temperature, diluted
with brine and 2 N HCI. The aqueous mixture was extracted with EtOAc (6x10
mL),
dried (MgSO4), and concentrated. The residue was purified by flash
chromatography
eluting with 20% EtOAc/ petroleum ether to give 1.3 g(91 %) of the desired
nitrile.
The above nitrile (150 mg, 0.6 mmol) in EtOH (5 mL) was heated to 100 C in
the
presence of 10 N NaOH for 2 h. The reaction was cooled to room temperature,
neutralized with 50 % HCI, extracted with EtOAc (6x10 mL), dried (MgSO4) and
concentrated to give the title compound 26 (130 mg, 80%).

179


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
EXAMPLE 27

HZN, O
NHZ NH CN ~
1. NaNOZ N~ NHz
/ - / -
I 2. SnC12 I
N N

O~ N
27
5-Amino-2-methoxypyridine (5.0 g, 40 mmol) was dissolved in 6 N HCl (10 mL),
cooled
to 0 C, and vigorously stirred throughout the procedure. Sodium nitrite (2.8
g, 41 mmol)
was dissolved in water (10 mL) and this solution was added to the reaction
solution.
After 30 min, tin (II) chloride dihydrate (52 g, 230 mmol) in 6 N HC1 (20 mL)
was
added, and the reaction slurry was stirred at 0 C for 2.5 h. The pH was
adjusted to 13
with 40% aqueous potassium hydroxide solution. Ethyl ether was added and the
mixture
was extracted with EtOAc (4x70 mL), dried (MgSO4) and concentrated to give 5-
hydrazino-2-methoxypyridine as an orange solid (5.1 g).

A solution of 5-hydrazino-2- methoxypyridine (2.5 g, 18 mmol) and 4,4-dimethyl-
3-
oxopentanenitrile (2.3 g, 18 mmol) in toluene (50 mL) was refluxed for 17 h in
a flask
fitted with a Dean-Stark trap, then cooled to room temperature. The reaction
mixture was
concentrated and the residue purified by column chromatography on silica gel,
eluting
with 30% EtOAc/petroleum ether to give the title compound 27 as a tan solid
(3.5 g,
80%).

EXAMPLE 28
5-Amino-3-tert-butyl-l-(2-pyridone-5-yl)pyrazole

180


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
N/
11 N NH2
27 HBr
H cA
NH
O 28

To a solution of the product of Example 27 (0.6 g, 2.4 mmol) in acetic acid (3
mL) was
added 48% HBr in acetic acid (3 mL). The reaction mixture was heated to 120 C
for 15
min, cooled to room temperature, and the pH was adjusted to 7.5 with 10%
aqueous
sodium hydroxide solution. The aqueous mixture was extracted with EtOAc (4x15
mL),
dried (MgSO4), and concentrated to give a tan solid. The title compound 28
(0.46 g,
82%) was obtained after recrystallization from ether.

EXAMPLE 29
5-Amino-3-tert-butyl-l-(2-cyanoethyl)pyrazole
O
H CN
N, NH2 N~
`N NH 2
CN

CN 29
A solution of 2-cyanoethylhydrazine (3.0 g, 35 mmol) and 4,4-dimethyl-3-
oxopentanenitrile (4.2 g, 34 mmol) in toluene (50 mL) was refluxed for 17 h in
a flask
fitted with a Dean-Stark trap, then cooled to room temperature. The slurry was
filtered
and the filtrate was concentrated. Column chromatography of the residue on
silica gel,

181


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
eluting with 50% EtOAc/petroleum ether) afforded the title compound 29 as a
colorless
solid (2.6 g, 40%).

EXAMPLE 30

1-[5-tert-Butyl-2-(2-methylthiopyrimidin-5-yl)-2H-pyrazol-3-yl]-3-{ 4-[6-
(morpholin-
4-ylmethyl) pyri di n-3-yl] naphth alen-1-yl } urea:

0 1) LiHMDS
Diethyl oxalate 1) KOtBu
DMSO
- / \ --~ N~
2) Hydrazine NN C02Et 2) t-Butylbromo- N C02Et
HOAc, 90 C H acetate
COztBu
TFA N 1) DMF, POCI3
/ N CO2Et N~ C02Et
2) NaPFs, H20 N
+
COzH Me2N NMez
PF6 XCVIII

HzNC(SMe)NHz iCO2Et LiOH N/ N\ C02H
--~
MeOH/H20 /
~ I II
N\\ N N\\ N

SMe SMe
XCVIV
1. DPPA, NEt3 O
N
2. NaHCO3 N\N H H N O
3. LXXXIV r~,

N\\/N
~S'Me 30

182


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
Pinacolone (100 nlniol) and diethyloxalate (120 mmol) were dissolved in THF
(200 mL),
cooled to -78 C and treated with LiHMDS (120 mmol. I M in THF). The ice bath
was
removed and the reaction allowed to warnl to room temperature. After 2 h,
volatiles were
removed and the crude residue was dissolved in alacial HOAc (200 mL).
Hydrazine
monohydrate (1 10 mmol) was added and the reaction placed in a 90 C oil bath
and
stirred overnight. The HOAc was removed under reduced pressure and the crude
residue
was taken up in aqueous NaHCO3 to give a pH 6 solution. Solids were filtered.
washed
with water and dried to give the desired pyrazole ester (12.9 g, 66%).

KOt-Bu (67 mmol) was dissolved in DMSO (120 mL). The pyrazole ester from above
(12 g, 61 mmol) was added in one portion and the reaction was stirred for 15
min. t-
Butyl bromoacetate (92 mmol) was added and the reaction was stirred at room
temperature for 45 min. DMSO was removed under reduced pressure and the crude
residue was diluted with ice water and extracted with CHZC12. The organics
were
combined, dried over MgSO4 and concentrated to leave an isomeric mixture of
pyrazoles
as an orange oil (21 g). The desired isomer was isolated as an oil via silica
gel
chromatography. eluting with CH2C12 (13.3 g, 70%).

The pyrazole diester (13.3 g, 43 mmol) was dissolved in neat TFA (150 mL) and
stirred
at room temperature for 3 h. Volatiles were removed and the crude residue was
diluted
with ice water and extracted with CH~CI2. Organics were combined, washed with
water,
dried over MgSO4 and concentrated to leave the desired carboxylic acid as a
thick oil that
partially crystallized (10.2 g, 94%).

Anhydrous DMF (282 mmol) was cooled to 0 C and treated with POC13 (161 mmol).
After 5 min, the above pyrazole acetic acid derivative (10.2 g, 40 mmol) was
added and
the suspension was transferred to a 110 C oil bath. The reaction was stirred
for 2 h,
during which all solids dissolved. After cooling to room temperature, the
reaction was
poured into a stirred solution of NaPF6, (80 mmol) in water (400 mL). When
precipitation of solids was complete, they were filtered, washed with water
and dried
giving the desired vinamidinium salt XCVIII (14.6 g, 78%).

183


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865

Salt XCVIII from above (233 mg. 0.5 mmol) was taken up in DMSO (10 mL) and
treated
with S-methylisothiourea sulfate (0.25 mmol) and K2C03 (0.25 mmol). The
reaction was
transferred to a 90 C oil bath and stirred for 2 h. Volatiles were removed
under reduced
pressure after allowing the reaction to cool to room temperature. The residue
was taken
up in ice water and extracted with diethyl ether. Organics were combined,
dried over
MgSOa and concentrated to leave a brown tar. The desired ethyl ester was
purified by
chromatography on a silica gel column eluting with CH2C1)/EtOAc. 1:1 to give a
yellow
oil that crystallized upon standing (157 mg, 98%).


The ester from above (150 mg, 0.47 mmol) was dissolved in MeOH (4 mL) and
water (1
mL), treated with LiOH monohydrate (0.7 mmol) and stirred at room temperature
overnight. Volatiles were removed, the residue was diluted with water,
neutralized to pH
4 with 1N sulfuric acid. Solids were filtered, washed with water and dried
(113 mg,
82%).

The resulting carboxylic acid (105 mg, 0.36 mmol) was suspended in benzene (4
mL) and
treated with triethylamine (0.61 mmol). The resulting solution was treated
with
diphenylphosphoryl azide (DPPA) (0.54 mmol) and allowed to stir at room
temperature
for 6 h. Organics were washed with aqueous NaHCO3, water, dried over MgSO4 and
filtered. The resulting solution was treated with LXXXIV (Example 4) (115 mg,
0.36
mmol) and the reaction was placed in a 90 C oil bath for 1 h. Volatiles were
removed
and the crude residue was purified on two preparative TLC plates eluting with
CH2C1-,/MeOH, 9:1 to give the title compound 30 as an off-white solid (61 mg,
28%).

By substituting for the S-methylisothiourea sulfate used in reaction with
XCVIII, one
may obtain other substituted pyrimidines corresponding to XCVIV. For example,
using
acetamidine hydrochloride would provide the 2-methylpyrimidine analog of
XCVIV. 0-
Methylisothiourea sulfate and guanidine carbonate would give the 2-
methoxypyrimidine
and 2-aminopyrimidine analogs respectively. By replacing S-methylisothiourea
sulfate
with hydrazine monohydrate or N-methylhydrazine, one may obtain a pyrazol-4-yl
or 1-
184


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
methylpyrazol-4-vl ring respectively in place of the substituted pyrimidine in
XCVIV.
Each of these analogs of XCVIV mav be taken on as described above to provide
the
corresponding analogs of 30.

Examples 31-36 exemplify syntheses of substituted napthylamines which may be
used as
intermediate VI (D'-NH2) as described in Methods B and C in General Synthetic
Methods to produce various compounds of the invention

EXAMPLE 31
5-(4-Aminonapthalen-1-yl)-2-pyridin-3-ylmethylphenol
0 Pd cat.
Br
6 NaHCO3 O
H /
N DMF N
H 150 OC H

0
Boc-anhydride
NEt3 toluene H
100 oC 0 0 N
~
O N 1) t-BuOK
H t-BuOH
reflux
2) TFA-DCM
/ I I ~

~ \ O N
H~N / H
I
H ~
31
185


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
To a tube containing a solution of 2.0 g of 1-amino-4-bromonaplithalene (9.0
mmol; I
equiv.) in 70 mL DMF were added 1.75 mL of 2-cyclohexen-l-one (18.0 mmol; 2.0
equiv.), 2.3 g of sodium bicarbonate (27.0 mmol; 3.0 equiv.) and 186 mg of 1,3-
bis-
(diphenylphosphino)propane (dppp; 0.45 mmol; 0.05 equiv.). A stream of dry
nitrogen
gas was bubbled through the mixture for 15 min. then 316 mg of bis-
(triphenylphosphino)palladium(II) chloride (0.45 mmol:, 0.05 equiv.) was added
and the
tube was sealed. The mixture was heated at 150 C for 8 h, then cooled to
ambient
temperature, diluted with EtOAc (150 mL) and filtered through diatomaceous
earth. The
mixture was washed with water, then brine. The organic layer was dried
(MgSO4),
1 o filtered and concentrated. The crude oil was purified by column
chromatography on Si02
using 10 to 50% EtOAc in hexane mixtures as eluents to give 2.0 g of a thick
liquid
consisting of 3-(4-aminonapthalen-l-yl)cycloxex-2-enone and DMF (molar ratio
1:2
respectively; 5.22 mmol of naphthylamine; 58% of theoretical yield).

To a solution of 4.0 g of 3-(4-aminonapthalen-l-yl)cycloxex-2-enone : DMF (1:
2; 10.4
mmol; 1 equiv.) in 50 mL toluene was added 2.72 g of di-tert-butyl dicarbonate
(12.5
mmol; 1.2 equiv.) and 1.5 mL triethylamine (10.4 mmol; 1 equiv.). The mixture
was
heated to 100 C overnight, then cooled to ambient temperature. The reaction
mixture
was washed with 0.1% aqueous HCI (2 X 50 mL), water, brine, dried (MgSOa),
filtered
2o and concentrated. The crude product precipitated and was washed with 10%
EtOAc in
hexane to afford, after filtration, 2.5 g of desired tert-butyl carbamate (7.4
mmol; 71 % of
theoretical yield).

To a solution of 186 mg of the above tert-butyl naphthyl carbamate (0.55 mmol;
1
equiv.) in 1.6 mL anhydrous tert-butanol was added 52 uL of pyridine-3-
carboxaldehyde
(0.55 mmol; I equiv.) and 1.65 mL potassium tert-butoxide solution (1.0 M;
1.32 mmol;
3 equiv.). The mixture was heated to reflux overnight, then cooled. MeOH (5
mL) and
HCl solution in dioxane (4.0 M) were added until pH - 1, the reaction was then
stirred
for 1.5 h at ambient temperature. The mixture was then quenched with saturated
NaHCO3
aqueous solution and extracted with EtOAc (2 x 50 mL). The aqueous layer was
treated
with 4 N NaOH aqueous solution until pH - 12 and extracted 2 more times. The

186


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
combined organic extracts were washed with brine, dried (MbSOA filtered and
concentrated to afford a mixture of crude products. including naphthylamine
still
protected as the carbamate. The residue ,vas therefore taken up in
dichloromethane (3
mL), treated with 2 mL TFA and left stirring over a weekend at ambient
temperature. The
mixture was quenched and neutralized with saturated aqueous NaHCO3, extracted
with
dichloromethane (3 x 50 mL), dried (MgSO4) and filtered. The volatiles were
removed in
vacuo and the crude product purified by column chromatography on SiO-' using
50 to
100% EtOAc in hexane eluent mixtures giving 35 mg (0.11 mmol; 20% of
theoretical
yield) title compound 31.

EXAMPLE 32
5-(4-Aminonapthalen-1-yl)-2-(tetrahydrofuran-3-ylmethyl)phenol
O~
HCI
0 H H.1 N 0 O_ Dibal-H 0
O DCC, NEt3 T 78 CI

CH2C12
0 cat DMAP O 0
O
H
O O 0 O O
H, N H
O N 1) t-BuOK
H t-BuOH H
reflux
2) TFA-DCM 32
RT

To a solution of 3.16 g of tetrahydro-3-furoic acid (27 mmol; 1 equiv.) in 25
mL
anhydrous dichloromethane was added 7.85 g of dicyclohexylcarbodiimide (38
mmol;
1.4 equiv.) and 4.54 mL triethylamine (32.6 mmol; 1.2 equiv.). N-methyl-
methanolamine hydrochloride was then added, followed by 60 mg of DMAP (4-
187


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
dimethylamino)pyridine. An exothermic reaction ensued and a fiirther 25 mL of
dichloromethane were added. The mixture was stirred at ambient temperature
overnight,
then filtered through diatomaceous earth and concentrated. The residue was
treated with
ether and the white solid filtered off and removed. The solvent was removed
from the
mother liquor and the residue purified by column chromatography on SiO2 using
15-25%
EtOAc in hexanes as eluent mixtures to provide the desired amide as a
colorless oil (55%
of theoretical yield) that still contained 10% of dicyclohexyl urea. This was
used without
further purification in the next reaction.

1o To a solution of 1.0 g of the above amide (6.28 mmol; I equiv.) in 60 mL
anhydrous THF
at -78 C was added 12.6 mL of 1.0 M DIBAL-H solution in toluene dropwise vict
syringe (12.6 mmol; 2.0 equiv.). After stirring 30 min at -78 C the reaction
mixture was
quenched with 50 mL MeOH and 50 mL water. The reaction mixture was transferred
to a
separatory funnel and 250 mL ether were added. 1 N HCl aqueous solution was
added
until all the solids had dissolved. The layers were separated and the aqueous
portion was
extracted further with 2 x 100 mL ether. The combined organics were washed
with
saturated aqueous NaHCO3 solution, then brine, dried over Na2SO4, filtered and
concentrated. The crude product was purified by chromatography on silica gel
using 0-
5% MeOH in dichloromethane as eluent mixtures. The desired 3-tetrahydrofuroic
2o aldehyde was obtained as a very volatile, impure colorless oil (200 mg).

To a solution of 200 mg of tei=t-butyl naphthyl carbamate (0.59 mmol; 1
equiv.) in 1.6
mL anhydrous tert-butanol was added 200 mg of 3-tetrahydrofuroic aldehyde from
above
(excess) and 1.78 mL potassium tert-butoxide solution in tert-butanol (1.0 M;
1.78 mmol;
3 equiv.). The mixture was heated to 40 C overnight, then cooled and quenched
with
NH4CI saturated aqueous solution. The product was extracted with a
dichloromethane/methanol mixture (3 x 100 mL). The combined extracts were
washed
with brine, dried over MgSO4, and concentrated. 'H NMR analysis revealed that
only
10% of the enone was consumed. The residue (300 mg) was dissolved in 4.0 mL
dichloromethane and treated with 4 mL of a 1: 1 mixture dichloromethane : TFA.
The
mixture was stirred for 1.5 h, then neutralized with saturated NaHCO3 aqueous
solution,
188


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
basified with 4 N NaOH solution and extracted with dichloromethane / methanol
(3 x 100
mL). The combined organic extracts were washed with brine, dried (MgSO4) and
filtered
and concentrated. The crude product was purified by column chromatography on
silica
gel using 10 to 50% EtOAc in hexane eluent mixtures to give the title compound
32 (35
mg 0.11 mmol; 19% of theoretical yield).
EXAMPLE 33
4-[5-(4-Aminonapthalen-1-yl)pyridin-2-yloxy]butyronitrile

- OH
CBZNH B
~OH

Bf Bf XCV~X
NaHMDS/THF
N B~ DMSO N CN DME, 2M Na2CO3
HO/\\//\CN Pd(PPh3)4, 900C

CBZNH ~ ~ ~ / O'\/~CN O H2N ~ ~ ~ / O~~\CN
N CZH50H,10% Pd/C N
\ / 700C ~ ~
33
To 2,5-dibromopyridine (500mg, 2.1 mmol) and 3-cyano-l-propanol (270 mg, 3.1
mmol) in DMSO (2 mL) was added 1 M sodium hexamethyldisilazide (2.1 mL, 2.1
mmol). The reaction was stirred at room temperature overnight. EtOAc was added
to the
reaction and the mixture was washed with water (2 x 10 mL). The EtOAc fraction
was
dried over anhydrous sodium sulfate and evaporated on a rotary evaporator. The
crude
product was purified by flash column chromatography over silica gel using
40%EtOAc/hexanes to give 200 mg of 5-bromo-2-cyanopropyloxypyridine as a pale
yellow solid (39.3%).

To the above intermediate (100 mg, 0.4 mmol) and CBZ-protected naphthylboronic
acid
XCVIX (prepared as described for the Boc-analog XCI in Example 17) (200 mg,
0.62
mmol) in DME (4 mL) was added 2M sodium carbonate solution (2 mL). The
solution

189


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
was purged with nitrogen for 10 min and to this was added palladium
tetrakistriphenylphosphine (20 m`: ). The reaction was heated at 90 C for 48 h
and then
cooled to room temperature. EtOAc w-as added to the reaction and the mixture
was
washed with water (2 x 10 mL). The EtOAc fraction was dried over anhydrous
sodium
sulfate, filtered and concentrated. "The crude product was purified by flash
column
chromatography over silica gel eluting with 40%EtOAc/hexanes to give 70 mg of
product
(39%).

To the above coupled product (70 ma. 0.16 mmol) in EtOH (5 mL) was added
1o cyclohexene (263 mg, 3.2 mmol) and 10%Pd/C (20 mg). The reaction was heated
under
nitrogen overnight and cooled to room temperature. The reaction was filtered
over
diatomaceous earth, washed with MeOH and concentrated. The crude product was
purified by flash column chromatography over silica gel eluting with 50%
EtOAc/hexanes to give 15 mg of the title compound 33 (31 %).

EXAMPLE 34
[5-(4-Aminonapthalen-1-yl)pyridin-2-yl]-(tetrahydrothiopyran-4-yl) amine
dihydrochloride

190


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
,OH
O N NHZ Br
~ ~ Br
NHZOH LiAIH4 ~
D N Br
NaOAc THF N N
cs EtOH S S H\,\/"
--7C O
XCI /`~
~ \ ~ \ N H--C HCI/dioxane
DME, 2M NaZCO3
(PPh3)2PdCl2, 900C
xcx
HZN \ N HS

.2HCI /
34

To tetrahydro-1,4-thiopyrone (2.0 g, 17.2 mmol) and hydroxylamine
hydrochloride (2.0
g, 28.7 mmol) in EtOH (10 mL) was added sodium acetate trihydrate (4.0 g, 29.4
mmol)
in 20 mL water. The reaction was heated at reflux for 3 h, cooled to room
temperature
and concentrated to 15 mL on a rotary evaporator. The residue was cooled in an
ice-bath
and filtered to give 2.0 g of the oxime product as a white solid m.p. 80-83 C
(88.7%).
To a dry flask containing THF (20 mL) and 1 M lithium aluminium hydride in
diethyl
ether (19 mL) at room temperature, was added the oxime from above (500 mg,
3.82
mmol). The reaction was heated at reflux for 3 h, cooled to room temperature
and the
excess LAH was quenched with ice/water. Extraction with EtOAc and
concentration gave
340 mg (76%) of the desired 4-aminotetrahydrothiopyran.

To the above amine (170 mg, 1.4 mmol) in dry pyridine (1 mL) was added 2,5-
dibromopyridine (250 mg, 1.1 mmol) and the reaction was heated at 110-120 C
for 5
days. The reaction was extracted with EtOAc, washed with water, dried over
anhydrous
sodium sulfate and concentrated to give the crude product. The crude product
was

191


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
purified by flash column chromatography over silica gel using 30%
EtOAc/hexanes as
eluent to give 100 m(i of pure product (33.3%).

To the above intermediate (80 mg. 0.293 mmol) and BOC-protected
naphthylboronic
acid XCI (Example 17) (140 mg, 0.488 mmol) in DME (4 mL) was added 2 M sodium
carbonate (2 mL) and bis(triphenylphosphine)palladium chloride (15 mg). The
reaction
was heated at 90 C under nitrogen for 18 h and cooled to room temperature.
The
reaction was extracted with EtOAc, xvashed with water, dried over anhvdrous
sodium
sulfate and concentrated to give the crude product. The crude product was
purified by
flash column chromatography over silica ael usino 30% EtOAc/hexanes as eluent
to give
110 mg of pure product XCX (86.0%)

To the XCX (35 mg, 0.08 mmol) in dioxane (1 mL) was added 4 M HCl/dioxane (0.6
mL). The reaction was stirred at room temperature for 48 h. Addition of
diethyl ether
gave the product as the hydrochloride salt which was filtered, giving 18 mg
(55%) of the
title compound 34.

EXAMPLE 35

[5-(4-Aminonapthalen-1-yl)pyridin-2-yl]-(tetrahydropyran-4-yl) amine
dihydrochloride

Br XCI /o c~O
\/ \ N
H NH
~ C2H~CI2, CH3COOH
NHZ DME, 2M Na2CO3 2
(PPh3)2PdC12 NaBH(OAC)3

xcx
\ 0
~j
0---~ TFA/CHZCI2
H \ N H~O HZN \/ \ N HO
/

XCXI 35
192


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
To 2-amino-5-bromopyridine (250 m(-,. 1.44 mniol) and BOC-protected
naphthvlboronic
acid XCI (Example 17) (688 mg, 2.4 mmol) in 5 mL DME was added 2 M sodium
carbonate (2.5 mL) and bis(triphenylphosphine)palladium chloride (30 mg). The
reaction
was heated at 90 C under nitrogen for 18 h and cooled to room temperature.
The reaction
mixture was extracted with EtOAc, washed with water, dried over anhydrous
sodium
sulfate and concentrated. The residue was purified by flash column
chromatography over
silica gel eluting with 40% EtOAc/hexanes to give 370 mg coupled product XCX
(76.4%).

1o To the above intermediate (200 mg, 0.597 mmol) and tetrahvdropyranone (120
mg, 1.19
mmol) in dichloroethane (5 mL) was added glacial acetic acid (0.2 mL. 3.58
mmol) and
sodium triacetoxyborohydride (380 mg. 1.79 mmol). The reaction was stirred at
room
temperature for 48 h and then extracted with EtOAc, washed with water, dried
over
anhydrous sodium sulfate and concentrated. The residue was purified by flash
column
chromatography over silica gel using 50% EtOAc/hexanes as eluent to give 120
mg
XCXI (48.0%).

The above product, XCX, was dissolved in dichloromethane (3mL) and
treated with trifluoroacetic acid (1 mL). The reaction was stirred for 3 h and
concentrated. The residue was dissolved in EtOAc (20 mL), washed with

sodium bicarbonate solution, dried over anhydrous sodium sulfate
concentrated to give 90 mg of the title compound 35 (98.5%).
EXAMPLE 36


[5-(4-Aminonapthalen-1-yl)pyridin-2-yl]-(1-methylpiperidin-4-yl) amine
193


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
O O
O-~ - - 0 N- ~O-~ - -
NH2 ~ N N
N C H CI- CH3COOH (J H--CN-
NaBH(OAC)3 \ /
xcx

TFA/CH2CI2 H2N N-CN H N~
36
To a mixture of XCX (Example 35) (110 mg. 0.33 mmol) and 1-methyl-4-piperidone
(80
mg, 0.7 mmol) in dichloroethane (6 mL) was added glacial acetic acid (120 mg,
2.0
mmol) and sodium triacetoxyborohydride (220 mg, 1.03 mmol). The reaction was
stirred
at room temperature for 96 h and then extracted with EtOAc, washed with water,
dried
over anhydrous sodium sulfate and concentrated. The residue was purified by
flash
column chromatography over silica gel using 10%MeOH/ CH2C12/0.1 %TEA as eluent
to
1 o give 60 mg of pure product (42.0%).

The above product was dissolved in dichloromethane (3 mL) and treated with
trifluoroacetic acid (1 mL). The reaction was stirred for 2.5 h and the
concentrated to give
94 mg of the title compound 36 (100%).


EXAMPLE 37

Example 37 illustrates the synthesis of a compound of formula III in which E
is O.
[4-(6-Morpholin-4-ylmethylpyridin-3-yl)napthalen-1-yl)carbamic acid 3-tert-
butylphenyl ester

194


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
LXXXIV I N O

1 I ~ \ I
OH phosgene
O N
H
37

LXXXIV (Example 4) (100 mg, 0.31 mmol) was dissolved in dichloromethane (20
mL). An equal volume of sat. aqueous sodium bicarbonate was added, and the
biphasic
solution was cooled to 0 C. During the addition of phosgene (1.93 M in
toluene, 0.40

mL), stirring was stopped. Immediately afterward, stirring was resumed for 15
min
with the reaction mixture at 0 C. The layers were separated, the organics were
dried
over solid magnesium sulfate, and concentrated to approximately 5 mL of
solution. 3-
tert-Butylphenol (100 mg, 0.67 mmol) in dichloromethane (5 mL) was added. The

1 o reaction mixture was stirred at room temperature for 19 h. Flash
chromatography
using EtOAc as eluent provided 71 mg of the title compound 37.

EXAMPLE 38

Example 38 illustrates the synthesis of a compound of formula III in which E
is CH2.
2-(5-tert-Butyl-2-methoxyphenyl)-N-[4-(6-morpholin-4-ylmethylpyridin-3-
yl)napthalen-l-yl] acetamide

N
LXXXIV O N ~O
COONa
N
0 O H
38
LXXXIV (Example 4) (100 mg, 0.4 mmol) and the sodium salt of 5-tert-butyl-2-
methoxyphenylacetic acid (154 mg, 0.4 mmol) were dissolved in dichloromethane
(15

195


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
mL). 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (172 mg, 0.9
mmol) was added, and the reaction mixture was stirred at ambient temperature
for 16
h. HPLC purification afforded 30 mg of the title compound 38.

The following additional examples were prepared bv methods analogous to those
described above:

1-(2-tert-Butyl-5-methyl-pyridin-4-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;
1-(5-tert-Butyl-2-methylphenyl]-3-{4-[6-(morpholin-4-ylmethyl)pyridin-3-
yl]naphthalen-
1-yl} urea:

1-(3,3-Dimethyl-2-oxo-2,3-dihydro-1 H-indol-5-yl)-3-[4-(6-morpholin-4-ylmethyl-

pyridin-3-yl)-naphthalen-l-yl]-urea

1-(3-Amino-5-tert-butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea

1-(3-tert-Butyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-
l-yl]-
urea;

1-(4-Methyl-biphenyl-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-vl)-
naphthalen-l-
yl]-urea;
1-(4-tert-Butyl-biphenyl-2-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen- I -
yl]-urea;

1-(5-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-l-yl } -pyridin-
2-
ylmethyl)-piperidine-3-carboxylic acid amide
1-(5-Isopropyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(5-sec-Butyl-2-methoxy-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-(5-tert-Butyl-2-methoxymethyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea;
1 -(5-tert-Butyl-2-methoxy-phenyl)-3 -(4- { 6-[(tetrahydro-furan-3 -ylamino)-
methyl]-
pyridin-3-yl } -naphthalen-l-yl)-urea

196


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4- { 6-[4-(3-methoxy-phenyl)-piperazin-l-
ylmethyl]-pyridin-3-yl } -naphthalen-l-yl)-urea
1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(5-morpholin-4-ylmethyl-pyrazin-2-yl)-
naphthalen- l -yl] -urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6- { [(2-cyano-ethyl)-(tetrahydro-
fiiran-2-
ylmethyl)-amino]-methyl } -pyridin-3-yl)-naphthalen-1-yl]-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-{ [(2-cyano-ethyl)-pyridin-3-
ylmethyl-amino]-
methyl}-pyridin-3-yl)-naphthalen-l-yl]-urea
1-(5-tert-Butyl-2-methoxy-phenyl)-3 - [4-(6-morpholin-4-ylmethyl-pyridin-3 -
yl)-
naphthalen-l-yl]-urea;
1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-thiomorpholin-4-ylmethyl-pyridin-3-
yl)-
naphthalen-l-yl]-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(1-oxo-1 k4-thiomorpholin-4-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3- { 4-[6-(1-oxo-tetrahydro-thiopyran-4-
ylamino)-
pyridin-3-yl]-naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(2,6-dimethyl-morpholin-4-ylmethyl)-

pyr,idin-3-yl]-naphthalen-l-yl }-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2,6-dimethyl-piperidin-l-ylmethyl)-
pyridin-
3-yl]-naphthalen-l-yl } -urea
1-(5-tert-Butyl-2-methoxy-phenyl)-3- { 4-[6-(2-methoxymethyl-morpholin-4-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3 - { 4-[6-(2-methyl-3-oxo-piperazin-l-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl }-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(2-oxa-5-aza-bicyclo[2.2.1 ]hept-5-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl } -urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(2-thia-5-aza-bicyclo[2.2.1 ]hept-5-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl}-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3 - { 4-[6-(3 -oxo-piperazin-l-ylmethyl)-
pyridin-3-yl]-
naphthalen-l-yl}-urea

197


CA 02362003 2001-08-16
WO 00/55139 PCTIUSOO/03865
1-(5-tert-Butyl-2-methoxy-phenyl)-3- {4-[6-(4-methyl-piperazin-l-ylmethyl)-
pyridin-3-
yl]-naphthalen-l-yl }-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(4-pyridin-2-yl-piperazin-l-
ylmethyl)-
pyridin-3-yl]-naphthalen-l-yl}-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3- { 4-[6-(morpholine-4-carbonyl)-pyridin-3-
yl]-
naphthalen-l-yl }-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(pyridin-3-yloxy)-pyridin-3-yl]-
naphthalen-l-
yl}-urea

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-(tetrahydro-pyran-4-ylamino)-pyridin-
3-yl]-
naphthalen-l-yl } -urea
1-(5-tert-Butyl-2-methyl-phenyl)-3 -(4- { 6- [(3 -methoxy-propyl)-methyl-
amino]-pyridin-3-
yl } -naphthalen- l -yl)-urea;

1-(5-tert-Butyl-2-methyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen- l -yl]-urea;

1-(5-tert-Butyl-2-methyl-pyridin-3 -yl)-3- [4-(6-morpholin-4-ylmethyl-pyridin-
3-yl)-
naphthalen-l-yl]-urea;

1-(6-tert-Butyl-3-oxo-3,4-dihydro-2H-benzo [ 1,4] oxazin-8-yl)-3-[4-(6-
morpholin-4-
ylmethyl-pyridin-3-yl)-naphthalen-l-yl]-urea
1-[4-(6-{ [Bis-(2-cyano-ethyl)-amino]-methyl}-pyridin-3-yl)-naphthalen-l-yl]-3-
(5-tert-
butyl-2-methoxy-phenyl)-urea
1-[5-(1,1-Dimethyl-propyl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-l-yl]-urea;

1-[5-tert-Butyl-2-(1 H-pyrazol-4-yl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-yl)-
naphthalen-l-yl]-urea;

1-[5-tert-Butyl-2-(2-methyl-pyrimidin-5-yl)-phenyl]-3-[4-(6-morpholin-4-
ylmethyl-
pyridin-3-yl)-naphthalen-l-yl]-urea;

1-[5-tert-Butyl-2-(3-hydroxy-propyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-
pyridin-3-
yl)-naphthalen-I -yl]-urea;

1-[5-tert-Butyl-2-(morpholine-4-carbonyl)-phenyl]-3-[4-(6-morpholin-4-ylmethyl-

pyridin-3-yl)-naphthalen-l-yl]-urea;

198


CA 02362003 2001-08-16
WO 00/55139 PCT/USOO/03865
N-(5-{4-[3-(5-tert-Buty1-2-methoxy-phenyl)-ureido]-naphthalen-l-yl } -pyridin-
2-yl)-
acetamide

N-(5-tert-Butyl-2-methox\ -3 - {3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-acetamide

N-(5-tert-Butyl-2-methox} -3- {3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-1-
yl]-ureido } -phenyl)-N-methyl-acetamide

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-2,2.2-trifluoro-acetamide
N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-
naphthalen-l-
yl]-ureido } -phenyl)-methanesulfonamide.
20 ASSESSMENT OF BIOLOGICAL PROPERTIES
Inhibition of TNF Production in THP Cells

The inhibition of cytokine production can be observed by measuring inhibition
of TNFa
in lipopolysaccharide stimulated THP cells (for example, see W. Prichett et
al., 1995, J.
Inflammation, 45, 97). All cells and reagents were diluted in RPMI 1640 with
phenol red
and L-glutamine, supplemented with additional L-glutamine (total: 4 mM),
penicillin and
streptomycin (50 units/ml each) and fetal bovine serum (FBS, 3%) (GIBCO, all
conc.
final). Assay was performed under sterile conditions; only test compound
preparation was
nonsterile. Initial stock solutions were made in DMSO followed by dilution
into RPMI
1640 2-fold higher than the desired final assay concentration. Confluent THP.1
cells
(2x106 cells/ml, final conc.; American Type Culture Company, Rockville, MD)
were
added to 96 well polypropylene round bottomed culture plates (Costar 3790;
sterile)
containing 125 l test compound (2 fold concentrated) or DMSO vehicle
(controls,

blanks). DMSO concentration did not exceed 0.2% final. Cell mixture was
allowed to
preincubate for 30 min, 37 C, 5% CO-) prior to stimulation with
lipopolysaccharide (LPS;
199


CA 02362003 2001-08-16
WO 00/55139 PCT/US00/03865
I g/ml final; Siga L-2630, from E.coli serotype 0111.B4; stored as 1 mg/mi
stock in
endotoxin screened distilled H-,O at -80 C). Blanks (unstimulated) received
H,O vehicle;
final incubation volume was 250 l. Overnight incubation (18 - 24 hr)
proceeded as
described above. Assay was terminated by centrifuging plates 5 min, room
temperature,
1600 rpm (400 x g); supernatants were transferred to clean 96 well plates and
stored -
80 C until analyzed for human TNFa by a commercially available ELISA kit
(Biosource
#KHC3015, Camarillo. CA). Data was analyzed by non-linear regression (Hill
equation)
to generate a dose response curve using SAS Software System (SAS institute,
Inc.. Cary,
NC). The calculated IC50 value is the concentration of the test compound that
caused a
1o 50% decrease in the maximal TNFa production.

Preferred compounds including those from the synthetic examples above were
evaluated
and had IC50 < 10 M in this assay.

Inhibition of other cytokines

By similar methods using peripheral blood monocytic cells, appropriate
stimuli, and
commercially available ELISA kits (or other method of detection such as

radioimmunoassay), for a particular cytokine, inhibition of IL-1 P, GM-CSF, IL-
6 and
IL-8 can be demonstrated (for example, see J.C. Lee et al., 1988, Int. J.
Immunopharmacol., 10, 835).

200

Sorry, the representative drawing for patent document number 2362003 was not found.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Admin Status

Title Date
Forecasted Issue Date 2009-04-21
(86) PCT Filing Date 2000-02-16
(87) PCT Publication Date 2000-09-21
(85) National Entry 2001-08-16
Examination Requested 2003-11-19
(45) Issued 2009-04-21

Abandonment History

There is no abandonment history.

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Filing $300.00 2001-08-16
Registration of Documents $100.00 2001-08-28
Maintenance Fee - Application - New Act 2 2002-02-18 $100.00 2002-01-16
Maintenance Fee - Application - New Act 3 2003-02-17 $100.00 2003-01-20
Request for Examination $400.00 2003-11-19
Maintenance Fee - Application - New Act 4 2004-02-16 $100.00 2004-01-16
Maintenance Fee - Application - New Act 5 2005-02-16 $200.00 2005-01-19
Maintenance Fee - Application - New Act 6 2006-02-16 $200.00 2006-01-24
Maintenance Fee - Application - New Act 7 2007-02-16 $200.00 2007-01-19
Maintenance Fee - Application - New Act 8 2008-02-18 $200.00 2008-01-22
Final Fee $1,008.00 2009-01-05
Maintenance Fee - Application - New Act 9 2009-02-16 $200.00 2009-01-23
Maintenance Fee - Patent - New Act 10 2010-02-16 $250.00 2010-02-04
Maintenance Fee - Patent - New Act 11 2011-02-16 $250.00 2011-02-03
Maintenance Fee - Patent - New Act 12 2012-02-16 $250.00 2012-02-02
Maintenance Fee - Patent - New Act 13 2013-02-18 $250.00 2013-02-04
Maintenance Fee - Patent - New Act 14 2014-02-17 $250.00 2014-02-03
Maintenance Fee - Patent - New Act 15 2015-02-16 $450.00 2015-02-02
Maintenance Fee - Patent - New Act 16 2016-02-16 $450.00 2016-02-08
Maintenance Fee - Patent - New Act 17 2017-02-16 $450.00 2017-02-06
Maintenance Fee - Patent - New Act 18 2018-02-16 $450.00 2018-02-05
Maintenance Fee - Patent - New Act 19 2019-02-18 $450.00 2019-02-04
Current owners on record shown in alphabetical order.
Current Owners on Record
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
Past owners on record shown in alphabetical order.
Past Owners on Record
BETAGERI, RAJASHEKHAR
BREITFELDER, STEFFEN
CIRILLO, PIER, F.
GILMORE, THOMAS, A.
HICKEY, EUGENE, R.
KIRRANE, THOMAS, M.
MORIAK, MONICA, H.
MOSS, NEIL
PATEL, USHA, R.
PROUDFOOT, JOHN, R.
REGAN, JOHN, R.
SHARMA, RAJIV
SUN, SANXING
SWINAMER, ALAN, D.
TAKAHASHI, HIDENORI
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.

To view selected files, please enter reCAPTCHA code :




Filter Download Selected in PDF format (Zip Archive)
Document
Description
Date
(yyyy-mm-dd)
Number of pages Size of Image (KB)
Cover Page 2009-04-01 2 40
Abstract 2001-08-16 1 63
Claims 2001-08-16 80 2,879
Description 2001-08-16 200 7,576
Claims 2003-05-29 81 2,895
Claims 2003-08-01 93 3,313
Cover Page 2001-12-14 2 40
Claims 2007-08-27 15 471
Description 2007-08-27 202 7,617
Claims 2008-01-24 16 517
Description 2008-01-24 202 7,611
Prosecution-Amendment 2003-11-19 1 39
Prosecution-Amendment 2007-11-23 2 47
PCT 2001-08-16 8 303
Assignment 2001-08-16 3 114
Assignment 2001-08-28 7 183
Correspondence 2001-12-18 1 22
Assignment 2002-02-14 1 44
Correspondence 2002-02-14 1 44
Prosecution-Amendment 2003-05-29 2 49
Prosecution-Amendment 2003-08-01 29 1,007
Prosecution-Amendment 2008-01-24 8 265
Prosecution-Amendment 2007-05-24 2 55
Prosecution-Amendment 2007-08-27 21 676
Correspondence 2009-01-05 1 39